



(86) Date de dépôt PCT/PCT Filing Date: 2004/07/07
(87) Date publication PCT/PCT Publication Date: 2005/01/13
(85) Entrée phase nationale/National Entry: 2005/12/22
(86) N° demande PCT/PCT Application No.: AU 2004/000914
(87) N° publication PCT/PCT Publication No.: 2005/003328
(30) Priorités/Priorities: 2003/07/07 (60/485,241) US;
2003/09/22 (60/504,703) US

(51) Cl.Int./Int.Cl. *C12N 1/20* (2006.01),
A61K 35/74 (2006.01), *A01N 63/02* (2006.01)
(71) Demandeur/Applicant:
FLINDERS TECHNOLOGIES PTY. LTD., AU
(72) Inventeurs/Inventors:
FRANCO, CHRISTOPHER MILTON MATHEW, AU;
COOMBS, JUSTIN TAYLOR, AU
(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : METHODE ET AGENTS POUVANT AMELIORER LA PRODUCTIVITE DE VEGETAUX IMPLIQUANT DES
ACTINOMYCETES ENDOPHYTES ET LEURS METABOLITES
(54) Title: A METHOD AND AGENTS FOR IMPROVING PLANT PRODUCTIVITY INVOLVING ENDOPHYTIC
ACTINOMYCETES AND METABOLITES THEREOF

(57) **Abrégé/Abstract:**

The present invention relates to a method for improving plant productivity, and in particular crop yields, via the introduction of an endophytic microorganism to the subject plant. More particularly, the present invention is directed to a method for improving cereal crop productivity via the introduction of an endophytic actinomycete to the subject crop. The method of the present invention facilitates the improvement of crop productivity, such as increasing germination, by, inter alia, providing the subject plant with disease bio-control capabilities and up-regulating plant growth promoting activities. The present invention is also directed to novel endophytic microorganisms and uses thereof.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number
WO 2005/003328 A1

(51) International Patent Classification⁷: C12N 1/20,
A61K 35/74, A01N 63/02

(21) International Application Number:
PCT/AU2004/000914

(22) International Filing Date: 7 July 2004 (07.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/485,241 7 July 2003 (07.07.2003) US
60/504,703 22 September 2003 (22.09.2003) US

(71) Applicant (for all designated States except US):
FLINDERS TECHNOLOGIES PTY. LTD. [AU/AU];
Bedford Park, South Australia 5042 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRANCO, Christo-
pher, Milton, Mathew** [AU/AU]; 21 John Street, Payne-
ham, South Australia 5070 (AU). **COOMBS, Justin, Tay-
lor** [AU/AU]; 2/90 High Street, Glen Iris, Victoria 3146
(AU).

(74) Agents: **OBRANOVICH, Tania, D.** et al.; Davies Col-
lison Cave, 1 Nicholson Street, Melbourne, Victoria 3000
(AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: A METHOD AND AGENTS FOR IMPROVING PLANT PRODUCTIVITY INVOLVING ENDOPHYTIC ACTINO-
MYCETES AND METABOLITES THEREOF

(57) Abstract: The present invention relates to a method for improving plant productivity, and in particular crop yields, via the introduction of an endophytic microorganism to the subject plant. More particularly, the present invention is directed to a method for improving cereal crop productivity via the introduction of an endophytic actinomycete to the subject crop. The method of the present invention facilitates the improvement of crop productivity, such as increasing germination, by, *inter alia*, providing the subject plant with disease bio-control capabilities and up-regulating plant growth promoting activities. The present invention is also directed to novel endophytic microorganisms and uses thereof.



WO 2005/003328 A1

A Method and agents for improving plant productivity involving endophytic actinomycetes and metabolites thereof.

FIELD OF THE INVENTION

5

The present invention relates to a method for improving plant productivity, and in particular crop yields, via the introduction of an endophytic microorganism to the subject plant. More particularly, the present invention is directed to a method for improving cereal crop productivity via the introduction of an endophytic actinomycete to the subject crop. The method of the present invention facilitates the improvement of crop productivity, such as increasing germination, by, *inter alia*, providing the subject plant with disease bio-control capabilities and up-regulating plant growth promoting activities. The present invention is also directed to novel endophytic microorganisms and uses thereof.

15 **BACKGROUND OF THE INVENTION**

Bibliographic details of the publications referred to by author in this specification are collected alphabetically at the end of the description.

20 The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

The wheat crop in Australia is subject to attack by many pests and diseases which reduce the potential grain yields. The major cause of yield reductions is the fungal disease "take all" caused by a major fungal pathogen of wheat crops *Gaeumannomyces graminis* var. *tritici* (Ggt) followed by *Rhizoctonia*. There are currently no reliable means to control these pathogens either by biological or chemical means. In addition to controlling such pathogens, the importance of the agricultural industry in Australia necessitates optimal crop productivity. Accordingly, there is an ongoing need to develop new techniques directed to improving crop productivity in terms of facilitating growth promotion and/or controlling the adverse activity of crop pathogens.

- 2 -

Endophytes are plant associated microorganisms obtained from surface-sterilised plant tissue. It is thought that they inhabit and coexist with the innermost of cells of plants. They are found in the cortex and vascular systems of plant roots and are present in leaves, stems
5 and seeds. Due to their location within the plant, these organisms are free from competition with general microflora in the soil and are protected to a large extent from environmental stresses. Agriculturally, this type of relationship can be put to practical use since metabolites produced by some bacteria may exhibit plant growth promotion and/or pathogen control properties and may induce systemic resistance in plants.

10

In work leading up to the present invention, the inventors have determined that the microflora of some wheat isolates differs significantly from the microflora commonly found in soil and, surprisingly, even in other wheat isolates. In particular, the inventors have determined that some species of actinomycetes can exist as endophytes in wheat plants and,
15 moreover, contribute to improved productivity of the host plant by virtue of exhibiting functional activities such as pathogen antagonism and production of growth promotion metabolites. In a related aspect, the inventors have further identified a number of novel species of wheat plant endophytic actinomycetes which, *inter alia*, can provide these benefits. The surprising elucidation of both the endophytic existence of several
20 actinomycete species which were previously thought only to exist in the rhizosphere and the identification of novel actinomycete species in wheat plants, together with the yet more unexpected determination that only some of these wheat plant endophytic actinomycetes also function as modulators of improved plant productivity has now facilitated the development of methodology for improving plant productivity, in particular cereal crop
25 productivity, based on introducing to a plant the subject actinomycete.

- 3 -

SUMMARY OF THE INVENTION

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will
5 be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The subject specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 3.1, presented herein after the bibliography. Each
10 nucleotide sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (eg. <210>1, <210>2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification
15 are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (eg. <400>1, <400>2, etc).

One aspect of the present invention is directed to a method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:
20

- (i) an effective number of cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof; which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
- 25 (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce, in the subject plant, said characteristic.

30 Another aspect of the present invention provides a method of improving cereal plant productivity said method comprising introducing into said cereal plant or propagation

- 4 -

material thereof:

- 5 (i) an effective number of cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof; which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
- (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;
- 10 for a time and under conditions sufficient to induce, in the subject cereal plant, said characteristic.

Still another aspect of the present invention provides a method of improving plant productivity said method comprising introducing into said plant or propagation material

15 thereof:

- (i) an effective number of cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof; which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
- 20 (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;
- for a time and under conditions sufficient to induce, in the subject plant, growth promotion
- 25 and/or bio-control activity.

Yet still another aspect of the present invention provides a method of improving cereal plant productivity said method comprising introducing into said plant or propagation material

thereof:

30

- 5 -

(i) an effective number of endophytic actinomycetes of the genus *Microbispora*, *Streptomyces*, *Micromonospora*, Streptosporangiaceae, *Nocardiodes*, *Tsukamurella* or *Streptosporangium* or variants, mutants or homologues thereof; and/or

5 (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce, in the subject cereal plant, said characteristic.

10

Still yet another aspect of the present invention provides a method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:

15 (i) an effective number of cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof; which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or

(ii) an effective amount of one or more metabolites derived from the actinomycetes of (i)
20 or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce, in the subject cereal plant, said characteristic, wherein said actinomycete is selected from the list of:

25 (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30 (b) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence

- 6 -

capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 5 (c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (d) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (f) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30 (h) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C or a

- 7 -

variant, mutant or homologue of said actinomycete

- 5 (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of hybridising to <400>9 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (j) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (k) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable of hybridising to <400>11 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (l) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (m) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30 (n) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 8 -

- 5 (o) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (p) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (q) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (r) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (s) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30 (t) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 9 -

- (u) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5

- (v) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable of hybridising to <400>22 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10

- (w) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

- (x) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

- (y) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

25

- (z) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

- 10 -

(aa) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5

(ab) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>28 or a nucleotide sequence capable of hybridising to <400>28 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10

(ac) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>29 or a nucleotide sequence capable of hybridising to <400>29 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

(ad) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>30 or a nucleotide sequence capable of hybridising to <400>30 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

A further aspect of the present invention provides a method of improving cereal plant productivity said method comprising introducing into said cereal plant or propagation material thereof:

25 (i) an effective number of actinomycetes selected from EN2, EN3, EN5, EN6, EN7, EN9, EN16, EN17, EN19, EN23, EN26, EN27, EN28, EN35, EN39, EN46, EN57, EN60, SE1, SE2, PM36, PM40, PM41, PM87, PM144, PM171, PM185, PM208, PM228, PM252 AND PM342 or variants, mutants or homologues thereof; and/or

30 (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

- 11 -

for a time and under conditions sufficient to induce in the subject cereal plant bio-control activity.

5 Another further aspect of the present invention provides a method of improving cereal plant productivity said method comprising introducing into said cereal plant or propagation material thereof:

10 (i) an effective number of actinomycetes selected from EN2, EN3, EN6, EN9, EN16, EN27, EN57, EN60, SE1, SE2, PM87, PM185 and PM208 or variants, mutants or homologues thereof; and/or

15 (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce in the subject cereal plant growth promotion.

20 Still another further aspect of the present invention provides a method for improving cereal plant productivity said method comprising introducing into said cereal plant or propagation material thereof:

25 (i) an effective number of actinomycetes selected from EN2, EN3, EN9, EN16, EN23, EN27, EN28, EN35, EN46, EN57, EN60, SE1, SE2 and PM87 or variants, mutants or homologues thereof; and/or

(ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

30 for a time and under conditions sufficient to induce in a subject plant both growth promoting activity and bio-control activity.

- 12 -

In yet still another further aspect there is provided a method of improving cereal plant productivity said method comprising introducing into said cereal plant productivity said method comprising introducing into said cereal plant or propagation material thereof:

5

(i) an effective number of actinomycetes selected from EN2, EN3, EN5, EN16, EN17, EN19, EN23, EN27, EN28, EN35, EN46, EN57, PM36, PM40, PM41, PM87, PM110, PM119, PM144, PM171, PM185, PM208, PM228, PM252, PM342, SE1 and SE2 or variants, mutants or homologues thereof; and/or

10

(ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

15

for a time and under conditions sufficient to induce in the subject cereal plant bio-control activity.

Another aspect of the present invention is directed to a method of improving plant productivity said method comprising introducing into said plant or propagation materials thereof:

20

(i) an effective number of novel endophytic actinomycetes or variants, mutants or homologues thereof; and/or

(ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

25

for a time and under conditions sufficient to induce in the subject plant at least one characteristic of improved productivity.

30 Preferably, said novel endophytic actinomycete is selected from the list consisting of:

- 13 -

- (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

5

- (b) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

10

- (c) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

15

- (d) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

20

- (e) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

25

- (f) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

30

- 14 -

- (g) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

5

- (h) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

10

- (i) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

15

In yet another most preferred embodiment said actinomycete corresponds to EN2, EN3, EN16, EN23, EN27, EN28, EN46, EN60 or PM87.

20

In another preferred embodiment, said novel endophytic actinomycete is selected from the list consisting of:

- (a) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

25

- (b) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

30

- 15 -

- (c) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

5

- (d) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

10

- (e) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

15

- (f) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of hybridising to <400>9 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

20

- (g) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable of hybridising to <400>11 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

25

- (h) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

30

- 16 -

- (i) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

5

- (j) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

10

- (k) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

15

- (l) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

20

- (m) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

25

- (n) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable of hybridising to <400>22 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

30

- 17 -

- (o) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

5

- (p) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

10

- (q) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

15

- (r) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

20

- (s) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

25

- (t) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>28 or a nucleotide sequence capable of hybridising to <400>28 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

30

- 18 -

- (u) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>29 or a nucleotide sequence capable of hybridising to <400>29 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

5

In yet another aspect the present invention is directed to the cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof or metabolites derived therefrom or derivatives, homologues, analogues, chemical equivalents or mimetics thereof for use in the method of the present invention.

10

In yet still another aspect there is provided an agricultural composition comprising the endophytic actinomycetes hereinbefore described or metabolites derived therefrom together with one or more agriculturally acceptable carriers and/or diluents.

- 15 Another aspect of the present invention is directed to a novel, isolated plant-derived endophytic actinomycete or variant, mutant or homologue thereof.

More particularly, the present invention is directed to a novel, isolated cereal plant-derived endophytic actinomycete or variant, mutant or homologue thereof.

20

The present invention still more particularly provides a novel, isolated wheat plant-derived endophytic actinomycete or variant, mutant or homologue thereof.

- 25 In one aspect, the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 30 Preferably, the subject actinomycete corresponds to EN2 (AGAL Deposit No.NM03/35895).

- 19 -

In another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or
5 homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN3 (AGAL Deposit No. NM03/36501).

10 In yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

Preferably, the subject actinomycete corresponds to EN16 (AGAL Deposit No. NM03/35604).

In still another aspect the present invention provides an isolated actinomycete wherein said
20 actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

25 Preferably, the subject actinomycete corresponds to EN23 (AGAL Deposit No. NM03/35605).

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the
30 nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or

- 20 -

homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN27 (AGAL Deposit No. NM03/35606).

5

In still yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or

10 homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN28 (AGAL Deposit No. NM03/35607).

15 In yet another further aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

Preferably, the subject actinomycete corresponds to EN46 (AGAL Deposit No. NM03/35609).

In still another further aspect the present invention provides an isolated actinomycete
25 wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30 Preferably, the subject actinomycete corresponds to EN60 (AGAL Deposit No. NM03/35896).

- 21 -

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM87 (AGAL Deposit No. NM03/35608).

10

In another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

Preferably, the subject actinomycete corresponds to EN5.

In yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

25 Preferably, the subject actinomycete corresponds to EN6.

In still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

- 22 -

Preferably, the subject actinomycete corresponds to EN7.

In yet still another aspect the present invention provides an isolated actinomycete wherein
5 said actinomycete is characterised either by a nucleotide sequence corresponding to the
nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of
hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or
homologue of said actinomycete.

10 Preferably, the subject actinomycete corresponds to EN9.

In a further aspect the present invention provides an isolated actinomycete wherein said
actinomycete is characterised either by a nucleotide sequence corresponding to the
nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of
15 hybridising to <400>8 under low stringency conditions at 42°C or a variant, mutant or
homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN17.

20 In another further aspect the present invention provides an isolated actinomycete wherein
said actinomycete is characterised either by a nucleotide sequence corresponding to the
nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of
hybridising to <400>9 under low stringency conditions at 42°C or a variant, mutant or
homologue of said actinomycete.

25

Preferably, the subject actinomycete corresponds to EN19.

In yet another aspect the present invention provides an isolated actinomycete wherein said
actinomycete is characterised either by a nucleotide sequence corresponding to the
30 nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable
of hybridising to <400>11 under low stringency conditions at 42°C or a variant, mutant or

- 23 -

homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN26.

5 In still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10

Preferably, the subject actinomycete corresponds to EN35.

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the
15 nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

Preferably, the subject actinomycete corresponds to EN39.

In still yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or
25 homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN57.

In another aspect the present invention provides an isolated actinomycete wherein said
30 actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable

- 24 -

of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to SE1.

5

In yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or
10 homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to SE2.

In still another aspect the present invention provides an isolated actinomycete wherein said
15 actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20 Preferably, the subject actinomycete corresponds to PM36.

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable
25 of hybridising to <400>22 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM40.

30 In a further aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the

- 25 -

nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5 Preferably, the subject actinomycete corresponds to PM41.

In another further aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable
10 of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM87.

15 In still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

Preferably, the subject actinomycete corresponds to PM171.

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the
25 nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM185.

30

- 26 -

In still yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or
5 homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM208.

In another aspect the present invention provides an isolated actinomycete wherein said
10 actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>28 or a nucleotide sequence capable of hybridising to <400>28 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15 Preferably, the subject actinomycete corresponds to PM228.

In yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>29 or a nucleotide sequence capable
20 of hybridising to <400>29 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM252.

25 In still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>30 or a nucleotide sequence capable of hybridising to <400>30 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

Preferably, the subject actinomycete corresponds to PM342.

- 27 -

Yet another aspect of the present invention is directed to metabolites derived from the novel actinomycetes hereinbefore defined and derivatives, homologues, analogues, chemical equivalents, mutants and mimetics of said metabolites.

5

Yet another aspect of the present invention is directed to antibodies to the novel actinomycetes or metabolites hereinbefore defined or derivative, homologue, analogue, chemical equivalent, or mimetic of said antibody. Accordingly, still another aspect of the present invention is directed to the use of the novel actinomycetes hereinbefore defined and
10 metabolites derived therefrom in relation to therapeutic and prophylactic applications in respect of both medical purposes and for nay non-medical purpose sch as agricultural purposes.

15

- 28 -

BRIEF DESCRIPTION OF THE DRAWINGS

5 **Figure 1** is a graphical representation of the disease control levels of those isolates with statistically significant results in the field soil trial.

Figure 2 is a schematic representation of the primers used for complete 16S DNA sequencing.

10 **Figure 3** is a graphical representation of the grain yield compared to untreated control at Alford Site 2002 with Take-all disease. Red bars indicate statistically significant yield increases after analysis with ANOVA.

15 **Figure 4** is a graphical representation of the effect of actinomycete seed inoculation on height of wheat grown in soil infested with *Pythium irregulare*. Red bars indicate statistically significant yield increases ($P < 0.01$) after analysis with ANOVA

20 **Figure 5** is a graphical representation of the effect of actinomycete seed inoculation on germination and emergence of wheat grown in soil infested with *Pythium irregulare*. Red bars indicate statistically significant yield increases ($P < 0.01$) after analysis with ANOVA.

25 **Figure 6** is a graphical representation of the growth of wheat seeds inoculated with actinobacterial spores and an uninoculated control (+Py) in soil infested with *Pythium irregulare*. A control treatment with no disease or actinobacteria inoculation was also included (-Py).

30 **Figure 7** is a graphical representation of the growth of wheat seeds inoculated with actinobacterial spores and an uninoculated control (+Py) in soil infested with *Pythium irregulare*. A control treatment with no disease or actinobacteria inoculation was also included (-Py). The plants were grown at 21°C instead of 12°C. Growth was measured as dry weight of the root or shoot.

- 29 -

Figure 8 is a schematic representation of neighbour-joining phylogenetic tree of the full 16S rDNA sequences from selected isolates. The sequence data for several closely related actinobacterial type cultures were recovered from GenBank and included in the tree. The
5 accession numbers for the sequences are: *Bacillus subtilis* NC_000964 (Region: 9809..11361), *Microbispora amethystogenes* U48988, *Nocardioides albus* X53211, *S. scabies* D63862; *S. galilaeus* AB045878; *S. argenteolus* AB045872; *S. setonii* D63872; *S. caviscabies* AF112160, *Streptosporangiaceae* str. PA147 AF223347. The bootstrap values from 5000 pseudo-replications are shown at each of the branch points on the tree.

Figure 9 is a graphical representation of the relative density of aphids on plants treated with endophytes.

Figure 10 is an image of *egfp*-expressing *Streptomyces* sp. EN27 under the LSCM at 1800x
15 magnification.

Figure 11 is an image of *egfp*-expressing *Streptomyces* sp. EN27 in a 24h old wheat embryo. Figure 11.1 shows the image under blue excitation/green emission, figure 6.2 shows the image under UV excitation/blue emission. Figure 11.3 shows an image enhanced
20 merge of the two images, 11.1 shown in green, while 11.2 is shown in red. All images are at 400x magnification. EM-embryonic wheat tissue, EN27-*egfp* expressing endophytic actinomycete (colour image available upon request).

Figure 12 is an image of *egfp*-expressing *Streptomyces* sp. EN27 microcolonies in 3 day old
25 wheat embryo tissue (plumule). Figure 12.1 shows the image under blue excitation/green emission, figure 12.2 shows the image under UV excitation/blue emission. Figure 12.3 shows an image enhanced merge of the two images, 12.1 shown in green, while 12.2 is shown in red. All images are at 400x magnification. EM-embryonic wheat tissue, EN27-*egfp*-expressing endophytic actinomycete (colour image available upon request).

- 30 -

Figure 13 is an image of *egfp*-expressing *Streptomyces* sp. EN27 microcolony in the emerging radicle. Figure 13.1 shows the image under blue excitation/green emission, figure 13.2 shows the image under UV excitation/blue emission. Figure 13.3 shows an image enhanced merge of the two images, 13.1 shown in green, while 13.2 is shown in red. All
5 images are at 200x magnification. RA-radicle, EN27-*egfp*-expressing endophytic actinomycete (colour image available upon request).

Figure 14 is an image of *egfp*-expressing *Streptomyces* sp. EN27 microcolonies in the endosperm after 3 days. Figure 14.1 shows the image under blue excitation/green emission,
10 figure 14.2 shows the image under UV excitation/blue emission. Figure 14.3 shows an image enhanced merge of the two images, 14.1 shown in green, while 14.2 is shown in red. All images are at 200x magnification. AL-aleurone, ES-endosperm, PE-pericarp, EN27-*egfp*-expressing endophytic actinomycete (colour image available upon request).

15 **Figure 15** is a schematic representation of the sequences of actinomycete isolates EN2, EN3, EN16, EN23, EN27, EN28, EN46, EN60, PM87.

Figure 16 is a schematic representation of the sequences of actinomycete isolates EN5, EN6, EN7, EN9, EN17, EN19, EN26, EN35, EN39, EN57.

20

Figure 17 is a schematic representation of the sequences of actinomycete isolates SE1 and SE2.

Figure 18 is a schematic representation of the sequences of actinomycete isolates PM36,
25 PM40, PM41, PM144, PM171, PM185, PM208, PM228, PM252, PM342.

Figure 19 is a schematic representation of the sequences of actinomycete isolates EN4, EN10, EN22, EN30, EN43, EN47 and EN59.

- 31 -

It should be understood that in each of Figures 15-18, and the sequence listing attached herewith, "n" is an unknown nucleotide and, in accordance with IUB notation, "m" is adenine or cytosine, "k" is guanine or thymine and "w" is adenine or thymine.

5 **Figure 20** is a graphical representation of indole acetic acid production.

Figure 21 is a graphical representation showing T-RFLP HnfI profiles for the roots of wheat grown from (a) uninoculated seed, (b) *Microbispora* sp. EN2 inoculated seed, (c) *Streptomyces* sp. EN27 inoculated seed and (c) *Nocardioides albus* EN46 inoculated seed.

10 The highlighted peaks correspond to the specific fragment of the actinobacterial endophyte inoculated onto the seed.

- 32 -

DETAILED DESCRIPTION OF THE INVENTION

The present invention is predicated, in part, on the surprising and unexpected determination:

- 5 (i) that a proportion of wheat plants are, in fact, colonised by actinomycete species which are either novel or else were not previously known to exhibit the capacity to exist in an endophytic relationship; and
- 10 (ii) that only some of these wheat plant endophytic actinomycetes also function as modulators of improved plant productivity and provide growth promotion advantages (such as improved seed germination) and/or bio-control advantages to that plant, which advantages are not seen in wheat plants lacking the subject endophytic actinomycetes.
- 15 This has now led to the development of methodology which facilitates the routine cultivation of plants, in particular cereal crops, which exhibit growth productivity advantages due to introduction into the plant a population of actinomycetes and/or their metabolites which have been identified by the inventors, in accordance with the present invention, to both form an endophytic relationship with the plant and provide the above-
- 20 identified productivity advantages.

Accordingly, one aspect of the present invention is directed to a method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:

- 25 (i) an effective number of cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof; which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
- 30 (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

- 33 -

for a time and under conditions sufficient to induce, in the subject plant, said characteristic.

Reference to a "plant" should be understood as a reference to any naturally or non-naturally
5 occurring plant in respect of which improved productivity is sought. For example, flowering
crops, cereal crops (eg. wheat, barley, rye, triticale maize, oats, canary seed, sorghum, millet
and rice) and horticultural crops (eg. tomatoes, onion, potato, peanut, chickpea, pea, lentil,
mung bean, faba bean, canola, linola, mustard, sunflower, safflower, soybean, lupins and
cotton). By "non-naturally" is meant that the subject plant has undergone some form of
10 manipulation of modification prior to treatment in accordance with the method of the present
invention. Examples of manipulation include, but are not limited to, genetic modification of
a plant or treatment of a seedling or propagating material with an extraneous proteinaceous
or non-proteinaceous molecule such as *Bacillus thuringiensis* toxin, genes for provitamin A
synthesis, genes for vitamin E synthesis, protease inhibitors or genes for virus coat proteins.
15 Although some manipulations, such as genetic modification, may lead to the improvement
of a productivity characteristic, such modification may be of limited value due to its
improvement of only some of the desired productivity characteristics. For example, where a
genetic modification is introduced to provide a plant with certain bio-control characteristics,
the subject plant may still not exhibit other desirable productivity characteristics such as
20 improved plant vigour or yield. In this case, these latter productivity improvements can be
achieved by treating the genetically modified plant in accordance with the method of the
present invention to induce early plant vigour or increased yield, for example. The non-
naturally occurring plant may be derived from any source. For example, to the extent that
the non-naturally occurring plant is one which is genetically modified, the plant may be one
25 which has itself undergone genetic modification or it may have been cultivated from a seed
which has undergone genetic modification. Alternatively, the plant may be derived from a
seed which itself was itself derived from a genetically modified plant. Preferably, the plant
is a cereal crop and even more particularly a wheat crop, barley crop, maize, triticale, rye,
oats, canary, sorghum, millet or rice.

- 34 -

Reference to "propagation material" should be understood as a reference to any type of cellular material from which a plant would germinate or otherwise arise. Examples of propagating material include, but are not limited to, a seed, cutting, cell suspension, callus culture, tissue culture, protocorm, explants or germplasm. The propagating material may
5 take any suitable form. For example, it may have been freshly harvested or it may be derived from a stock sample, such as a seed sample or a frozen stock of cells.

Accordingly, the present invention more particularly provides a method of improving cereal plant productivity said method comprising introducing into said cereal plant or propagation
10 material thereof:

- (i) an effective number of cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof; which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
15
- (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce, in the subject cereal plant, said
20 characteristic.

Preferably, said cereal plant is a wheat plant, barley, maize, triticale, rye, oats, canary, sorghum, millet or rice plant.

25 Reference to "metabolite" should be understood as a reference to any proteinaceous or non-proteinaceous molecule produced by the subject endophytic actinomycetes or produced by the plant in response to the actinomycete colonisation or actinomycete metabolite actions which directly or indirectly modulate the metabolism or other functional activity of the host plant. It should be understood, for example, that a molecule which functions as a bio-
30 control agent is an example of a metabolite which is functioning indirectly since it acts to down-regulate or otherwise inhibit the detrimental actions of a pathogen, which pathogenic

- 35 -

activity would otherwise adversely affect the viability/health of the host plant. An example of a metabolite which functions directly is a molecule which acts directly on a host plant cell to upregulate its proliferation and/or differentiation, for example thereby providing a growth promoting activity such as promotion of germination. Examples of such metabolites
5 includes, but is not limited to, auxins, gibberellins, cytokinins, indole acetic acid and kinetin.

Reference to "improving plant productivity" should be understood as a reference to achieving a level of productivity in treated plants which is greater than the level of productivity which would be observed in untreated plants. By "productivity" is meant any
10 aspect of the subject plant's development. For example, reference to productivity includes, but is not limited to, growth promotion characteristics such as rate of growth, plant vigour, yield of flower/fruit/grain, health or viability of crop (for example due to reduction in the application of fertilisers and/or chemical pesticides, increased nutrient uptake, increased systemic resistance or herbicidal resistance) and improved seed germination or bio-control
15 characteristics such as those which lead to reduction in disease by decreasing susceptibility to infection by pathogens and/or increasing clearance of existing infections. Reference to "improving" productivity should be understood to include either:

- (i) inducing a given productivity characteristic to occur at a level or degree which is
20 greater than that which would be observed in a corresponding, healthy plant which is not treated according to the method of the present invention. An example of this occurring would be the induction of increased yield due to the synthesis of metabolites by the endophytic actinomycetes which facilitate yield production at a level greater than that which is normally observed or the induction of bio-control
25 characteristics which are not normally exhibited by the subject plant; and/or
- (ii) facilitating the induction of a given characteristic at a level or degree which one would normally expect to occur in a corresponding healthy, untreated plant but which characteristic is not observed due to extraneous, unexpected or abnormal
30 events. For example, inducing a normal level of vigour in plants which are cultivated in poor quality soils and could not otherwise achieve a normal level of

- 36 -

vigour or providing a plant with bio-control characteristics which enables a normal rate of plant development to thereby occur despite the presence of pathogenic microorganisms which would usually adversely affect the rate of development in a corresponding untreated plant.

5

Reference to a "characteristic related to improved productivity" should therefore be understood to mean any feature which directly or indirectly contributes to a plant's overall productivity. Preferably, the subject characteristic is growth promotion and/or bio-control activity.

10

Accordingly, in a preferred embodiment there is provided a method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:

15

(i) an effective number of cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof; which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or

20

(ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce, in the subject plant, growth promotion and/or bio-control activity.

25

Preferably said plant is a cereal crop and even more preferably a wheat plant or a barley plant.

30

By "facilitate" is meant that the subject endophytic actinomycete metabolite or metabolites either directly or indirectly induces occurrence of the subject characteristic. For example, in relation to the induction of bio-control characteristics, the endophytic actinomycete may secrete an expression product which is itself directly toxic to a given pathogen.

- 37 -

Alternatively, the endophytic actinomycete may secrete an expression product which acts on the host plant to signal/induce the subject plant to synthesise an expression product which is toxic or inhibitory to the pathogen of interest. The former scenario is an example of a direct relationship while the latter is an example of an indirect relationship.

5

The present invention is predicated on the surprising determination that some wheat plants are host to endophytic actinomycete species and that some of these species in fact facilitate the induction of one or more characteristics of improved productivity. Accordingly, by "cereal plant-derived endophytic actinomycete" is meant a species of actinomycete which can be found in a cereal plant (although not necessarily all cereal plants), and in particular in wheat plants, and which actinomycetes exhibit the functional activity of facilitating the induction of at least one characteristic of improved productivity. Reference to "facilitating induction of at least one characteristic related to improved productivity" should be understood to have the same meaning as hereinbefore provided. It should also be understood that the subject actinomycete may be isolated from any suitable source and, in accordance with the present invention, is not necessarily required to be isolated specifically from cereal crops. For example, an actinomycete species of interest may be sourced from any naturally or non-naturally occurring source. It should also be understood that any reference herein to a particular species should also be understood to include reference to a related species.

20

Preferably, the subject cereal plant-derived endophytic actinomycete is an actinomycete species of the genus *Microbispora*, *Streptomyces*, *Micromonospora*, *Streptosporangiaceae*, *Nocardiodes*, *Tsukamurella* or *Streptosporangium*.

25

Accordingly, in a more preferred embodiment there is provided a method of improving cereal plant productivity said method comprising introducing into said plant or propagation material thereof:

30

- (i) an effective number of endophytic actinomycetes of the genus *Microbispora*, *Streptomyces*, *Micromonospora*, *Streptosporangiaceae*, *Nocardiodes*, *Tsukamurella* or

- 38 -

Streptosporangium or variants, mutants or homologues thereof; and/or

- (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

5

for a time and under conditions sufficient to induce, in the subject cereal plant, said characteristic.

In a more preferred embodiment, where the endophytic actinomycete is of the genus
10 *Streptomyces*, said *Streptomyces* is of the species *triticum*, *caviscabies*, *setonii*, *galilaeus*,
peuceticus, *bikiniensis*, *fimbriatus*, *pseudovenezuelae*, *argenteolus*, *platensis*, *griseus*,
lincolnensis or related species.

In another preferred embodiment, where the endophytic actinomycete is of the genus
15 *Micromonospora* said *Micromonospora* is of the species *peucetica*, *fulvoviolaceus*,
yulongensis or related species.

In yet another preferred embodiment, where the endophytic actinomycete is of the genus
Nocardiodes said *Nocardiodes* is of the species *fulvus*, *flavus*, *luteus*, *albus* or related
20 species.

In still another preferred embodiment, where the endophytic actinomycete is of the genus
Microbispora, said *Microbispora* is of the species *amethystogenes* or related species.

25 In yet another preferred embodiment, where the endophytic actinomycete is of the genus
Tsukamurella, said *Tsukamurella* is of the species *tyrosinovorans-D1498*, *IM-7430*,
pulmonis or related species.

In still another preferred embodiment, where the endophytic actinomycete is of the genus
30 *Streptomycetaceae*, said *Streptomycetaceae* is of the species *SR11* or related species.

- 39 -

In still yet another preferred embodiment, where the endophytic actinomycete is of the species *Streptosporangium*, said *Streptosporangium* is of the genus *cinnabarium* or related species.

- 5 In work leading up to the present invention, the inventors identified cereal plant-derived endophytic actinomycetes which are functional, in terms of growth productivity, in plants. These actinomycete isolates have been deposited and are identified herein by reference to an "EN", "SE", "PM" or "SC" numeral.
- 10 Without limiting the present invention to any one theory or mode of action, the inventors have characterised the subject actinomycetes based on their 16S rDNA sequences and have determined that EN2, EN3, EN5, EN6, EN7, EN9, EN16, EN17, EN19, EN23, EN26, EN27, EN28, EN35, EN39, EN46, EN57, EN60, SE1, SE2, PM36, PM40, PM41, PM87, PM144, PM171, PM185, PM208, PM228, PM252 AND PM342 correspond to previously
- 15 unidentified species of actinomycete. The actinomycete isolates described herein are thought to correspond to the actinomycete species as listed below:
- (a) Actinomycete isolates EN19, EN23, EN27, EN28, EN35, EN57, EN87, SE1, SE2, PM36, PM40, PM41, PM87, PM110, PM119, PM171, PM228 and PM252
- 20 correspond to *Streptomyces triticum* species.
- (b) Actinomycete isolates EN5, EN16, EN17, PM144, PM185, PM208 and PM342 correspond to *Streptomyces triticum* var. *griseoviside*.
- 25 (c) Actinomycete isolate EN46 corresponds to *Nocardioides* species and is closely related to *Nocardioides albus*.
- (d) Actinomycete isolates EN3 and EN39 corresponds to *Streptomyces galilaeus*.
- 30 (e) Actinomycete isolate EN60 corresponds to a new species related to *Streptomyces argenteolus*.

- 40 -

- (f) Actinomycete isolate EN2 corresponds to a novel *Microbispora* species.
- (g) Actinomycete isolate EN6 corresponds to a novel species related to *Streptomyces*
5 *pseudovenezuelae*.
- (h) Actinomycete isolate EN7 is related to *Streptomyces lincolnesis*.
- (i) Actinomycete isolate EN9 is related to *Streptomyces bikiniensis*.
10
- (j) Actinomycete isolate EN26 is a novel *Streptomyces* species.

More specifically, and still without limiting the present invention in any way:

- 15 (a) EN2 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>1.
- (b) EN3 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>2.
- 20 (c) EN5 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>3.
- (d) EN6 is thought to correspond to a population of actinomycetes comprising the rDNA
25 sequence substantially as set forth in <400>4.
- (e) EN7 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>5.
- 30 (f) EN9 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>6.

- 41 -

- (g) EN16 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>7.
- 5 (h) EN17 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>8.
- (i) EN19 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>9.
- 10 (j) EN23 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>10.
- (k) EN26 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>11.
- 15 (l) EN27 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>12.
- 20 (m) EN28 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>13.
- (n) EN35 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>14.
- 25 (o) EN39 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>15.
- (p) EN46 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>16.
- 30

- 42 -

- (q) EN57 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>17.
- 5 (r) EN60 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>18.
- (s) SE1 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>19.
- 10 (t) SE2 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>20.
- (u) PM36 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>21.
- 15 (v) PM40 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>22.
- (w) PM41 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>23.
- 20 (x) PM87 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>24.
- 25 (y) PM171 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>25.
- (z) PM185 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>26.

- 43 -

- (aa) PM208 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>27.
- (ab) PM228 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>28.
- (ac) PM252 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>29.
- (ad) PM342 is thought to correspond to a population of actinomycetes comprising the rDNA sequence substantially as set forth in <400>30.

Accordingly, in a preferred embodiment the present invention provides a method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:

- (i) an effective number of cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof; which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
- (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce, in the subject cereal plant, said characteristic, wherein said actinomycete is selected from the list of:

- (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 44 -

- (b) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5

- (c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10

- (d) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

- (e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

- (f) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

25

- (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

- 45 -

- 5
- (h) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete
- 10
- (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of hybridising to <400>9 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15
- (j) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20
- (k) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable of hybridising to <400>11 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25
- (l) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30
- (m) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 46 -

- 5
- (n) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10
- (o) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15
- (p) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20
- (q) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25
- (r) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30
- (s) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 47 -

- 5
- (t) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10
- (u) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15
- (v) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable of hybridising to <400>22 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20
- (w) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25
- (x) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30
- (y) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 48 -

- (z) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5

- (aa) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10

- (ab) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>28 or a nucleotide sequence capable of hybridising to <400>28 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

- (ac) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>29 or a nucleotide sequence capable of hybridising to <400>29 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

- (ad) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>30 or a nucleotide sequence capable of hybridising to <400>30 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

25

Preferably, the subject actinomycete is characterised by a nucleotide sequence which has at least about 45% similarity to all or part of the nucleotide sequence indicated by the nucleotide sequence identification numbers detailed above. More preferably, said similarity is 50%, still more preferably 55%, even more preferably 60%, still more preferably 65%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96.5%, 97%, 97.5%, 98%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%,

30

- 49 -

99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or higher.

In accordance with the preceding embodiments and aspect of the invention, still more preferably:

5

(i) In one embodiment, the actinomycete is characterized by a nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence with at least 95% identity thereto and wherein said isolate is not *Streptomyces caviscabies* or *Streptomyces setonii*.

10

(ii) In another preferred embodiment, the actinomycete is characterized by a nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence with at least 95% identity thereto and wherein the actinomycete is classified as *Streptomyces triticum* as defined in Example 3.

15

(iii) In another embodiment, the actinomycete comprises the spore coloration of any one of isolates EN19, EN27, EN35, EN57, EN28, SE1, SE2, PM40, PM41, PM228, PM36, PM87, PM252 or PM 171 as set forth in Table 4.

20

(iv) In another embodiment, the actinomycete comprises the carbohydrate utilization of any one of isolates EN19, EN27, EN35, EN57, EN28, SE1, SE2, PM40, PM41, PM228, PM36, PM87, PM252 or PM 171 as set forth in Table 4.

25

(v) In a particularly preferred embodiment, the actinomycete is able to utilize sucrose as a sole carbon source.

30

(vi) In a yet another embodiment, the actinomycete comprises the soluble pigmentation profile of any one of isolates EN19, EN27, EN35, EN57, EN28, SE1, SE2, PM40, PM41, PM228, PM36, PM87, PM252 or PM 171 as set forth in Table 5.

- 50 -

- (vii) In a particularly preferred embodiment, the actinomycete produces a light brown, brown, dark brown or black pigment on either ISP5 or ISP7 media. In a yet more preferred embodiment, the actinomycete is able to produce melanin.
- 5 (viii) In a yet another embodiment, the actinomycete comprises the biochemical analysis profile of any one of isolates EN19, EN27, EN35, EN57, EN28, SE1, SE2, PM40, PM41, PM228, PM36, PM87, PM252 or PM 171 as set forth in Table 5.
- 10 (ix) In another preferred embodiment, the actinomycete is characterized by a nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence with at least 95% identity thereto and wherein the actinomycete may be classified as a *Streptomyces triticum* var. *griseoviride* as defined in Example 3.
- 15 (x) In one embodiment, the actinomycete comprises the spore coloration of any one of isolates EN16, EN17, PM144, PM185, PM208, PM342 as set forth in Table 6.
- (xi) In another embodiment, the actinomycete comprises the carbohydrate utilization of any one of isolates EN16, EN17, PM144, PM185, PM208, PM342 as set forth in Table 6.
- 20 (xii) In a particularly preferred embodiment, the actinomycete is able to utilize sucrose as a sole carbon source.
- (xiii) In a yet another embodiment, the actinomycete comprises the soluble pigmentation profile of any one of isolates EN16, EN17, PM144, PM185, PM208, PM342 as set forth in Table 7.
- 25 (xiv) In a yet another embodiment, the actinomycete comprises the biochemical analysis profile of any one of isolates EN16, EN17, PM144, PM185, PM208, PM342 as set forth in Table 7.
- 30

- 51 -

Reference to "at least 95%" or "more than 95%" identity includes reference to at least 95%, 95.1%, 95.2%, 95.3%, 95.4%, 95.5%, 95.6%, 95.7%, 95.8%, 95.9%, 96%, 96.1%, 96.2%, 96.3%, 96.4%, 96.5%, 96.6%, 96.7%, 96.8%, 96.9%, 97%, 97.1%, 97.2%, 97.3%, 97.4%, 97.5%, 97.6%, 97.7%, 97.8%, 97.9%, 98%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%,
 5 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.9% and 100%.

Most preferably, the subject actinomycete is selected from the following list of isolates:

10	(a)	EN2	(b)	EN3	(c)	EN5	(d)	EN6
	(e)	EN7	(f)	EN9	(g)	EN16	(h)	EN17
	(i)	EN19	(j)	EN23	(k)	EN26	(l)	EN27
	(m)	EN28	(n)	EN35	(o)	EN39	(p)	EN46
	(q)	EN57	(r)	EN60	(s)	SE1	(t)	SE2
15	(u)	PM36	(v)	PM40	(w)	PM41	(x)	PM87
	(y)	PM144	(z)	PM171	(aa)	PM185	(ab)	PM208
	(ac)	PM228	(ad)	PM252	(ae)	PM342		

Reference to the subject actinomycete being "characterised" by the subject nucleotide
 20 sequence should be understood to mean that the subject nucleotide sequence forms part of the nucleic acid composition of the actinomycete. The subject nucleotide sequence may be located at any intracellular location such as on the actinomycete chromosome or at a non-chromosomal location, such as the ribosome. Preferably, the nucleotide sequence comprises part of the gene encoding the 16S species of the small sub-unit of the actinomycetes
 25 ribosomal RNA.

Reference herein to a low stringency includes and encompasses from at least about 0% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions.
 30 Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about

- 52 -

30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for
5 hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions. Stringency may be measured using a range of temperature such as from about 40EC to about 65EC. Particularly useful stringency conditions are at 42EC. In general, washing is carried out at $T_m = 69.3 + 0.41 (G + C) \% [19] = -121^{\circ}\text{C}$. However, the T_m of a duplex DNA decreases by 11C with every increase of 1% in the number of mismatched based pairs
10 (Bonner *et al* (1973) *J.Mol.Biol*, 81:123).

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids
15 that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. The percentage similarity may be greater than 50% such as at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
20 94%, 95%, 96%, 97%, 98%, 99% or higher.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences may be aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a
25 second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions can then be compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of
30 identical positions shared by the sequences (i.e. % identity = # of identical positions/total # of overlapping positions x 100). Preferably, the two sequences are the same length. The

- 53 -

determination of percent identity or homology between two sequences can be accomplished using a mathematical algorithm. A suitable, mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

In another preferred embodiment, the subject stringency conditions are moderate and in yet another preferred embodiment are high.

A "variant" or "mutant" of the subject actinomycete should be understood to mean a microorganism which exhibits at least some of the functional activity of the actinomycete of which it is a variant or mutant. The variation or mutation characterising such an actinomycete may take any form including a genetic or a non-genetic variation or mutation. The subject variation or mutation may be naturally or non-naturally occurring. By

- 54 -

"homologue" is meant that the microorganism utilised in the method of the present invention is of a species or genera other than that defined. This may occur, for example, where it is determined that an actinomycete of another species exhibits the same functional characteristics and colonisation properties as the actinomycete of interest.

5

Derivatives of the metabolite defined herein include fragments, parts, portions, mutants, variants and mimetics from natural, synthetic or recombinant sources including fusion proteins. Parts or fragments include, for example, active regions of the metabolite.

Derivatives may be derived from insertion, deletion or substitution of amino acids. Amino acid insertional derivatives include amino and/or carboxylic terminal fusions as well as intrasequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterised by the removal of one or more amino acids from the sequence. Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. An example of substitutional amino acid variants are conservative amino acid substitutions. Conservative amino acid substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. Additions to amino acid sequences including fusions with other peptides, polypeptides or proteins.

Reference to "derivatives" of metabolites also includes reference to small molecular weight, non-peptide, organic compound molecules.

Chemical and functional equivalents of the metabolite should be understood as molecules exhibiting any one or more of the functional activities of the metabolite and may be derived from any source such as being chemically synthesized or identified via screening processes such as natural product screening.

- 55 -

Derivatives of the metabolite include fragments having particular epitopes or parts of the entire metabolite fused to peptides, polypeptides or other proteinaceous or non-proteinaceous molecules.

- 5 Analogues of the metabolite contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecules or their analogues.
- 10 Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of
- 15 amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

- 20 The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

- 25 Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-
- 30 nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

- 56 -

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

5

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carboethoxylation with diethylpyrocarbonate.

10 Examples of incorporating unnatural amino acids and derivatives during protein synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid contemplated herein is shown in Table 1.

- 57 -

TABLE 1

5	Non-conventional amino acid	Code	Non-conventional amino acid	Code
	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
10	carboxylate		L-N-methylaspartic acid	Nmasp
	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl-	Norb	L-N-methylglutamine	Nmgln
	carboxylate		L-N-methylglutamic acid	Nmglu
	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
15	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Das	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
20	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
25	D-lysine	Dlys	L-N-methylthreonine	Nmthr
	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
30	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib

- 58 -

	D-valine	Dval	α -methyl- -aminobutyrate	Mgab
	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
5	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
10	D- α -methyllleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methylllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
15	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
20	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
25	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl))glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl))glycine	Nhis
30	D-N-methyllleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methylllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen

- 59 -

	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
5	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
10	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylassparagine	Masn
	L- α -methylasspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
15	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
20	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe
25	N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
	carbamylmethyl)glycine		carbamylmethyl)glycine	
	1-carboxy-1-(2,2-diphenyl-Nmbc			
	ethylamino)cyclopropan			

- 60 -

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having $(CH_2)_n$ spacer groups with $n=1$ to $n=6$, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety.

Actinomycetes may be introduced to the plant or its propagation material by any suitable means. It should be understood that reference to "actinomycete" includes reference to both the bacterium itself, the spore of the bacterium or the mycelium of the bacterium. Examples of means by which actinomycetes can be introduced to the plant include, but are not limited to:

- (i) treatment of seeds with a spore or mycelial or cellular preparation of the actinomycete of interest.
- (ii) treatment of seeds with the actinomycete derived metabolite of interest.
- (iii) treatment of plants with the spore or bacterial preparation of the actinomycete of interest.
- (iv) treatment of plants with the actinomycete derived metabolite of interest.
- (v) treatment of seeds with actinomycete, or actinomycetes, of interest, together with actinomycete derived metabolite or metabolites of interest.
- (vi) incorporation into soil of the actinomycete or actinomycetes of interest as a bacterial suspension either at the time of sowing, or prior to or after sowing.
- (vii) incorporation into soil of the actinomycete-derived metabolites of interest as a solution or suspensions either at the time of sowing, or prior to or after

- 61 -

sowing.

(viii) incorporation into soil of the actinomycete or actinomycetes of interest as a bacterial suspensions, together with actinomycete-derived metabolite or metabolites of interest, either at the time of sowing, or prior to, or after sowing.

(ix) incorporation into soil of the actinomycete or actinomycetes of interest as a powder or pellet adjacent to the seed either at the time of sowing, or prior to, or after sowing.

(x) incorporation into soil of the actinomycete derived metabolite or metabolites of interest as a powder or pellet adjacent to the seed either at the time of sowing or prior to, or after sowing.

(xi) incorporation into soil of the actinomycete or actinomycetes of interest, together with actinomycete-derived metabolite or metabolites of interest, as a powder or pellet adjacent to the seed either at the time of sowing, or prior to, or after sowing.

It is within the skill of the person of skill in the art to determine both the most appropriate time point (in terms of crop cultivation) at which to apply the method of the present invention and the most suitable means of introducing the subject actinomycete to the plant in terms of both route of administration and appropriate formulation of actinomycete or metabolite thereof. For example, where the treatment is intended to be utilised as a prophylactic bio-control agent it may be most appropriate to pre-treat seeds prior to germination, planting and cultivation. However, where it is desired to utilise the present invention in order to minimise the detrimental impact of an existing pathogenic infection, it may be necessary to treat the plant itself.

- 62 -

Reference to "effective number" or "effective amount" means that number or amount necessary to at least partly attain the desired effect (for example growth promoting activity or bio-control activity), or to delay the onset of, inhibit the progression of, or halt altogether the onset or progression of the particular agricultural condition being
5 treated. Such amounts will depend, of course, on the particular situation, the severity of the condition (for example the severity of infection or likely infection or the severity of growth related defects) and the individual crop parameters including its physical condition, stage of germination and any other concurrent treatments which are being applied (such as other bio-control agents or fertilisers). These factors are
10 well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that an optimum dose of actinomycete formulation be used, that is, the highest safe dose according to sound agricultural judgment. It will be understood by those of ordinary skill in the art, however, that a lower dose or tolerable dose may be administered for any other
15 reason.

Without limiting the invention to any one theory or mode of action, it is thought that the actinomycetes of the present invention will establish an endophytic existence within the root system of the subject plant. However, it should nevertheless be
20 understood that endophytic bacteria are known to coexist with the plant at other locations such as in the leaves or stems.

The inventors have determined that the endophytic actinomycetes disclosed herein exhibit one or more functional activities which lead to improvement in the
25 productivity of the plant with which an endophytic relationship has been established. In particular, the inventors have determined that the actinomycete isolates defined as EN2, EN3, EN9, EN16, EN17, EN19, EN23, EN26, EN27, EN28, EN35, EN39, EN46, EN57, EN60, SE1 and PM87 function as bio-control agents. Further, the inventors have determined that the pathogens in respect of which bio-control is
30 provided include *Gaeumannomyces graminis* var. *tritici*, *Pythium* spp. and *Rhizoctonia solani*, *Fusarium* sp., aphids and a range of insect and nematode pests.

- 63 -

The inventors have also determined that actinomycete isolates EN2, EN3, EN6, EN9, EN16, EN27, EN57, EN60, SE1, SE2, PM87, PM185 and PM208 induce growth promotion activity and, in particular, induce germination promotion. Finally, it has been determined that EN2, EN3, EN9, EN16, EN23, EN27, EN28, EN35, EN46, EN57, EN60, SE1, SE2 and PM87 exhibit both growth promotion and bio-control activity. Still further, it has been determined that some of the actinomycete strains detailed herein produce high levels of the plant growth hormone indole acetic acid while some strains induce genes related to Induced Systemic Resistance in plants. Without limiting the present invention in any way some of the strains disclosed herein exhibit both properties.

Accordingly, in a most preferred embodiment there is provided a method of improving cereal plant productivity said method comprising introducing into said cereal plant or propagation material thereof:

- (i) an effective number of actinomycetes selected from EN2, EN3, EN5, EN6, EN7, EN9, EN16, EN17, EN19, EN23, EN26, EN27, EN28, EN35, EN39, EN46, EN57, EN60, SE1, SE2, PM36, PM40, PM41, PM87, PM144, PM171, PM185, PM208, PM228, PM252 AND PM342 or variants, mutants or homologues thereof; and/or
 - (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;
- for a time and under conditions sufficient to induce in the subject cereal plant bio-control activity.

Preferably, said bio-control activity is bio-control in relation to *Gaeumannomyces graminis* var. *tritici*, *Pythium* spp., *Rhizoctonia solani* or *Fusarium* sp.

- 64 -

In another most preferred embodiment there is provided the method of improving cereal plant productivity said method comprising introducing into said cereal plant or propagation material thereof:

- 5 (i) an effective number of actinomycetes selected from EN2, EN3, EN6, EN9, EN16, EN27, EN57, EN60, SE1, SE2, PM87, PM185 and PM208 or variants, mutants or homologues thereof; and/or
- (ii) an effective amount of one or more metabolites derived from the
10 actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce in the subject cereal plant growth promotion.

15

Preferably, said growth promotion is early growth vigour, grain yield increases and/or germination promotion.

In still yet another most preferred embodiment there is provided the method for
20 improving cereal plant productivity said method comprising introducing into said cereal plant or propagation material thereof:

- (i) an effective number of actinomycetes selected from EN2, EN3, EN9, EN16, EN23, EN27, EN28, EN35, EN46, EN57, EN60, SE1, SE2 and PM87 or
25 variants, mutants or homologues thereof; and/or
- (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

30

for a time and under conditions sufficient to induce in a subject plant both growth

- 65 -

promoting activity and bio-control activity.

In yet another most preferred embodiment there is provided a method of improving cereal plant productivity said method comprising introducing into said cereal plant
5 productivity said method comprising introducing into said cereal plant or propagation material thereof:

- (iii) an effective number of actinomycetes selected from EN2, EN3, EN5, EN16, EN17, EN19, EN23, EN27, EN28, EN35, EN46, EN57, PM36, PM40, PM41, PM87, PM110, PM119, PM144, PM171, PM185, PM208, PM228, PM252, PM342, SE1 and SE2 or variants, mutants or homologues thereof; and/or
10
- (iv) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;
15

for a time and under conditions sufficient to induce in the subject cereal plant bio-control activity.

20 Preferably said bio-control activity is bio-control in relation to aphids.

In accordance with these preferred embodiments, said cereal plant is preferably wheat, barley, maize, rye, triticale, oats, canary seed, sorghum, millet or rice.

25 As detailed hereinbefore, the inventors of the present invention have isolated several novel species of endophytic actinomycetes.

Accordingly, another aspect of the present invention is directed to a method of improving plant productivity said method comprising introducing into said plant or
30 propagation materials thereof:

- 66 -

- (i) an effective number of novel endophytic actinomycetes or variants, mutants or homologues thereof; and/or
- (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;

for a time and under conditions sufficient to induce in the subject plant at least one characteristic of improved productivity.

10

Preferably, said novel endophytic actinomycete is selected from the list consisting of:

- (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- (b) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- (c) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- (d) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

- 67 -

- 5 (e) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 10 (f) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 15 (g) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 20 (h) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 25 (i) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

In yet another most preferred embodiment said actinomycete corresponds to EN2, EN3, EN16, EN23, EN27, EN28, EN46, EN60 or PM87.

- 30 In another preferred embodiment, said novel endophytic actinomycete is selected from the list consisting of:

- 68 -

- 5 (a) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 10 (b) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 15 (c) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 20 (d) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 25 (e) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 30 (f) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of hybridising to <400>9 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

- 69 -

- 5
- (g) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable of hybridising to <400>11 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 10
- (h) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 15
- (i) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 20
- (j) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 25
- (k) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 30
- (l) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

- 70 -

- 5
- (v) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 10
- (w) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable of hybridising to <400>22 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 15
- (x) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 20
- (y) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 25
- (z) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.
- 30
- (aa) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

- 71 -

(bb) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

5

(cc) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>28 or a nucleotide sequence capable of hybridising to <400>28 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

10

(dd) An actinomycete characterised either by nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>29 or a nucleotide sequence capable of hybridising to <400>29 under low stringency conditions at 42°C or a variant, mutant or homologue thereof.

15

Preferably, the subject actinomycete is characterised by a nucleotide sequence which has at least 45% similarity to all or part of the nucleotide sequence indicated by the nucleotide sequence identification numbers detailed above. More preferably, said similarity is 50%, still more preferably 55%, even more preferably 60%, still more preferably 65%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96.5%, 97%, 97.5%, 98%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or higher.

20

In accordance with the preceding embodiments and aspect of the invention, still more preferably:

25

(i) In one embodiment, the actinomycete is characterized by a nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence with at least 95% identity thereto and wherein said isolate is not *Streptomyces caviscabies* or *Streptomyces setonii*.

30

- 72 -

- (ii) In another preferred embodiment, the actinomycete is characterized by a nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence with at least 95% identity thereto and wherein the actinomycete is classified as *Streptomyces triticum* as defined in Example 3.
- 5
- (iii) In another embodiment, the actinomycete comprises the spore coloration of any one of isolates EN19, EN27, EN35, EN57, EN28, SE1, SE2, PM40, PM41, PM228, PM36, PM87, PM252 or PM 171 as set forth in Table 4.
- 10
- (iv) In another embodiment, the actinomycete comprises the carbohydrate utilization of any one of isolates EN19, EN27, EN35, EN57, EN28, SE1, SE2, PM40, PM41, PM228, PM36, PM87, PM252 or PM 171 as set forth in Table 4.
- 15
- (v) In a particularly preferred embodiment, the actinomycete is able to utilize sucrose as a sole carbon source.
- (vi) In a yet another embodiment, the actinomycete comprises the soluble pigmentation profile of any one of isolates EN19, EN27, EN35, EN57, EN28, SE1, SE2, PM40, PM41, PM228, PM36, PM87, PM252 or PM 171 as set forth in Table 5.
- 20
- (vii) In a particularly preferred embodiment, the actinomycete produces a light brown, brown, dark brown or black pigment on either ISP5 or ISP7 media. In a yet more preferred embodiment, the actinomycete is able to produce melanin.
- 25
- (viii) In a yet another embodiment, the actinomycete comprises the biochemical analysis profile of any one of isolates EN19, EN27, EN35, EN57, EN28, SE1, SE2, PM40, PM41, PM228, PM36, PM87, PM252 or PM 171 as set forth in Table 5.
- 30

- 73 -

- (ix) In another preferred embodiment, the actinomycete is characterized by a nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence with at least 95% identity thereto and wherein the actinomycete may be classified as a *Streptomyces triticum* var. *griseoviride* as defined in Example 3.
- (x) In one embodiment, the actinomycete comprises the spore coloration of any one of isolates EN16, EN17, PM144, PM185, PM208, PM342 as set forth in Table 6.
- (xi) In another embodiment, the actinomycete comprises the carbohydrate utilization of any one of isolates EN16, EN17, PM144, PM185, PM208, PM342 as set forth in Table 6.
- (xii) In a particularly preferred embodiment, the actinomycete is able to utilize sucrose as a sole carbon source.
- (xiii) In a yet another embodiment, the actinomycete comprises the soluble pigmentation profile of any one of isolates EN16, EN17, PM144, PM185, PM208, PM342 as set forth in Table 7.
- (xiv) In a yet another embodiment, the actinomycete comprises the biochemical analysis profile of any one of isolates EN16, EN17, PM144, PM185, PM208, PM342 as set forth in Table 7.

Reference to "at least 95%" or "more than 95%" identity includes reference to at least 95%, 96%, 97%, 98%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.9% and 100%.

- 74 -

In yet another most preferred embodiment, said actinomycete corresponds to EN5, EN6, EN7, EN9, EN17, EN19, EN26, EN35, EN39, EN57, SE1, SE2, PM36, PM40, PM41, PM171, PM185, PM208, PM228, PM252, PM342 or PM144.

5 As described hereinbefore, although the preferred aspects of the present invention are to introduce a single species of actinomycete into a plant in order to achieve productivity improvements, the present invention also encompasses the administration of two or more species of actinomycete into any given plant. In this regard, the inventors have determined that particularly effective actinomycete
10 combinations for use in the method of the present invention include:

(i) EN2 and EN9 and EN23

(ii) EN9 and EN27 and EN28

15

(ii) EN39 and EN46

However, it should be understood that the method of the present invention extends to any other suitable combination of actinomycetes, which combination can be
20 identified without undue experimentation based on the teachings provided herein.

In still yet another aspect the present invention is directed to the cereal plant-derived endophytic actinomycetes or variants, mutants or homologues thereof or metabolites derived therefrom or derivatives, homologues, analogues, chemical equivalents or
25 mimetics thereof for use in the method of the present invention.

In yet still another aspect there is provided an agricultural composition comprising the endophytic actinomycetes hereinbefore described or metabolites derived therefrom together with one or more agriculturally acceptable carriers and/or
30 diluents. Preparation of said agricultural compositions would be known to those of skill in the art.

- 75 -

As detailed hereinbefore, the inventors have surprisingly identified novel species of actinomycetes, which actinomycetes were identified due to their co-existence in an endophytic relationship with cereal plants, such as wheat plants. These
5 actinomycetes, and the metabolites produced therefrom, are useful in a range of applications including, but not limited to, agricultural applications (such as growth promotion or bio-control activity), biodegradation and therapeutic or prophylactic medical treatments for animals or humans.

10 Accordingly, another aspect of the present invention is directed to a novel, isolated plant-derived endophytic actinomycete or variant, mutant or homologue thereof.

More particularly, the present invention is directed to a novel, isolated cereal plant-derived endophytic actinomycete or variant, mutant or homologue thereof.

15

Reference to "plant" and "cereal plant-derived endophytic actinomycete" should be understood to have the same meaning as hereinbefore defined. In this regard, the subject cereal plant is preferably a wheat plant.

20 Accordingly, the present invention still more particularly provides a novel, isolated wheat plant-derived endophytic actinomycete or variant, mutant or homologue thereof.

It should be understood that the isolated actinomycete according to this aspect of the
25 present invention is defined as "endophytic" on the basis that in appropriate circumstances, it can co-exist with a plant in an endophytic relationship. However, it should be understood that the subject actinomycete may exhibit a range of characteristics including, *inter alia*, the ability to exist in the rhizosphere. Further, although the actinomycete may exhibit the ability to co-exist in an endophytic
30 relationship with a cereal plant, it may be that such co-existence is only possible with some members of a particular family of plants but not all members. This may be

- 76 -

due, for example, to characteristics which are inherent in the host plant.

It should also be understood that although the novel actinomycete is defined by reference to it being "plant-derived", this is a reference merely to the fact that these
5 novel actinomycetes have been identified in the defined plant, but not that the isolated actinomycetes falling within the scope of this invention are necessarily isolated directly from a plant. For example, it may be that the subject actinomycetes, although originally identified in a cereal plant, are isolated from ongoing *in vitro* cell cultures. Alternatively, it may be that the subject actinomycetes are also found in
10 non-plant sources, such as in the rhizosphere, and can be isolated from these non-plant sources.

By "isolated" is meant that the actinomycete has undergone at least one step of purification from a biological source. Preferably, the actinomycete is also pure
15 meaning that a composition comprises at least about 20%, more preferably at least about 40%, still more preferably at least about 65%, even still more preferably at least about 80-90% or greater of the actinomycete as determined by weight, activity or other convenient means, relative to other compounds in the composition.

20 The inventors have characterised the subject actinomycetes based on their 16S rDNA sequences and have determined that the actinomycetes comprising isolates EN2, EN3, EN5, EN6, EN7, EN9, EN16, EN17, EN19, EN23, EN26, EN27, EN28, EN35, EN39, EN46, EN57, EN60, SE1, SE2, PM36, PM40, PM41, PM87, PM144, PM171, PM185, PM208, PM228, PM252 and PM342 correspond to previously unidentified
25 species of actinomycetes. These isolates correspond to populations of actinomycetes comprising the rDNA sequence substantially as set forth in the nucleic acid sequences detailed earlier.

Accordingly, in one aspect, the present invention provides an isolated actinomycete
30 wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a

- 77 -

nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN2 (AGAL Deposit
5 No.NM03/35895).

Without limiting the present invention to any one theory or mode of action, EN2 is thought to correspond to a new species of *Microbispora*.

10 In another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15 Preferably, the subject actinomycete corresponds to EN3 (AGAL Deposit No. NM03/36501).

Without limiting the present invention to any one theory or mode of action, EN3 is
20 thought to correspond to a novel *Streptomyces* species.

In yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence
25 capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN16 (AGAL Deposit No. NM03/35604).

30

- 78 -

Without limiting the present invention to any one theory or mode of action, EN16 is thought to correspond to a new species termed *Streptomyces triticum* var *griseoviride*.

5 In still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10

Preferably, the subject actinomycete corresponds to EN23 (AGAL Deposit No. NM03/35605).

Without limiting the present invention to any one theory or mode of action, EN23 is
15 thought to correspond to a new species termed *Streptomyces triticum*.

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a
20 nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN27 (AGAL Deposit No. NM03/35606).

25

Without limiting the present invention to any one theory or mode of action, EN27 is thought to correspond to a new species termed *Streptomyces triticum*.

In still yet another aspect the present invention provides an isolated actinomycete
30 wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a

- 79 -

nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN28 (AGAL Deposit No.
5 NM03/35607).

Without limiting the present invention to any one theory or mode of action, EN28 is thought to correspond to a new species termed *Streptomyces triticum*.

10 In yet another further aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15 Preferably, the subject actinomycete corresponds to EN46 (AGAL Deposit No. NM03/35609).

Without limiting the present invention to any one theory or mode of action, EN46 is
20 thought to correspond to *Nocardioides albus*.

In still another further aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a
25 nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN60 (AGAL Deposit No. NM03/35896).

30 Without limiting the present invention to any one theory or mode of action, EN60 is

- 80 -

thought to correspond to a novel species related to *Streptomyces argenteolus*.

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence
5 corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM87 (AGAL Deposit No.
10 NM03/35608).

Without limiting the present invention to any one theory or mode of action, PM87 is thought to correspond to a new species termed *Streptomyces triticum*.

15 In another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

Preferably, the subject actinomycete corresponds to EN5.

In yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to
25 the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN6.

30

In still another aspect the present invention provides an isolated actinomycete

- 81 -

wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5

Preferably, the subject actinomycete corresponds to EN7.

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence
10 corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN9.

15

In a further aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C or a
20 variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN17.

In another further aspect the present invention provides an isolated actinomycete
25 wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of hybridising to <400>9 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30 Preferably, the subject actinomycete corresponds to EN19.

- 82 -

In yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable of hybridising to <400>11 under low stringency conditions at 42°C
5 or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN26.

In still another aspect the present invention provides an isolated actinomycete
10 wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15 Preferably, the subject actinomycete corresponds to EN35.

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a
20 nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to EN39.

25 In still yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

Preferably, the subject actinomycete corresponds to EN57.

- 83 -

In another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide
5 sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to SE1.

10 In yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

Preferably, the subject actinomycete corresponds to SE2.

In still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence
20 corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM36.

25

In yet still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable of hybridising to <400>22 under low stringency
30 conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 84 -

Preferably, the subject actinomycete corresponds to PM40.

In a further aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to
5 the nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM41.

10

In still another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency
15 conditions at 42°C or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM171.

In yet still another aspect the present invention provides an isolated actinomycete
20 wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

25 Preferably, the subject actinomycete corresponds to PM185.

In still yet another aspect the present invention provides an isolated actinomycete wherein said actinomycete is characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a
30 nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 85 -

Preferably, the subject actinomycete corresponds to PM208.

In another aspect the present invention provides an isolated actinomycete wherein
5 said actinomycete is characterised either by a nucleotide sequence corresponding to
the nucleotide sequence substantially as set forth in <400>28 or a nucleotide
sequence capable of hybridising to <400>28 under low stringency conditions at 42°C
or a variant, mutant or homologue of said actinomycete.

10 Preferably, the subject actinomycete corresponds to PM228.

In yet another aspect the present invention provides an isolated actinomycete wherein
said actinomycete is characterised either by a nucleotide sequence corresponding to
the nucleotide sequence substantially as set forth in <400>29 or a nucleotide
15 sequence capable of hybridising to <400>29 under low stringency conditions at 42°C
or a variant, mutant or homologue of said actinomycete.

Preferably, the subject actinomycete corresponds to PM252.

20 In still another aspect the present invention provides an isolated actinomycete
wherein said actinomycete is characterised either by a nucleotide sequence
corresponding to the nucleotide sequence substantially as set forth in <400>30 or a
nucleotide sequence capable of hybridising to <400>30 under low stringency
conditions at 42°C or a variant, mutant or homologue of said actinomycete.

25

Preferably, the subject actinomycete corresponds to PM342.

Reference to the subject actinomycete being "characterised" by the subject nucleotide
sequence should be understood to have the same meaning as hereinbefore defined.

30 Similarly, reference herein to "low stringency conditions" has also been previously
defined. "Variants", "mutant" and "homologue", when defined in terms of

- 86 -

actinomycetes, has also been previously defined.

Yet another aspect of the present invention is directed to metabolites derived from the novel actinomycetes hereinbefore defined and derivatives, homologues,
5 analogues, chemical equivalents, mutants and mimetics of said metabolites.

Reference to "metabolite" and "derivatives, homologues, analogues, chemical equivalents, mutants and mimetics" has the same meaning as hereinbefore provided.

10 Yet another aspect of the present invention is directed to antibodies to the novel actinomycetes or metabolites hereinbefore defined or derivative, homologue, analogue, chemical equivalent, or mimetic of said antibody. Antibodies may be utilised, *inter alia*, to screen for the subject actinomycetes or to function as an antagonistic agent to the functional activity of the subject actinomycetes. Antibodies
15 may also be directed to metabolites produced by the novel actinomycetes hereinbefore defined. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies or may be specifically raised. In the case of the latter, an antibody may be raised to the actinomycete in its active or attenuated form or it may be raised to an antigen or epitope isolated from said
20 actinomycete. To the extent that an antigen or epitope is utilised, it may first require association with a carrier molecule. Alternatively, fragments of antibodies may be used such as Fab fragments. Furthermore, the present invention extends to recombinant and synthetic antibodies and antibody hybrids. A "synthetic antibody" is considered herein to include fragments and hybrids of antibodies.

25

The identification of novel actinomycetes of the present invention, and the metabolites derived therefrom, now facilitates the development of both agricultural and medical applications. For example, the novel actinomycetes of the present invention and metabolites derived therefrom are particularly useful, but in no way
30 limited to:

- 87 -

- (i) improving plant productivity by, *inter alia*, providing the subject plant with bio-control capabilities and up-regulating growth promoting activities.
- (ii) facilitating biodegradation of non-degraded or only partially degraded organic or inorganic material (herein referred to as "biodegradable material").
- (v) medical/therapeutic applications by the use of metabolites as medicine to treat diseases in humans and animals.
- 10 (iv) use of metabolites for agricultural application.
- (v) use of actinomycete as an agent for the introduction of genetic material to plants, plant tissues or plant cell culture.
- 15 (vi) use of actinomycete as a microbial partner to enhance phytoremediation.

Accordingly, still another aspect of the present invention is directed to the use of the novel actinomycetes hereinbefore defined and metabolites derived therefrom in relation to therapeutic and prophylactic applications in respect of both medical
20 purposes and for nay non-medical purpose sch as agricultural purposes.

The present invention is further defined by the following non-limiting Figures and/or Examples.

- 88 -

EXAMPLE 1

ENDOPHYTIC ACTINOMYCETE ISOLATION

5 *Sampling and isolation*

Plants from 9 fields from three major wheat growing regions in South Australia were sampled at 6-7 week intervals across the growing season. The sites sampled on the Eyre Peninsula were Tuckey, Lock, Yabmana and Yabmana*. Yabmana* was adopted as a sample site at the 11 week sampling when it was observed that the crop in this field was particularly vigorous. These sample sites were characterised by sandy alkaline soils and relatively low rainfall (Tuckey, rainfall = 330 mm/year). The sites sampled in the South-East region were Bool Lagoon, Struan and Wolseley. These were characterised by cracking clay soils and higher rainfall. The sites sampled in the mid-North region were Avon and Wild Horse Plains. These were of a loamy earth type soil. Avon was chosen as a sample site as this soil has shown to be suppressive to *Rhizoctonia* root rot of wheat and Take-all (Ggt) (Roget *et. al*, 1999). These plants were used for endophyte isolation using protocol

Endophyte isolation from root tissue

20 Wheat plants were left to air dry for 48 hours before being thoroughly washed to remove all soil from the root mass. The roots were then excised and the shoots discarded. The roots were then subjected to a three-step surface sterilisation procedure. This involved a 60 second wash in 99% ethanol, followed by a 6 minute wash in 3.125% NaOCl, followed by a 30 second wash in 99% ethanol and then a final rinse in sterile RO water. Some of these fragments were then rapidly dipped in 100% ethanol and flamed, then placed onto the plate. These surface-sterilised roots were then aseptically sectioned into 1cm long fragments and plated onto the isolation media as shown in section 1.4 below, and incubated at 27°C for 4 weeks.

- 89 -

Endophyte Isolation from seed

A method for the isolation of endophytes from wheat seeds was developed. After surface sterilising the seeds (with a 60 second wash in 99% ethanol, followed by a 6 minute wash in 3.125% NaOCl, followed by a 30 second wash in 99% ethanol and then a final rinse in
5 sterile RO water) each individual seed was sliced aseptically into 5 slices. These seed slices were placed onto the isolation media, as shown below. The slices were left for 4 weeks at 27 C for any endophytes to appear.

Isolation media

10 Several isolation media were used throughout the experiment, the recipes are given below. For each plant, root fragments were plated onto the following isolation media. All plant fragments were plated onto TWYE and HV, YCED, FYSC and FCC. All media were supplemented with BenlateR (active ingredient Benomyl) at 50mg/l to control fungal contamination.

15

Tap Water Yeast Extract medium (TWYE) per litre of tap water: Yeast Extract 0.25g, K₂HPO₄ 0.5 g, Agar 18.0 g. Adjust pH to 7.2.

Humic acid Vitamin B medium (HV) per litre RO water: Humic Acid 1.0 g in 10ml, 0.2M
20 NaOH, Na₂HPO₄ 0.5 g, KCl 1.71 g, MgSO₄·7H₂O 0.05g FeSO₄·7H₂O 0.01 g, CaCO₃ 0.2 g, Agar 18.0 g, Vitamin B solution (100x) 10.0 ml after autoclave. Adjust pH to 10.0.

Vitamin B solution (100x) per 100 ml RO water: Thyamine hydrochloride 5 mg, Riboflavin 5 mg, Niacin 5 mg, Pyridoxine hydrochloride 5 mg, Inositol 5 mg, Calcium
25 pantothenate 5 mg, Para-amino benzoic acid 25 mg, Biotin 25 mg. Adjust pH to 4.5 and filter sterilise.

Yeast Extract Casamino Acids medium (YCED) per litre RO water: Yeast Extract 0.3 g, Casamino Acids 0.3 g, D-Glucose 0.3 g, K₂HPO₄ 2.0 g, Agar 18.0 g. Adjust pH to 7.2.

30

- 90 -

Flour Yeast Extract Sucrose Casein Hydrolysate medium (FYSC) per litre RO water:
Plain Flour 6g, Yeast Extract 0.3 g, Casein Hydrolysate 0.3 g, Calcium Carbonate 0.3 g,
Sucrose 0.3 g, Agar 18 g. Adjust pH to 7.2.

- 5 *Flour Calcium Carbonate medium* (FCC) per litre of RO water: Plain Flour 4 g, Calcium carbonate 0.4 g, Agar 16 g. Adjust pH to 7.2

All media were autoclaved for 15 min at 121°C.

10

EXAMPLE 2

ACTINOMYCETE CHARACTERISATION USING PARTIAL 16S rDNA SEQUENCING

15 METHODOLOGY

DNA Extraction from actinomycetes

For each isolate to be extracted, a loopful of mycelium and spores were scraped from solid growth media and suspended in 400ul of saline-EDTA (0.15M NaCl, 0.1M EDTA pH 8.0)
20 by vortexing. To this, 10ul of lysozyme was added which was then incubated at 37°C for 45 minutes. Following this, 10 ul of 1%(w/v) proteinase K and 10ul of 25% SDS was added followed by incubation at 55°C for 30 min. A further 10ul of 25% SDS was added and the tubes were re-incubated at 55°C for 30 minutes. The tubes were then centrifuged at 10000rpm for 5 mins in a microcentrifuge to pellet the cell debris, and the supernatant was
25 transferred to a new tube. An equal volume of TE-equilibrated phenol was added to the supernatant, and mixed. The phases were then separated by centrifugation, and the upper aqueous layer transferred to a new tube. The aqueous layer was then extracted with an equal volume of chloroform and mixed, and again the phases separated by centrifugation. Again the upper aqueous layer was transferred to a new tube. To this 2 volumes of ice cold
30 ethanol was added and mixed. The tubes were then held overnight at 4°C, to allow precipitation of the DNA. The precipitate was pelleted by centrifugation (10000 rpm, 5

- 91 -

minutes), and resuspended in 70% ethanol. The suspension was pelleted by centrifugation as above and the supernatant was removed. The pellet was then left to air-dry in the laminar flow hood before being re-suspended in 20ul of sterile RO water. This solution was purified using a prep-a-gene kit (BioRad) according to the manufacturers instructions, with 10ul of DNA binding matrix. This kit is used to purify, concentrate and desalt the DNA to make it suitable for PCR. This kit involves the use of a DNA binding matrix. The matrix, with bound DNA is then washed using ethanol and iso-propyl alcohol to remove contaminants. The DNA is then eluted from the matrix with water. The extracts were stored at -20°C .

Partial 16S rDNA sequencing

DNA for 16S rDNA sequencing was prepared for each actinomycete. The primers for this PCR reaction were "universal" 16S rDNA primers and should amplify the 16S gene for any bacteria. The primers are designed to amplify a region between position 27 and 765 of the 16S rRNA gene (based on *E. coli* base numbering) in actinomycetes, and should yield a PCR product of approximately 738bp long. The primers are designated 27f (5' AGAGTTTGATCMTGGCTCAG) (<400>31) (where M is adenine or cytosine) and 765r (CTGTTTGCTCCCCACGCTTTC) (<400>32). PCR reactions were done in 100ul reaction volumes with the following reagents: 27f (200ng. μl^{-1}) 4 ul, 765r (200ng. μl^{-1}) 4ul, 5x taq buffer (5% 40mM dNTP's, 40% 25mM MgCl, 50% 10x PCR buffer, 5% water) 20 ul, water 67 ul, Taq polymerase (2U. μl^{-1}) 1ul, template DNA 4ul. The reactions were run using the following profile: 94°C - 8mins, (94°C - 1 min, 45°C - 1 min, 72°C - 2 min) x 30 cycles, 45°C - 1 min, 72°C - 10 min.

The PCR products were purified using the protocol "Preparation of PCR products for sequencing", detailed herein. The products were sequenced using a Hewlett Packard automated sequencer and the 765r primer. The products were sequenced undiluted from the Wizard kit and the primer was supplied at 22ng. μl^{-1} (3.2 picomole. μl^{-1}). The sequences obtained were compared to online databases using BLAST (Altschul *et al.*, 1997) on the National Centre for Biotechnology Information (NCBI) website (www.ncbi.nlm.nih.gov).

- 92 -

The standard blastn (nucleotide-nucleotide) algorithm was used with the default settings. The three highest match coefficients by the bit score were entered into the table.

Full rDNA sequencing of those endophytic actinomycetes with bio-control or growth promotion activity

The isolates that showed activity in the growth promotion and/or bio-control assays were chosen for detailed characterisation using full 16S rDNA sequencing.

DNA for 16S sequencing was prepared for the selected isolates using the protocol "DNA isolation and purification from actinomycetes", detailed hereinbefore. The 27 to 1492 region of the 16S gene was amplified using the 27f (5' AGAGTTTGATCMTGGCTCAG) (<400>31) (where M is adenine or cytosine) and the 1492r (5' TACGGYTACCTTGTTACGACTT) (<400>33) (where Y is cytosine or thymine) primers. The reaction profile was identical for the amplification of the 27-765 region of the 16S gene. The resultant 1465 bp PCR product was purified using the protocol "Preparation of PCR products for sequencing" detailed hereinbefore, and sent for sequencing.

To allow sequencing of the complete PCR product, four sequencing primers were needed, as automated sequencing reads only up to 500bp of sequence. These primers, and their sequences are given below.

Primer label	Sequence
27f	5' AGAGTTTGATCMTGGCTCAG <400>32
765r	5' CTGTTTGCTCCCCACGCTTTC <400>33
704f	5' GTAGCGGTGAAATGCGTAGA <400>35
1492r	5' TACGGYTACCTTGTTACGACTT <400>34

The 27f primer is used to read from position 27 to 500 of the gene, 765r reads from 765 back to approximately base 200, the 704f reads from position 704 to approximately 1200, while the 1492r primer reads from 1492 back to approximately position 1000 of the gene. This is summarised in figure 2.

- 93 -

Due to the reverse primers reading from the 'minus' strand of the 16S rDNA gene, these sequences had to be reverse complemented, ie. read from back to front and as a complement, to make them read in the same strand and orientation as the forward primers.

- 5 Once this was done, the four fragments were then aligned using the parts of the sequence that overlap between each fragment to assemble the complete sequence from position 27 to 1492 (based on *E. coli* numbering). The final complete sequence was then submitted to a BLAST search and the matches recorded.

10 *Agarose gel electrophoresis*

- All DNA samples were analysed using agarose gel electrophoresis. 2% agarose in 0.5x TBE were used in all cases. Gels were run in 0.5x TBE buffer at 90V. DNA samples were prepared for electrophoresis by mixing 5ul of sample with 1ul of agarose gel loading buffer. Samples were then loaded with the gel submerged in ½TBE in the gel tank. Once
15 run, gels were stained for 20-30 minutes in ethidium bromide, then destained in water for 15-30 minutes. DNA in the gels was visualised using a UV transilluminator and a Tractel image capture system.

Preparation of PCR products for sequencing

- 20 PCR products were prepared for sequencing using a Promega Wizard PCR prep kit. The manufacturer-supplied protocols 'Direct purification of PCR amplifications' and 'Purification using a vacuum manifold' were followed before sending the samples to an automated sequencing facility. As with the prep-a-gene kit described in "DNA extraction and purification from actinomycetes", this kit also uses a DNA binding resin, which
25 preferentially binds DNA fragments in the 200-2000bp range. The PCR reaction reagents, the genomic DNA and the primers are then washed away using iso-propyl alcohol. The DNA is then eluted from the DNA-binding resin using water.

- 94 -

RESULTS

Sequencing results

5 Table 2 shows the full 16S rDNA sequence matches of selected isolates with bio-control or growth promotion activity. The bit score indicates both the length and accuracy of the sequence match, while the percentage describes the accuracy of the match.

Table 3 shows the actinomycete identification summary of a second batch of actinomycete
10 isolates.

EXAMPLE 3

STREPTOMYCES triticum

15 **Description of *Streptomyces triticum* gen nov. sp. nov**

This description relates members of the major group consisting of endophytic actinobacterial strains EN19, EN23, EN 27, EN 28, EN 35, EN57, SE 1, SE 2, PM36, PM40, PM41, PM 87, PM110, PM119, PM171, PM228 and PM252.

20

Streptomyces triticum gen nov. sp. nov. is a saprophytic actinobacteria, with endophytic capabilities. These members of this genus were isolated from surface-sterilised tissue of healthy wheat and barley plants. The healthy cereal samples were collected from 12 different districts within the South Australian cereal belt.

25

The spores are smooth and cylindrical and attached end to end with a diameter of 0.4 um and length of 0.8-1.4 um. The colony characteristics on the International Streptomyces Project media include production of white to cream spores and a dark soluble pigment on International Streptomyces Project Medium (ISP) 2. On ISP 3, the spores were white in
30 colour, and the strains have variable pigmentation, which was either colourless, cream or brown. On ISP 4 the strains belonging to this new species produced spores that were

- 95 -

mostly white in colour with either no soluble pigment or a light brown colour. On ISP 5 and ISP 7 the isolates showed the presence of melanin production with spore colour varying between brown to black or white. Nutrient agar showed no pigment formation and all isolates had white spores.

5

All strains belonging to this species showed glucose assimilation. The isolates did not utilise inositol, cellulose, dulcitol, rhamnose or arabinose. Of the other carbohydrate tested, the isolates showed variable utilization. All isolates showed hydrolysis of starch, gelatin and urea. The isolates showed variable H₂S production, nitrate reduction, and
10 peptonisation and coagulation of milk. All isolates were inhibited by concentrations of streptomycin ranging from 1-1.5 µg/ml. All isolates had a minimum pH tolerance of between pH 3-4, and a maximum salt tolerance of between 6-8%. The optimum temperature for growth was 27°C with no growth seen at 45°C for any of the strains belonging to *Streptomyces triticum*.

15

Description of *Streptomyces triticum* var. *griseoviride* gen nov. sp. nov

This description relates to the minor variants which are melanin-negative consisting of strains EN5, EN 16, EN 17, PM 144, PM 185, PM 208 and PM 342.

20

Streptomyces triticum var. *griseoviride* gen nov. sp. nov. is a saprophytic actinobacteria, with endophytic capabilities. These strains were isolated from surface-sterilised tissue of healthy wheat and barley plants. The healthy cereal samples were collected from 12 different districts within the South Australian cereal belt.

25

The spores are smooth and cylindrical and attached end to end with a diameter of 0.4 µm and length of 0.8-1.4 µm. The colony characteristics on the International Streptomyces Project media include production of white/cream, grey or green spores and no soluble pigment on International Streptomyces Project Medium (ISP) 2. On ISP 3, the spores were
30 white or green in colour, and the isolates had no soluble pigmentation. On ISP 4 the strains belonging to this new species produced spores that were white or grey in colour with either

- 96 -

no soluble pigment or a light brown colour. On ISP 5 and ISP 7 some of the isolates showed the presence of a light brown soluble pigment with spore colour varying between white or grey or green. Nutrient agar showed no pigment formation and all isolates had white spores.

5

All strains belonging to this species showed glucose assimilation. The isolates did not utilise cellulose, dulcitol, rhamnose or arabinose. One isolate showed utilisation of inositol and raffinose. Of the other carbohydrate tested, the isolates showed variable utilization. All isolates showed hydrolysis of starch and gelatin. The majority of the isolates showed no
10 H₂S production or peptonisation of milk, but displayed nitrate reduction, and a variable utilization of urea and coagulation of milk. All isolates were inhibited by a 1µg/ml concentration of streptomycin, and had a minimum pH tolerance of between pH 5, and a maximum salt tolerance of between 6-9%. The optimum temperature for growth was 27°C with no growth seen at 45°C for any of the isolates belonging to this variant of
15 *Streptomyces triticum*.

Comparison with the nearest matching type strains

The members of the new genus *Streptomyces triticum*, including variants, showed
20 significant differences with the 2 type cultures that showed the closest match on the basis of their 16S rDNA gene sequences; These were *Streptomyces caviscabies* (ATCC 51928), *Streptomyces setonii* (ATCC 25497). Differences between the type cultures and the isolates that belong to *Streptomyces triticum* gen. nov. sp. nov. are stated below.

- 25 • In comparison to both type strains the members of *Streptomyces triticum* gen. nov. sp. nov. showed less than a 98% similarity in the sequence of their 16S rDNA genes, indicating that they belong to a new species. For example, the percentage similarity either of the full gene sequence (denoted with a *) or the partial gene sequence is, for EN 27* (94%), EN 28* (96%), EN 35* (97%), SE 1* (95%), SE
30 2* (97%), PM 40 (93%), PM 41 (96%), PM 36 (95%), PM 87 (94%), PM 171(93%), PM 228 (96%), PM 252 (92%). For the strains belonging to the variant

- 97 -

Streptomyces triticum var. *griseoviride* gen. nov. sp. nov. the percentage similarity is, for EN16* (95%), EN 17 (90%), PM 144 (97%), PM 185 (98%), PM 208 (95%) and PM 342 (96%)

- 5 • *Streptomyces caviscabies* (ATCC 51928) did not show any variation in its spore colour on the various ISP media, whereas the majority of the endophytic isolates belonging to *Streptomyces triticum* or *Streptomyces triticum* var. *griseoviride* had different spore colour on some of the media. Also, there was no significant soluble pigment produced by *Streptomyces caviscabies* (ATCC 51928). In contrast to this
10 type culture the majority of the endophytic isolates belonging to *Streptomyces triticum* displayed some pigment production, and all displayed melanin production. This indicates a significant difference between the endophytic isolates and the type culture. The melanin-negative isolates of the variant *Streptomyces triticum* var. *griseoviride* differed in the morphological characteristics seen on ISP 2, 4 and 7
15 that were observed with the *Streptomyces caviscabies* (ATCC 51928).
- *Streptomyces setonii* (ATCC 25497) had similar morphological characteristics and carbohydrate utilization properties as *Streptomyces caviscabies* (ATCC51928). There were some differences in biochemical properties, but none of these were
20 identical to strains belonging to *Streptomyces triticum* or its variant.

Streptomyces caviscabies (ATCC 51928) and *Streptomyces setonii* (ATCC 25497) type cultures had similar carbohydrate utilization patterns. When compared to the type cultures of *Streptomyces caviscabies* (ATCC 51928) and *Streptomyces setonii* (ATCC 25497), the
25 *Streptomyces triticum* strains and variant strains had significant differences in their carbohydrate utilization from these two type cultures.

Table 4 shows the characterisation of isolates belonging to *Streptomyces triticum* gen nov. sp.nov. - spore coloration on International Streptomyces Project media, and carbohydrate
30 utilization

- 98 -

Table 5 shows the characterisation of isolates belonging to *Streptomyces triticum* gen nov. sp.nov. - soluble pigmentation and biochemical analysis.

Table 6 shows the characterisation of isolates belonging to *Streptomyces triticum* var. griseoviride gen nov. sp.nov. - spore coloration on International Streptomyces Project media, and carbohydrate utilization and comparison with nearest matching type.

Table 7 shows the characterisation of isolates belonging to *Streptomyces triticum* var. griseoviride gen nov. sp.nov. - soluble pigmentation and biochemical analysis and comparison with nearest matching type.

EXAMPLE 4

APPLICATION OF ENDOPHYTIC ACTINOBACTERIA FOR THE CONTROL OF CEREAL DISEASES (GLASSHOUSE TRIALS)

15

Further work investigated the application of endophytic actinobacteria for the control of other cereal diseases, such as *Pythium* damping-off, in glasshouse trials.

These trials yielded significant results with several actinobacterial endophyte strains giving almost complete symptom control on wheat. It is encouraging to discover that the most effective strains for the control of *Pythium* were in general the same strains belonging to the *Str. triticum* species that were effective for the control of Take-all. Therefore, the commercial development of at least one of these strains may have application as a broad-spectrum biofungicide for the control of several diseases. To validate this finding, the trials were repeated a further 3 times, yielding similar results (Figs 4 and 5).

Wheat seeds inoculated with actinobacterial spores and an uninoculated control (+Py) were grown in soil infested with *Pythium irregulare*. A control treatment with no disease or actinobacteria inoculation was also included (-Py) (Figure 6).

30

- 99 -

In the absence of actinobacteria inoculant (+Py) and for 3 of the actinobacteria inoculated treatments (EN17, EN19, EN26), no plants emerged during the duration of the experiment (6 weeks). Where no disease was present (-Py) or seed was inoculated with spores of 2 actinobacterial strains (EN 23, EN28) the wheat seeds were able to emerge and grow.

5

In a second experiment the plants were grown at 21°C instead of 12 °C . At this temperature, the effects of the disease weren't as drastic, however, there were highly significant effects on emergence and growth of the wheat. Root and shoot growth and plant emergence for wheat inoculated with the actinobacterias EN27 and EN28 were significantly higher (P, 0.05) than all other treatments except the treatment where no *Pythium* was added to the soil (-Py) (Figure 7).

10

EXAMPLE 5

***IN-VITRO* INHIBITION OF *GAEUMANNOMYCES GRAMINIS* VAR. *TRITICI* BY ENDOPHYTIC ACTINOMYCETES**

15

METHODOLOGY

In-vitro antifungal metabolite production assays

20 This assay was based on the protocol of Crawford *et al.* (1993). The actinomycetes were streaked into one third of a corn-meal agar (CMA) plate and allowed to grow for 8 days. This time allowed the actinomycete grow, sporulate and to produce secondary metabolites. After 8 days a 5mm x 5mm block of CMA agar with the fungal pathogen of interest growing on it was introduced to the actinomycete plate. Secondly, blocks of the fungus
25 were also added to at least 3 CMA plates that were not inoculated with the actinomycete. This was done to provide a control measurement of the fungal growth. The mean measure of the radial growth of the fungus on the control plates was compared with the growth of the fungus towards the actinomycete on the test plates to give an indicator of actinomycete antagonism of the fungal pathogen. The control plates were used instead of a measure of
30 fungal growth away from the actinomycete on the test plates as fungal growth was often inhibited in this direction as well, hence artificially reducing the antagonistic effect.

- 100 -

RESULTS

In-vitro antifungal assay

5 Table 11 below shows the *in-vitro* antagonism of *Gaeumannomyces graminis* var. *tritici* (Ggt) by each of the actinomycete isolates. The strength of the antifungal activity was calculated as a ratio of the growth of the fungus (in mm) on the actinomycete free control plate divided by the growth of the fungus (in mm) towards the actinomycete streak on the test plates.

10

The results show that 31.5% (18 isolates) of the isolates were able to strongly inhibit (++ or better) at least 1 of the strain of Ggt used in the assay and that 55% of these isolates (10 isolates) were able to strongly inhibit all three strains of Ggt used in the assay.

15

EXAMPLE 6

IN-VITRO INHIBITION OF *RHIZOCTONIA SOLANI* BY ENDOPHYTIC ACTINOMYCETES

METHODOLOGY

20

In-vitro antifungal metabolite production assays

This assay was based on the protocol of Crawford *et al.* (1993). The actinomycetes were streaked into one third of a corn-meal agar (CMA) plate and allowed to grow for 8 days. This time allowed the actinomycete grow, sporulate and to produce secondary metabolites.

25

After 8 days a 5mm x 5mm block of CMA agar with the fungal pathogen of interest

growing on it was introduced to the actinomycete plate. Secondly, blocks of the fungus were also added to at least 3 CMA plates that were not inoculated with the actinomycete.

This was done to provide a control measurement of the fungal growth. The mean measure of the radial growth of the fungus on the control plates was compared with the growth of

30

the fungus towards the actinomycete on the test plates to give an indicator of actinomycete antagonism of the fungal pathogen. The control plates were used instead of a measure of

- 101 -

fungal growth away from the actinomycete on the test plates as fungal growth was often inhibited in this direction as well, hence artificially reducing the antagonistic effect.

RESULTS

5

In-vitro antifungal assay

Table 12 below shows the *in-vitro* antagonism of *Rhizoctonia solani* by each of the actinomycete isolates. The strength of the antifungal activity was calculated as a ratio of the growth of the fungus (in mm) on the actinomycete free control plate divided by the
10 growth of the fungus (in mm) towards the actinomycete streak on the test plates.

The results show that 49.1% (28 isolates) of the isolates were able to strongly inhibit (++ or better) *R. solani*.

15

EXAMPLE 7

IN-VITRO INHIBITION OF *PYTHIUM* SPP. BY ENDOPHYTIC ACTINOMYCETES

METHODOLOGY

20

In-vitro antifungal metabolite production assays

This assay was based on the protocol of Crawford *et al.* (1993). The actinomycetes were streaked into one third of a corn-meal agar (CMA) plate and allowed to grow for 8 days. This time allowed the actinomycete grow, sporulate and to produce secondary metabolites.
25 After 8 days a 5mm x 5mm block of CMA agar with the fungal pathogen of interest growing on it was introduced to the actinomycete plate. Secondly, blocks of the fungus were also added to at least 3 CMA plates that were not inoculated with the actinomycete. This was done to provide a control measurement of the fungal growth. The mean measure of the radial growth of the fungus on the control plates was compared with the growth of
30 the fungus towards the actinomycete on the test plates to give an indicator of actinomycete antagonism of the fungal pathogen. The control plates were used instead of a measure of

- 102 -

fungal growth away from the actinomycete on the test plates as fungal growth was often inhibited in this direction as well, hence artificially reducing the antagonistic effect.

RESULTS

5

In-vitro antifungal assay

Table 13 below shows the *in-vitro* antagonism of *Pythium* spp. by each of the actinomycete isolates. The strength of the antifungal activity was calculated as a ratio of the growth of the fungus (in mm) on the actinomycete free control plate divided by the growth of the
10 fungus (in mm) towards the actinomycete streak on the test plates.

The results show that 22.8% (13 isolates) of the isolates were able to strongly inhibit (++ or better) 1 of the strains of *Pythium* used in the assay and that 46% of these isolates (6 isolates) were able to strongly inhibit both strains of *Pythium* used in the assay.

15

EXAMPLE 8

***IN VITRO* INHIBITION OF FUSARIUM GRAMINEARUM BY ENDOPHYTIC ACTINOMYCETES**

20 METHODOLOGY

In-vitro antifungal metabolite production assays

This assay was based on the protocol of Crawford *et al.* (1993). The actinomycetes were streaked into one third of a corn-meal agar (CMA) plate and allowed to grow for 8 days.

25 This time allowed the actinomycete grow, sporulate and to produce secondary metabolites.

After 8 days a 5mm x 5mm block of CMA agar with the fungal pathogen of interest growing on it was introduced to the actinomycete plate. Secondly, blocks of the fungus were also added to at least 3 CMA plates that were not inoculated with the actinomycete.

This was done to provide a control measurement of the fungal growth. The mean measure
30 of the radial growth of the fungus on the control plates was compared with the growth of the fungus towards the actinomycete on the test plates to give an indicator of actinomycete

- 103 -

antagonism of the fungal pathogen. The control plates were used instead of a measure of fungal growth away from the actinomycete on the test plates as fungal growth was often inhibited in this direction as well, hence artificially reducing the antagonistic effect.

5 RESULTS

In-vitro antifungal assay

Table 14 shows the *in-vitro* antifungal activity of the selected actinomycete endophytes against *Fusarium graminearum* actinomycetes.

10

EXAMPLE 9

IN-PLANTA WHEAT ROOT GROWTH AND GERMINATION REGULATION OF ENDOPHYTIC ACTINOMYCETES

15 METHODOLOGY

In-planta early growth promotion assays

Each of the isolates was tested using 25 individual plants. These were arranged as 5 plants in each of 5 pots which were rotated in the glasshouse at regular intervals to remove any positional effects of the pots. This layout of plants allowed for analysis of variance and t-tests to be performed on the results.

Seeds were surface sterilised using a 6 minute wash in 3.125% sodium hypochlorite, followed by washing in sterile water. Following surface sterilisation, batches of approximately 50 seeds were made and coated with a spore suspension of each isolate made from one 9 cm petri dish of well grown actinomycete culture mycelium and spores, in 3 ml of sterile RO water. These suspensions were then poured over the seeds and allowed to dry overnight in a laminar flow cabinet. Control batches were produced by soaking surface sterilised seeds in 3 ml of sterile water and left to dry overnight in a similar manner.

30

- 104 -

Endophytes were tested for their ability to enhance root or shoot growth of young wheat. The trial was broken up into batches of 10 treatments, each with a set of untreated controls. Pot trials were set up as above and seeds coated using the above protocol. The wheat seeds were planted at a depth of approximately 2 cm into steamed recycled UC soil. The plants
5 were then left to grow for 4 weeks, at which point they were harvested. The plants were then washed and allowed to dry for 2 weeks until brittle. Root and shoot dry masses were taken of all individual plants to give a mean for each treatment and for the control for the batch. Percentage increases or decreases for each treatment relative to the control were calculated to give a standard score that could be used to compare plants between batches.
10 Following this the mean for each treatment was compared to the control and the statistical significance of the differences observed was calculated using a paired t-test.

RESULTS

15 *In-planta early growth promotion assays*

Table 15 shows the growth regulatory effects of each of the endophytes tested in the early growth promotion assays, while table 16 shows a summary of the results indicating those isolates that show significant ($p < 0.05$ or $p < 0.10$) growth regulatory effects.

20

EXAMPLE 10

IN-PLANTA *GAEUMANNOMYCES GRAMINIS* VAR. *TRITICI* BIOCONTROL IN STEAMED SOIL BY ENDOPHYTIC ACTINOMYCETES

METHODOLOGY

25

In-planta steamed soil Gaeumannomyces graminis var. *tritici* (Ggt) bioassay

For each endophyte tested, 5 pots each planted with five endophyte-coated seeds were used. These pots were randomly spread out in the glasshouse, and rotated routinely to remove any positional effects of the pots. The control was also planted in the same way,
30 except the seeds were coated with water containing no actinomycete spores or mycelium.

- 105 -

Gaeumannomyces graminis var. *tritici* 8 (Ggt8) inoculum was added to steamed UC soil mix at a rate of 180 propagules/kg. Pots were half filled with this infested soil, then a 2 cm layer of uninfected soil was layered over this. Onto this layer the seeds were planted and then they were overlayed with a further 2 cm layer of uninfected soil.

5

The plants were allowed to grow for 4 weeks and then scored for Ggt disease symptoms. Scoring involved examining the seminal roots of the plant (ie those roots that emerge directly from the seed) and calculating a percentage on how many of these roots (there are five) exhibit the black lesions along the root characteristic of Ggt infection. A mean level of infection was calculated for each endophyte treatment and for the control. Each endophyte treatment was compared to the control and the statistical significance of any observed differences was assessed using 2-tailed t-tests.

10

RESULTS

15

Steamed soil Ggt bio-control assays

20

Table 17 shows the *in-planta* Ggt bio-control activity of the actinomycete endophytes, those isolates listed in bold are those closely related to *Streptomyces caviscabies*. The numbers in blue show a result with a t-test p-value of less than 0.10, while those in red indicate a t-test p-value of less than 0.05.

Of the 10 *S. triticum*-like isolates, 8 of them showed Ggt disease reductions of greater than 25% and 7 of these 8 had T-test p-values of less than 0.055. This would suggest that the group of *S. triticum*-like isolates had a high incidence of Ggt bio-control activity.

25

- 106 -

EXAMPLE 11**IN-PLANTA *GAEUMANNOMYCES GRAMINIS* VAR. *TRITICI*
AND *RHIZOCTONIA SOLANI* BIO-CONTROL IN FIELD SOIL BY
ENDOPHYTIC ACTINOMYCETES**

5

METHODOLOGY***In-planta Gaeumannomyces graminis var. tritici (Ggt) bio-control in field soil***

For those isolates that showed activity in the first *Gaeumannomyces graminis* var. *tritici*
10 (Ggt) bio-control assay, in the steamed soil with artificial inoculum, a second assay was
performed using a field soil naturally infected with both Ggt and *Rhizoctonia solani*. This
soil was taken from a paddock on the “Rolling Hills” property in Peake, SA.

This assay was performed as detailed earlier except that no extra Ggt inoculum was added
to the soil and no layers of clean soil were introduced into the pot. As above the plants
15 were allowed to grow for 4 weeks. After this period the plants were harvested and the
seminal roots were scored for Ggt infection (as described above) and *Rhizoctonia solani*
infection (which is characterised by roots with broken off tips which are blackened and
form a point – “spear tips”).

20 **RESULTS*****Field soil Ggt bio-control***

Table 18 shows the field soil Ggt bio-control activity of the isolates. The percentage
disease reductions reported are all relative to a batch of control plants that were planted
25 into the infected soil with no actinomycete seed coating.

The field soil used for this assay was naturally infected with both Ggt and *Rhizoctonia*
solani, and disease ratings were taken for both pathogens. Figure 1 shows a graphical
representation of disease control for those isolates with statistically significant results. The
30 results of the field soil assay were markedly more variable than those in the sterile soil,
meaning quite large disease reductions were not significantly significant (eg. Some isolates

- 107 -

had disease reductions of >30% but $p>0.05$). Several of the isolates such as EN2, EN9, EN22, EN23, EN43, EN57 and EN60 also exhibited control of *Rhizoctonia*, indicating these isolates may have broad spectrum antifungal activity.

- 5 For those isolates with significant activity in the field soil it was observed that the magnitude of the bio-control activity, ie the disease reduction was generally greater in the field soil, than was observed in the steamed soil assay.

EXAMPLE 12

10 IN-PLANTA APHID BIO-CONTROL

Long-term growth promotion assays- Aphid resistance

Selected isolates EN3, EN6, EN10, EN16, EN27, EN28, EN57, EN59, SE1 and SE2 were tested for their ability to induce resistance to foliar pests, i.e, in an aphid challenge assay.

- 15 These assays were set up as in the early growth promotion assays with some modifications to the protocol. Five seeds were planted into steamed UC soil mix in larger (150mm diameter) pots. The plants were then left to germinate. Once the plants had emerged, each pot was weeded to have only 3 plants per pot to eliminate compensatory growth effects in those pots with fewer plants.

20

The plants were then exposed to aphids 10 weeks after germination, and scored for infestation.

Aphid resistance observed

- 25 During the aphid infestation, it was observed that some pots were more heavily infested with aphids than others. Some observations were made on this attack.

- The pots were blindly classified into those pots with high levels of aphid infestation of the plants, and those pots with low levels of aphid infestation of the plants. The number of pots
30 for each endophyte treatment, at each of the aphid infestation levels was counted. The results are shown in figure 9.

- 108 -

EXAMPLE 13

GROWTH AND GERMINATION OF BARLEY AND OATS

5 Table 19 shows the effect of inoculation with actinomycete endophyte on the growth and germination of barley and oats in comparison to untreated control plants. This was carried out in 5 replicate pots containing 3 plants each.

Table 20 shows the effect of inoculation with actinomycete endophytes from the second
10 batch, on the growth and germination of wheat plants in comparison to untreated control plants. This was carried out in 5 replicate pots containing 3 plants each. The results shown below are all $p < 0.05$.

EXAMPLE 14

15 VISUALISATION OF AN ENDOPHYTIC *STREPTOMYCES* SP. IN WHEAT SEED USING GREEN FLUORESCENT PROTEIN

MATERIALS AND METHODS

20 *Construction of the egfp-tagged Streptomyces sp. EN27.*

Transformation of *Streptomyces* sp. EN27 with EGFP was performed as set out in Coombs and Franco (Appl. Environ. Microbiol. 69(7):4260-4262, 2003).

The plasmid DNA of the *E. coli* DH5 α was extracted using a Wizard Plus SV miniprep kit
25 (Promega). This plasmid DNA was then used to transform competent *E. coli* S17.1, which could be used for intergeneric recombination with *Streptomyces*, as it carries an integrated form of RK4 transfer genes necessary to integenerically transfer plasmids that carry the *oriT*/RK2 regions (Flett, F. *et al.* 1997; Mazodier, P. *et al.* 1989).

30 The intergeneric recombination protocol used was that of Flett *et al.* (1997) which is a modification of the method of Mazodier *et al.* (1989) as described in Practical

- 109 -

Streptomyces Genetics (Kieser, T. *et al.* 2000). Expression of *egfp* was detected using epifluorescence microscopy.

Inoculation of wheat cv. Excalibur with Streptomyces sp. EN27 pIJ8641.

- 5 Approximately 100 seeds were prepared for coating by surface sterilisation using a six minute wash in 3.125% NaOCl, followed by three double volume rinses in sterile RO water. After the final water rinse was drained off, the seeds were evenly separated into two petri dishes. The *egfp*-expressing actinomycete, *Streptomyces* sp. EN27 pIJ8641, was inoculated onto TSA plates supplemented with apramycin at 50ug.ml⁻¹. These plates were
- 10 incubated at 27°C until the cultures had sporulated. The mycelium was then scraped off the plate and transferred to a sterile eppendorf tube. 1.5 ml of sterile RO water was added to the tube, which was then vortexed thoroughly to ensure even distribution of the mycelium and spores in suspension. This spore suspension was added to one of the batches of seed, while 1.5 ml of sterile RO water was added to the other batch of seed, to act as a control.
- 15 The seeds were then dried overnight in a laminar flow cabinet. Some of this seed was then placed on a mannitol-soy flour (MS) medium plate and the seeds were allowed to germinate. 5 inoculated seed were planted aseptically, in duplicate, into autoclaved sterile sandy-loam soil placed in sterile 500 ml screw-capped flasks to a depth of 7 cm. The flasks were watered with sterile water and the lids loosely screwed on, and incubated in a
- 20 plant growth chamber with a 16hour light- 8 hour dark cycle at 25°C.

Visualisation of egfp-expressing pure cultures of Streptomyces sp. EN27 using LSCM.

- The cultures were grown on MS medium without selective pressure in triplicate, until thick growth had occurred. Loopfuls were taken off each of these plates and smeared onto
- 25 microscope slides. A drop of sterile water was placed on the smear, before being covered with a glass coverslip, which was then sealed with nail polish.

- The slides were visualised using a Nikon laser scanning confocal microscope with a Krypton/Argon laser with a 488nm emission filter, at 30% power with a green light
- 30 detection filter. A range of other filter sets and higher laser power was tested to ensure that the fluorescence observed was due to the *egfp* gene product, and not to the

- 110 -

autofluorescence of the actinomycete. Control strains, ie. non-transformed strains of *Streptomyces* sp. EN27, were also examined to ensure the non-transformed actinomycetes had no autofluorescence in the green range.

5 ***Visualisation of egfp-expressing Streptomyces sp. EN27 in seed sections using epifluorescence microscopy.***

Seeds coated with *Streptomyces* sp. EN27 and untreated control seeds were cut into 60-80um sections using a Leitz Wetzlar microtome with a freezing stage attachment after 24 hour incubation on MS agar medium. These sections were placed onto microscope slides
10 and mounted in water under a glass coverslip, which was then sealed using nail polish.

Prepared slides were examined under an Olympus BX-50 microscope using a mercury vapour lamp. The filter block used to visualise the EGFP-expressing actinomycetes was a Chroma 31001 with an excitation filter of 465-495nm and an emission filter of 515-
15 555nm. The structure of the plant tissue was visualised using the autofluorescence of the tissue. Several filter sets were tried, and the best visualisation was found to be with UV excitation and blue emission. These wavelengths were obtained using an Olympus U-MNUA filter set. This filter set gave an excitation wavelength of 360-370nm and an emission wavelength of 420-460nm. These filters were the most appropriate as the EGFP
20 molecule has very little excitation or blue light emission under UV light, and the Chroma 31001 filter block encompasses the peak excitation and emission wavelengths of the EGFP molecule (488nm excitation and 520nm emission).

This procedure was repeated on a daily basis for seeds that had been incubated for a further
25 3 days and undergone germination.

RESULTS

Transformation of E.coli S17.1 with pIJ8641.

30 700 ng of plasmid DNA was used for the transformation of E. coli S17.1. 400 transformants were recovered to give a transformation efficiency of 5.7×10^2

- 111 -

transformants per ug of plasmid DNA. No transformants were seen on the control reaction plate.

Intergeneric transformation of Streptomyces sp. EN27 with E. coli S17.1 pIJ8641.

- 5 After 16 hours incubation, a thin mat growth was observed on the transformation plates. To this was added 1 ml of sterile water containing 0.5 mg nalidixic acid, to eliminate the *E. coli*, and 1mg apramycin, to select for the transformed actinomycete. 3 days after the addition of the antibiotic mix, 14 distinct sporulating colonies were observed on the transformation plate for *Streptomyces sp. EN27*. These colonies were picked off onto TSA
- 10 supplemented with apramycin at 50ug/ml. The plates were examined under blue light with an orange filter to detect fluorescence. Fluorescent colonies were apicked off and examined under a fluorescence microscope to confirm expression of *egfp*.

Visualisation of egfp-expressing Streptomyces sp. EN27 using Laser Scanning Confocal

15 ***Microscopy.***

- Figure 5 shows the projection of an image stack of *Streptomyces sp. EN27-egfp* under the confocal microscope. 600x magnification was used with a 3x digital zoom to give an effective magnification of 1800x. A total of 51 optical slices were projected using Confocal Assistant version 4.0. The untransformed *Streptomyces sp. EN27* exhibited no
- 20 fluorescence in the green range of the spectrum. Neither the transformed nor the wild type *Streptomyces sp. EN27* showed significant fluorescence in any other part of the spectrum that was tested.

Visualisation of Streptomyces sp. EN27-egfp.

- 25 Visualisation of the *egfp* tagged *S. caviscabies/setonii* in the seed used epifluorescence microscopy with blue light excitation from a mercury vapour lamp, and green light emission filters. After 24 hours the presence of the actinomycete was only detected in the embryo, and around the break in the seed husk where the embryo emerges from the seed. No fluorescence was observed on the outer seed husk, indicating that these cells were non-
- 30 viable and no-longer expressing *egfp*, or more likely, these cells were washed away when the seeds were immersed in the freezing step during sectioning. Figure 6 shows the

- 112 -

actinomycete inhabiting the embryo tissue. The actinomycete was visualised using 465-495nm wavelength excitation light with 515-555nm emission filters, so only green light was visualised. Other filter sets including green excitation/red emission and UV excitation/blue emission were also tested to ensure the fluorescence was caused by EGFP.

5 The plant tissue was visualised using UV excitation and blue emission as this produced the strongest autofluorescence in the plant cell walls. The image generated from the green light detection was digitally coloured green and the image generated from the blue light detection was digitally coloured red. The images were then overlaid using Confocal Assistant 4.0. It appeared that the actinomycete preferentially grows intracellularly in close
10 proximity to the plant cell walls. It is also possible that this is intercellular growth and the microscope stage was slightly moved (down and to the right in the image) between the two image captures, as the actinomycete growth appears to mimic the shape of the plant cell wall in many places.

15 ***Visualisation of Streptomyces sp. EN27-egfp.***

After 3 days *egfp*-expressing microcolonies of the actinomycete were seen more frequently in the embryo tissue of the seed than at 24 hours, indicating that the actinomycete was actively growing in the plant tissue. Examples of these microcolonies are shown in figure 12. Actinomycete microcolonies were also detected in the emerging radicle (young root) of
20 the embryo, as seen in figure 13. After 3 days actinomycete growth was observed in the endosperm of the wheat seed, which was not observed at 24 hours (Figure 14).

EXAMPLE 15

**PRODUCTION OF THE AUXIN, INDOLE ACETIC ACID, BY ENDOPHYTIC
25 ACTINOMYCETE STRAINS**

Assay protocol

The ability of endophytic actinobacteria strains to produce indole-3-acetic acid (IAA) was assessed using a colorimetric assay using the protocol described by Glickmann and
30 Dessaux (1995). Each actinomycete strain was grown in 10 ml Tryptone soya broth (TSB), supplemented with tryptophan at 200 mg.l⁻¹. At day 7 after inoculation, 750 ul samples of

- 113 -

the culture broth were centrifuged at 12000 rpm to pellet the cells. 500ul of this supernatant was then mixed with Salkowski reagent R1 (12g.l⁻¹ FeCl₃ in 7.9M H₂SO₄) and allowed to stand for 20 min at room temperature. The optical density was measured at 530nm for each sample using an Amersham Pharmacia Biotech Ultrospec 3100 pro spectrophotometer. The sample blank used to zero the instrument was the uninoculated culture medium mixed with Salkowski reagent R1, in the same manner as with the culture broths.

Results

10

All the endophytic actinobacteria strains were able to produce detectable quantities of indole-3-acetic acid (IAA), as shown in the Figure 20.

EXAMPLE 16

15

WHEAT AND BARLEY SEED FIELD TRIALS

Field trials were conducted to test the efficacy of a range of endophytic actinobacteria against Take-all and other cereal diseases.

20 Field trials were carried out using wheat and barley seed that were coated with the spores of a range of the actinobacterial endophytes. Trials were carried out in quadruplicate at each site.

The field trials yielded a statistically significant result at the Alford site (Yorke Peninsula).
25 Before the trial, soil DNA testing conducted at the South Australian Research and Development Institute (SARDI) showed high levels of Take-all present at this site. At this site substantial and significant yield increases occurred after seed treatment with a commercial control fungicide "Jockey", and the actinobacterial endophytes *Nocardioides* sp. EN46 and *Streptomyces triticum* var. *griseoviride* EN16. Jockey is the currently the
30 most effective chemical control agent so far developed for Take-all, and our endophyte

- 114 -

treatments have resulted in statistically similar yields as was obtained with this treatment (Figure 3).

In the three other sites over the state, with each treatment replicated 4 times, an important trend was observed. Overall, consistent yield increases were seen at nearly all sites treated with *Streptomyces triticum* var. *griseoviride* EN16, *Streptomyces triticum* EN27 and *Nocardioides* sp. EN46 (Table 8). Furthermore, at these sites, the commercial fungicide (Jockey) had no effect indicating the absence of disease. It is significant that in all these fields the endophyte treatments, particularly *Streptomyces triticum* var. *griseoviride* EN16, *Streptomyces triticum* EN27 and *Nocardioides* sp. EN46, substantially outperformed the commercial fungicide. The endophytes selected for these trials, however, produce the plant growth hormone indole-3-acetic acid (IAA), and are known plant growth promotion agents, based on our glasshouse trials.

Table 9 is a summary of field trials at sites with Rhizoctonia disease.

Table 10 is a summary of growth promotion trials at sites which had a low disease status.

EXAMPLE 17

WHEAT AND BARLEY SEED FIELD TRIALS – II

Field trials were also conducted in the 2003 growing season to further test the efficacy endophytic actinomycetes against a range of fungal pathogens including *Gaeumannomyces graminis* var. *tritici* (Take All), *Fusarium* spp. (Crown Rot), *Rhizoctonia* spp., *Pythium* spp. as well as assess the activity of the endophytic actinomycetes as growth promoters.

Seed treatment in each case was performed essentially as set out in Example 9. Specifically, for each actinomycete, a suspension of spores in sterile water was produced. For the “high” treatments, the spores were applied at about 10^{11} spores per kilogram of seed. For the “low” treatments, spores were applied to the seed at about 10^{10} per kilogram of seed. The untreated seed or sham treated control was treated with sterile water. The

- 115 -

treated and sham-treated (control) seed was air-dried under sterile conditions in a laminar flow hood prior to planting.

5 Trial sites were selected on the basis of disease history of the site and by evaluation using the soil DNA testing service (SARDI, Adelaide). For each inoculant treatment, 4 replicate fields plots of 1.5 m width x 20 m length were used in a randomised complete block design. Untreated seed was used in the control plots. For trials against Take-all disease, the commercial fungicide Jockey was used. Four replicates of the untreated control and the chemical fungicide were used at each trial site. The sowing rate was 85 kg per hectare. At 10 harvest, grain yield was calculated as kg of seed per hectare and a comparison to the control was made.

The results of these field trials are presented in Tables 21 and 22.

15

EXAMPLE 18

CONFIRMATION OF ENDOPHYTIC ROOT COLONIZATION USING T-RFLP

20 Seeds coated with EN2, EN27, EN46 and uncoated control seed were prepared as set out in Example 9.

The coated seeds were then planted and plants were harvested after 6 weeks of growth. Endophytic bacterial DNA was extracted from the roots of the putatively colonized wheat using the method described in Conn and Franco (*Appl. Envir. Microbiol.* 70: 1787 – 1794, 25 2004).

Partial 16S rRNA gene sequences were amplified from the endophytic DNA using the actinobacteria biased primers 243f (5' GGA TGA GCC CGC CGC CTA 3') and 5'TET (6-carboxy-2',4,7,7'-tetrachlorofluorescein)-labelled 1492r (5' TA CGG GTA CCT TGT 30 TAC GAC TT 3'). Amplification was carried out according to Conn and Franco, *supra*. Single restriction digests of the 16S rRNA PCR products were performed using *Hinf*I,

- 116 -

HhaI and *MboI* (Promega) using 10µl of the PCR reaction mixture for 16 to 18 hours to achieve complete digestion, and then stored at -20°C. The size of the terminal 16S rRNA gene fragments present in the restriction digestions were determined on an automated, Applied Biosystems 373 DNA sequencer, Stretch, using 1µl of the restriction digest. Data
5 was analysed using the GeneScan Analysis program V.3.1.2 (Applied Biosystems). From the GeneScan data the terminal restriction fragment (TRF) sizes present for each restriction enzyme was determined.

The T-RFLP profile obtained with *HinfI* for each of these plants is shown in Figure 21; the
10 annotated peaks indicate the fragment corresponding to the introduced actinobacterial endophyte. The calculated terminal restriction fragment of the EN27 16S product digested with *HinfI* is about 241 nucleotides in length, the EN46 product is about 179 bp in length and the EN2 the product is about 175 bp in length.

15 From the results it was observed that the *HinfI* fragment for *Microbispora* sp. EN2 increased by approximately two fold indicating that colonisation has occurred. The specific 241bp *HinfI* fragment corresponding to *Streptomyces* sp. EN27 was not present in the uninoculated control which provided a good indication that colonisation has occurred.

20 Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or
25 more of said steps or features.

- 117 -

TABLE 2

Isolate	Strongest 16S rDNA sequence match (BLASTN)				
	Accession No	Nearest match	Accession	Bits	%
EN2	AY148073	<i>Streptosporangiaceae</i> str. PA147	AF223347	1830	94
		<i>Microbispora amethystogenes</i>	U48988	1709	93
EN3	AY148077	<i>Streptomyces galilaeus</i>	AB045878	2775	99
EN4	AY148080	<i>Streptomyces galilaeus</i>	AB045878	2708	99
EN6	AY148085	<i>Streptomyces pseudovenezuelae</i>	AJ399481	1667	95
EN9	AY148087	<i>Streptomyces bikiniensis</i>	X79851	2573	98
EN10	AY148071	<i>Strptomyces fimbriatus</i>	AB045868	2391	96
		<i>Streptomyces</i> sp. ASSF13	AF012736	2002	95
EN16	AY148072	<i>Streptomyces caviscabies</i>	AF112160	1994	95
EN22	AY291590	<i>Streptomyces peucetius</i>	AB045887	2579	98
EN23	AY148074	<i>Streptomyces caviscabies</i>	AF112160	2825	99
EN27	AY148075	<i>Streptomyces caviscabies</i>	AF112160	1776	94
EN28	AY148076	<i>Streptomyces caviscabies</i>	AF112160	2409	96
EN30	AY148078	<i>Streptomyces argenteolus</i>	AB045872	2706	98
EN35	AY148079	<i>Streptomyces caviscabies</i>	AF112160	2512	97
EN43	AY291589	<i>Micromonospora yulongensis</i>	X92626	2627	98
EN46	AY148081	<i>Nocardioides albus</i>	X53211	2516	98
EN47	AY148082	<i>Nocardioides albus</i>	X53211	2769	99
EN57	AY148083	<i>Streptomyces caviscabies</i>	AF112160	2684	99
EN59	AY148084	<i>Streptomyces galilaeus</i>	AB045878	1879	95
EN60	AY148086	<i>Streptomyces argenteolus</i>	AB045872	2375	96
SE1	AY148088	<i>Streptomyces caviscabies</i>	AF112160	1879	95
SE2	AY148089	<i>Streptomyces caviscabies</i>	AF112160	2528	97

- 118 -

TABLE 3

<u>Isolate</u>	<u>Preliminary Identification based on 16S rDNA sequencing (showing % similarity to nearest matching sequence)</u>
EN5	<i>Streptomyces caviscabies</i> /Str. setonii (92%)
EN7	<i>Streptomyces lincolnesis</i> (93%)
EN17	<i>Streptomyces caviscabies</i> (90%)
EN19	<i>Streptomyces caviscabies</i> /Str. setonii (92%)
EN26	<i>Streptomyces peruviansis</i> (94%)
EN39	<i>Streptomyces galilaeus</i> (93%)
EN41	<i>Micromonospora yulongensis</i> (92%)
EN42	<i>Micromonospora peucetica</i> (91%)
PM 20	<i>Streptomyces caviscabies</i> / Str. setonii (93%)
PM 22	<i>Streptomyces caviscabies</i> sp. (96%)
PM 23	<i>Streptomyces caviscabies</i> (93%)
PM 35	<i>Tsukamurella tyrosinovorans</i> D – 1498 (96%)
PM 36	<i>Streptomyces caviscabies</i> / Str. setonii (95%)
PM 40	<i>Streptomyces caviscabies</i> / Str. setonii (93%)
PM 41	<i>Streptomyces caviscabies</i> / Str. setonii (96%)
PM 87	<i>Streptomyces caviscabies</i> / Str. setonii (94%)
PM 89	<i>Streptomyces lincolnensis</i> (97%)
PM 124	<i>Tsukamurella</i> sp. IM – 7430 (97%)
PM 144	<i>Streptomyces caviscabies</i> / Str. setonii (97%)
PM 171	<i>Streptomyces caviscabies</i> / Str. setonii (93%)
PM 185	<i>Streptomyces caviscabies</i> / Str. setonii (98%)
PM 208	<i>Streptomyces caviscabies</i> / Str. setonii (95%)
PM 228	<i>Streptomyces caviscabies</i> / Str. setonii (96%)
PM 239	<i>Tsukamurella tyrosinovorans</i> D – 1498 (96%)
PM 247	<i>S. caviscabies</i> (95%)
PM 252	<i>Streptomyces caviscabies</i> / Str. setonii (92%)
PM 301	<i>Streptomyces caviscabies</i> (93%)
PM 342	<i>Streptomyces caviscabies</i> / Str. setonii (96%)
SC 19	<i>Micromonospora fulvoviolaceus</i> (97%)

- 119 -

TABLE 4

Isolate number	Spore coloration						Carbohydrate utilization														
	ISP2	ISP3	ISP4	ISP5	ISP7	NUTRIENT AGAR	gluc	fruc	suc	mantol	mal	inos	gal	man	lac	cell	dul	xyl	rham	raff	arab
EN 19	cream	green	white	white	black	white	+	+	+	+	+	-	+	+	-	-	+	-	-	-	-
EN 27	cream	white	white	brown	brown	white	+	+	+	+	+	-	+	+	+	-	+	-	-	-	-
EN 35	cream	white	white	brown	brown	white	+	+	-	-	+	-	-	+	-	-	+	-	-	-	-
EN 57	cream	white	white	brown	brown	white	+	+	+	+	+	-	+	-	+	-	+	-	-	-	-
EN 28	cream	cream	white	black	brown	white	+	+	+	+	+	-	+	+	+	-	-	-	-	+	-
SE 1	white	white	white	light brown	dark brown	white	+	+	+	+	+	-	-	+	-	-	-	-	-	-	-
SE 2	white	white	white	light brown	dark brown	white	+	+	+	+	+	-	+	+	-	-	-	-	-	-	-
PM 40	white	white	white	light brown	dark brown	white	+	+	+	+	+	-	-	+	+	-	+	-	-	-	-
PM 41	cream	white	white	brown	dark brown	white	+	+	+	-	-	-	+	+	+	-	-	-	-	-	-
PM 228	cream	white	white	brown	dark brown	white	+	-	-	-	+	-	+	-	+	-	+	-	-	-	-
PM 36	cream	white	white	dark brown	white	white	+	+	+	+	+	-	+	+	-	-	-	-	-	-	-
PM 87	cream	white	white	dark brown	white	white	+	+	+	+	-	-	-	+	-	-	-	-	-	-	-
PM 252	cream	white	white	dark brown	white	white	+	+	+	+	-	-	-	+	-	-	-	-	-	-	-
PM 171	cream	white	white	dark brown	pale green	white	+	+	-	+	+	+	+	+	-	-	-	+	-	-	-

KEY:- gluc- glucose; fruc- fructose; suc-sucrose; mantol-mannitol; mal-maltose; inos; inositol; gal-galactose; man- mannose; lac-lactose; cell-cellulose; dul-dulcitol; xyl-xylose; rham-rhamnose; raff-raffinose and arab-arabinose.

- 120 -

TABLE 5

Isolate Number		Soluble pigmentation							Biochemical analysis								
		ISP2	ISP3	ISP4	ISP5	ISP7	NUTRIENT AGAR	Starch Hydrolysis	Gelatin Digestion	Nitrate Reduction	Urea Utilization	H2S Production	Max naCl Tolerance	Min pH*	Streptomycin Inhibition**	Litmus Milk Test Pepton ^N	Coagul ^N
EN 19		dark brown	-	-	black	black	-	+++	+	-	+	-	7%	pH 5	1.5µg/ml	-	+
EN 27		brown	-	-	black	black	-	+++	+	+	+	-	7%	pH4	1µg/ml	-	-
EN 35		brown	-	-	black	black	-	++	+	-	+	-	7%	pH4	1.5µg/ml	+	-
EN 57		brown	-	-	black	black	-	+++	+	-	+	-	6%	pH4	1.5µg/ml	+	-
EN 28		brown	dark cream	-	black	black	-	++	+	-	+	+	7%	pH4	1µg/ml	+	-
SE 1		dark brown	brown	-	light brown	dark brown	-	++	+	-	+	-	7%	pH3	1.5µg/ml	-	+
SE 2		dark brown	brown	-	light brown	dark brown	-	++	+	-	+	-	7%	pH3	1µg/ml	-	-
PM 40		dark brown	brown	-	Light brown	dark brown	-	++	+	+	+	-	8%	pH3	1µg/ml	-	+
PM 41		dark brown	brown	Light brown	black	black	-	++	+	+	+	+	8%	pH4	1.5µg/ml	-	-
PM 228		dark brown	brown	light brown	black	black	-	+	+	-	+	-	7%	pH4	1µg/ml	-	-
PM 36		light brown	-	-	black	brown	-	+++	+	+	+	-	8%	pH4	1µg/ml	+	-
PM 87		light brown	-	-	black	brown	-	+	+	+	-	+	7%	pH3	1µg/ml	+	-
PM 252		light brown	-	-	black	brown	-	++	+	-	+	+	7%	pH4	2µg/ml	-	-
PM 171		brown	-	-	brown	black	-	+	+	-	+	+	6%	pH4	1µg/ml	-	+

Key: In Starch Hydrolysis- (+) -- minimum hydrolysis; (++) -- intermediate hydrolysis (+++) complete hydrolysis

TABLE 6

isolates		Spore colouration						Carbohydrate utilization														
		ISP2	ISP3	ISP4	ISP5	ISP7	NUTRIENT AGAR	gluc	fruc	suc	mantol	mal	inos	gal	man	lac	cell	dul	xyl	rham	raff	arab
	EN 16	green	green	grey	white	grey	white	+	-	+	-	+	-	+	+	-	-	-	-	-	-	-
	EN 17	grey	white	grey	white	white	white	+	+	+	+	+	-	+	+	+	-	-	+	-	-	-
	PM 144	green	white	white	white	green	white	+	+	+	+	+	+	+	+	+	-	-	-	-	+	-
	PM 185	grey	white	white	white	white	white	+	+	+	-	-	-	+	+	-	-	-	-	-	-	-
	PM 208	grey	white	white	white	white	white	+	+	-	+	-	-	-	+	+	-	-	-	-	-	-
	PM 342	white	white	white	white	grey	white	+	+	-	-	+	-	+	+	-	-	-	-	-	-	-
	S. caviscabies (ATCC 51928)	cream	white	white	white	white	white	+	+	+	+	+	+	+	+	+	-	-	+	-	-	-
	S.setonii (ATCC 25497)	cream	white	white	white	white	white	+	+	+	+	+	+	+	+	+	-	-	+	-	-	-

KEY:- gluc- glucose; fruc- fructose; suc-sucrose; mantol-mannitol; mal-maltose; inos; inositol; gal-galactose; man- mannose; lac-lactose; cell-cellulose; dul-dulcitol; xyl-xylose; rham-rhamnose; raff-raffinose and arab-arabinose.

TABLE 7

Isolate Number	soluble pigmentation							Biochemical analysis									
	ISP2	ISP3	ISP4	ISP5	ISP7	NUTRIENT AGAR	Starch Hydrolysis	Gelatin Digestion	Nitrate Reduction	Urea Utilisation	H2S Production	Max NaCl Tolerance	Min pH	Streptomycin Inhibition**	Peptonisation	Coagulation	Litmus Milk Test
EN 16	brown	-	-	-	grey	-	+	+	+	+	-	7%	pH 5	1µg/ml	-	-	+
EN 17	light brown	-	brown	light brown	light brown	-	+	+	+	+	-	6%	pH 5	1µg/ml	-	-	-
PM 144	brown	-	green	brown	-	-	+++	+	+	-	+	6%	pH 5	1µg/ml	-	-	-
PM 185	light brown	-	-	-	light brown	-	++	+	+	+	-	9%	pH 5	1µg/ml	-	-	-
PM 208	brown	-	-	-	-	-	++	+	-	-	-	9%	pH 5	1µg/ml	-	-	+
PM 342	-	-	-	-	-	-	+++	-	+	+	-	6%	pH 5	1µg/ml	-	-	-
S. cavaiscabies (ATCC 51928)	-	light orange	-	-	-	-	+++	+	+	+	-	7%	pH 5	1µg/ml	-	-	+
S. setonii (ATCC 25497)	-	-	-	-	-	-	+++	-	-	+	+	7%	pH 5	1µg/ml	+	+	-

Key: In Starch Hydrolysis- (+) – minimum hydrolysis; (++) – intermediate hydrolysis (++++) complete hydrolysis.

- 122 -

TABLE 8

	Sandilands	Freeling	Mallala	Mean
EN16	111	103	106	6.67
EN46	114	100	104	6.00
EN27	103	103	104	3.33
EN60	99	105	100	1.33
EN39	103	103	98	1.33
EN35	99	102	102	1.00
TAMix	92	102	106	0.00
Control	100	100	100	0.00
Jockey	98	102	99	-0.33
EN30	101	98	99	-0.67

- 123 -

TABLE 9

Treatment	*Alford	#Sandilands	*Haslam	#Wudinna	#Waddikie	Ave
EN9	109	103	100	102	109	105
EN23	100	118	101	97	109	105
EN27	91	113	102	103	110	104
EN28	96	109	100	102	105	102
EN60	91	97	100	101	112	100
Rmix1 EN2_9_23	117	99	99	100	100	103
RMix2 EN9_27_28	109	103	96	103	111	104
Rmix3 EN39_46	nd	nd	99	104	113	105
MR1	100	105	nd	nd	nd	103
Jockey	109	103	104	97	110	104
Untreated	100	100	100	100	100	100

nd = not done; *barley #wheat

TABLE 10**Locations: Frances and Mundulla, SE of SA**

	Frances		Mundulla	
Treatment	kg/ha	%Control	kg/ha	%Control
EN3	2219	94	2275	107
EN27	2235	95	2222	104
PM87	2291	97	2313	108
PM330	2281	97	2176	102
GPMix	2192	93	2280	107
Untreated	2356	100	2134	100

GPMix = EN6, EN27, PM87, PM330

- 124 -

TABLE 11

EN	Ggt – B100		Ggt – C3201		Ggt – 17916		EN	Ggt – B100		Ggt – C3201		Ggt – 17916	
	4 days	7 days	4 days	7 days	4 days	7 days		4 days	7 days	4 days	7 days	4 days	7 days
1	-	+	-	+/-	-	+/-	32	-	-	-	-	-	-
2	-	++	-	-	-	-	33	-	++	+++	++	+++	+++
3	-	+	-	+/-	+/-	+/-	34	-	-	-	-	-	+/-
4	-	+	-	+	-	+/-	35	-	-	+	++	-	-
5	-	-	-	-	-	+/-	36	-	-	-	+	-	+/-
6	+	+/-	-	-	-	-	37	-	-	-	+	-	-
7	-	-	-	+	-	+/-	38	-	-	-	+	-	+/-
8	+++	+++	+++	+++	+++	+++	39	-	+	-	+/-	-	-
9	-	-	-	-	-	-	40	-	-	-	+	-	-
10	-	-	-	+	-	+	41	-	-	-	-	-	-
11	+	+	-	-	-	-	42	-	-	-	-	-	-
12	ND	ND	ND	ND	ND	ND	43	-	-	-	-	-	-
13	+++	+++	+++	+++	+++	+++	44	-	-	-	-	-	-
14	ND	ND	ND	ND	ND	ND	45	-	+	+/-	+	+/-	+/-

- 125 -

TABLE 11 (cont'd)

	Ggt – B100		Ggt – C3201		Ggt – 17916		EN	Ggt – B100		Ggt – C3201		Ggt – 17916		Ggt – B100		Ggt – C3201		Ggt – 17916	
	4 days	7 days	4 days	7 days	4 days	7 days		4 days	7 days	4 days	7 days	4 days	7 days	4 days	7 days	4 days	7 days	4 days	7 days
EN																			
15	-	-	-	+	-	-	46	-	+	-	+/-	-	+	-	-	-	+/-	-	-
16	+	++	+	++	+	++	47	-	++	+	++	+	-	-	-	-	-	-	-
17	+/-	++	++	+++	++	+++	48	-	++	++	+++	++	-	+	++	++	++	+/-	+/-
18	-	-	-	+	-	+	49	-	+	-	+	+	+/-	-	+/-	+/-	+/-	+/-	+/-
19	+++	+++	+++	+++	+++	+++	50	-	+++	+++	+++	+++	+	-	+	+	+	+	+
20	-	-	-	-	-	-	51	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
21	ND	ND	ND	ND	ND	ND	52	-	+	ND	ND	ND	+	-	+	-	+	-	-
22	-	+/-	-	+	-	+	53	+++	++	-	-	-	++	++	+	-	+	-	+/-
23	-	+	-	+	-	+	54	+	+	-	+	+	+	+	+	-	+	-	+
24	ND	ND	ND	ND	ND	ND	55	+	+	ND	ND	ND	+	+	+	+	+	+	+
25	-	-	+/-	++	-	++	56	+++	+++	-	+	+	+++	+++	+++	+++	+++	+++	+++
26	++	+++	+++	+++	+++	+++	57	++	++	+++	+++	+++	++	++	+++	+++	+++	+++	+++
27	+++	+++	-	+	-	+	58	+++	+++	-	+	+	+++	+++	+++	+++	+++	+++	+++
28	-	+	+	+++	+++	+++	59	-	+	+++	+++	+++	+	-	+	+	-	-	+/-

- 126 -

TABLE 11 (cont'd)

	Ggt – B100		Ggt – C3201		Ggt – 17916		EN	Ggt – B100		Ggt – C3201		Ggt – 17916	
	4 days	7 days	4 days	7 days	4 days	7 days		4 days	7 days	4 days	7 days	4 days	7 days
EN													
29	-	-	-	+/-	-	-	60	-	-	-	-	-	+/-
30	-	+	-	+	+/-	+	61	++	+++	+++	+++	+++	+++
31	-	-	-	+/-	-	-							

Strength of antagonism of each actinomycete isolate against fungal wheat pathogens, measured after 4 and 7 days of incubation. Very strong antagonism (+++), Strong antagonism (++), Moderate antagonism (+), Weak antagonism (+/-), No antagonism (-), Not done (ND).

- 127 -

TABLE 12

	<i>R. solani</i>			<i>R. solani</i>	
EN	4 days	7 days	EN	4 days	7 days
2	+/-	-	27	+	++
3	+/-	++	28	++	+++
4	+	+	30	+/-	+/-
5	++	+++	35	+	+/-
6	-	+	39	+	+/-
7	+/-	+/-	43	-	+/-
9	+	+	46	++	+
16	+	++	47	+/-	+
17	+++	+++	57	+++	+++
19	+++	+++	59	++	++
23	-	+	60	++	+++
26	+++	+++			

Strength of antagonism of each actinomycete isolate against fungal wheat pathogens, measured after 4 and 7 days of incubation. Very strong antagonism (+++), Strong antagonism (++), Moderate antagonism (+), Weak antagonism (+/-), No antagonism (-), Not done (ND).

- 128 -

TABLE 13

	Pythium sp. KAP3		Pythium sp. BH40		EN	Pythium sp. KAP3		Pythium sp. BH40	
	4 days	7 days	4 days	7 days		4 days	7 days	4 days	7 days
EN					EN				
2	-	-	-	-	26	++	++	+++	+++
3	+	+	+	+/-	27	+	+	+	+
4	-	-	-	-	28	+++	+++	++	+
5	++	++	+/-	+/-	35	+/-	-	-	-
6	+/-	-	+/-	-	39	+/-	+/-	-	-
7	+	+/-	+/-	+/-	44	-	-	-	-
9	+	+	+/-	+/-	46	-	+/-	+	+/-
16	+	+	+	+/-	47	-	-	-	+/-
17	+++	+++	++	++	57	+/-	+/-	+	+
19	+++	+++	+++	+++	59	+	+/-	+	+
22	-	-	+/-	-	60	+	+	+/-	++
23	+	+	+	+					

Strength of antagonism of each actinomycete isolate against fungal wheat pathogens, measured after 4 and 7 days incubation. Very strong antagonism (+++), Strong antagonism (++), Moderate antagonism (+), Weak antagonism (+/-), No antagonism (-), Not done (ND).

- 129 -

TABLE 14

Isolate	Endophyte	Inhibition of <i>F. graminearum</i> on half strength PDA
	Nearest 16S rDNA match	
SE2	<i>S. triticum</i>	26.7%
EN27	<i>S. triticum</i>	60.0%
SE1	<i>S. triticum</i>	60.0%
EN28	<i>S. triticum</i>	53.3%
EN57	<i>S. triticum</i>	43.3%
EN35	<i>S. triticum</i>	50.0%
EN2	<i>Microbispora</i> sp.	43.3% ^a
EN59	<i>S. galilaeus</i>	46.7%
EN43	<i>Micromonospora</i> sp.	6.7%
EN39	<i>S. galilaeus</i>	16.7%

^a This isolate caused generally reduced vigour of the pathogen, including a reduction in aerial mycelium production and reduced growth even away from the actinomycete.

- 130 -

TABLE 15

Isolate	% root inc.	% shoot inc.	% germ inc.	Significant results
EN2	-1	-11	20	
EN3	24	2	20	root p<0.10
EN4	8	3	4	
EN5	2	1	16	root p<0.05, germination
EN6	36	8	24	p=0.073
EN7	19	8	12	
EN9	17	-1	20	
EN10	25	6	16	root p<0.10
EN16	24	9	-4	root p<0.10
EN17	9	-2	-4	

- 131 -

TABLE 15 (cont'd)

Isolate	% root inc.	% shoot inc.	% germ inc.	Significant results
EN19	-6	-6	24	germination p=0.034 root p<0.05 root p<0.05
EN22	14	16	0	
EN23	12	-3	0	
EN26	-3	2	0	
EN27	34	11	-4	
EN28	-28	-9	-16	
EN30	1	-4	4	
EN35	-2	0	-8	
EN39	-16	11	-12	
EN43	-2	-10	16	
EN46	-3	7	-4	
EN47	-9	-2	-4	

- 132 -

TABLE 15 (cont'd)

Isolate	% root inc.	% shoot inc.	% germ inc.	Significant results
EN57	7	14	-4	shoot p<0.01
EN58	5	6	-20	shoot p<0.10, germination
EN59	-3	15	-16	p=0.035
EN60	-2	3	0	
SE1	-25	-23	0	root and shoot p<0.01
SE2	29	-11	20	root p<0.10

Red numbers indicate results significant at p<0.05, blue numbers indicate results where p<0.10.

- 133 -

TABLE 16

Statistical data (T-tests)		
Isolate	% Change	plant part
p<0.05		
EN6	36	root
EN19	24	germination
EN27	34	root
EN28	-28	root
EN59	-16	germination
0.05<p<0.10		
EN3	24	root
EN6	24	germination
EN10	25	root
EN16	24	root
EN57	14	shoot
EN59	15	shoot
SE1	-25	root
	-23	shoot
SE2	29	root

Those isolates shown in bold type are isolates that belong to *Streptomyces triticum* or *Streptomyces triticum* var. *griseoviride*.

- 134 -

TABLE 17

In planta biocontrol activity of endophytic actinobacteria against Ggt8 in steamed soil.

EN Isolate	Ggt biocontrol ^a		EN	Isolate sequence match	Ggt biocontrol ^a	
	%	P			%	P
2 <i>Microbispora</i> sp.	31	0.066	17	<i>S. triticum</i>	27	0.107
43 <i>Micromonospora</i> sp.	25	0.044	19	<i>S. triticum</i>	-4	0.722
46 <i>Nocardioides albus</i>	25	0.064	22	<i>S. triticum</i>	41	0.028
47 <i>Nocardioides albus</i>	31	0.007	23	<i>S. triticum</i>	34	0.006
13 <i>Streptomyces</i> sp.	-4	0.749	27	<i>S. triticum</i>	27	0.018
18 <i>Streptomyces</i> sp.	-3	0.745	28	<i>S. triticum</i>	27	0.003
33 <i>Streptomyces</i> sp.	11	0.567	35	<i>S. triticum</i>	40	0.000
36 <i>Streptomyces</i> sp.	18	0.143	57	<i>S. triticum</i>	36	0.022
37 <i>Streptomyces</i> sp.	-4	0.774	3	<i>S. galilaeus</i>	15	0.349
38 <i>Streptomyces</i> sp.	10	0.446	4	<i>S. galilaeus</i>	29	0.006
51 <i>Streptomyces</i> sp.	21	0.094	39	<i>S. galilaeus</i>	61	0.001
58 <i>Streptomyces</i> sp.	-1	0.934	50	<i>S. galilaeus</i>	30	0.035
30 <i>S. argenteolus</i>	26	0.022	32	<i>S. neyagawensis</i>	-6	0.606
54 <i>S. argenteolus</i>	4	0.743	52	<i>S. pseudovenezuelae</i>	19	0.142
60 <i>S. argenteolus</i>	37	0.002	53	<i>S. pseudovenezuelae</i>	26	0.099
8 <i>S. bottropensis</i>	11	0.458	61	<i>S. maritimus</i>	3	0.794
9 <i>S. bikiniensis</i>	17	0.068	26	<i>S. peruviansis</i>	13	0.310
5 <i>S. triticum</i>	0	0.977	20	<i>S. subutilus</i>	13	0.307
16 <i>S. triticum</i>	35	0.054	34	<i>S. violarius</i>	7	0.463

^a Percentage of mean change in disease rating compared to the control. Negative values represent an increase in disease rating.

- 135 -

TABLE 18

Biocontrol of *Ggt* and *Rhizoctonia solani* naturally present in field soil by endophytic actinobacteria that showed significant activity in steamed soil

EN	Isolate	Ggt biocontrol ^a (steamed soil)		Ggt biocontrol ^a (field soil)		Rhizoctonia biocontrol ^a (field soil)	
		%	P	%	P	%	P
2	<i>Microbispora</i> sp.	31	0.066	53	0.001	39	0.10
43	<i>Micromonospora</i> sp.	25	0.044	22	0.233	-89	0.00
46	<i>Nocardioides albus</i>	25	0.064	71	0.001	36	0.20
47	<i>Nocardioides albus</i>	31	0.007	43	0.071	19	0.49
51	<i>Streptomyces</i> sp.	21	0.094	32	0.126	11	0.67
30	<i>S. argenteolus</i>	26	0.022	41	0.020	35	0.15
60	<i>S. argenteolus</i>	37	0.002	54	0.002	55	0.02
9	<i>S. bikiniensis</i>	17	0.068	18	0.231	43	0.08
16	<i>S. triticum</i> var. <i>griseoviride</i>	35	0.054	32	0.108	16	0.47
22	<i>S. triticum</i>	41	0.028	20	0.241	51	0.06
23	<i>S. triticum</i>	34	0.006	14	0.363	44	0.09
27	<i>S. triticum</i>	27	0.018	40	0.013	35	0.15
28	<i>S. triticum</i>	27	0.003	20	0.403	49	0.11
35	<i>S. triticum</i>	40	0.000	41	0.042	-20	0.44
57	<i>S. triticum</i>	36	0.022	19	0.295	44	0.06
4	<i>S. galilaeus</i>	29	0.006	11	0.541	16	0.55
39	<i>S. galilaeus</i>	61	0.001	22	0.239	29	0.30

^aPercentage of mean change in disease rating compared to the control. Negative values indicate an increase in disease rating.

- 136 -

TABLE 19

Endophyte	Barley shoot dry wt% change	Barley shoot length% change	Barley Germ % change	Oat Shoot dry wt% change
EN2	15.94	15.7	10	-
EN3	18.94	21.8	13.3	12.8
EN6	17.3	22.1	0	9.5
EN16	-	12.7	3.3	-
EN27	15.3	27.8	16.7	-
EN57	13.3	29.7	3.3	15.6
EN60	19.3	21.8	10.0	6.5
SE1	11.3	19.7	3.3	17
SE2	16.3	22.6	6.7	-

- 137 -

TABLE 20

Endophyte	Wheat root length % change	Wheat shoot length % change
PM87	56	25
PM185	41	23
PM208	-	20
PM330	65	24

- 138 -

Results of Field trials in the 2003 growing season

Table 21: Field Trial results showing increase in grain yield with actinomycete endophyte treatments

5

Treatment	Bute Take-all ² kg/ha	% of UT	Bute Crown Rot ³ kg/ha	% of UT	Murray Bridge Rhizoc ¹ kg/ha	% of UT	Pine Point Take- all/Growth ² kg/ha	% of UT	Smoky Bay Rhizoc ² kg/ha	% of UT
EN27 low	2182	99	1802	105	1517	91	2196	100	823	99.5
EN27 high	2253	102	1761	102	1829	109	2389*	109	872	105
EN16 low	2285	103	1685	98	1828	109	2179	100	865	105
En16 high	2326*	105	1726	100	1647	98	2174	99	859	104
EN46 low	2260	102	1953*	114	2052	122	2157	99	906*	110
EN46 high	2187	99	nd	nd	nd	nd	2009	92	nd	nd
EN28 low	nd	nd	1792	104	1438	86	2313	106	874	106
EN28 high	nd	nd	1701	99	1849*	110	2232	102	825	100
EN60 low	2272	103	nd	nd	nd	nd	nd	nd	nd	nd
EN60 high	2259	102	nd	nd	nd	nd	nd	nd	nd	nd
Jockey	2359*	107	nd	nd	nd	nd	2541*	116	nd	nd
Untreated	2212	100	1720	100	1676	100	2188	100	827	100
* these grain yields were statistically higher than the "untreated"										
% of UT = % of untreated		nd = not done								
¹ Barque barley	² Frame wheat	³ durum wheat								

- 139 -

Table 22: Field Trial results showing increase in grain yield with actinomycete endophyte treatments

Treatment	Haslam Rhizoc ¹	% of UT	Burra Rhizoc ²	% of UT	Esperance Rhizoc	% of UT	Tumby Bay Growth ²	% of UT	Paskeville Pythium ²	% of UT	Meningie Pythium ²	% of UT	Marinna NSW Pythium ²	% of UT	Tamworth Crown Rot ³	% of UT
	kg/ha		kg/ha		kg/ha		kg/ha		kg/ha		kg/ha		kg/ha		kg/ha	
EN27 low	1813	95	1740	100	nd		2394	98	2844	91	587	93	1616	93	nd	
EN27 high	1756	92	1626	93	2136	110	2387	98	2783	89	507	80	1476	85	3410	101
EN16 low	1996	105	1614	93	nd		2394	98	2744	88	396	63	1620	93	nd	
En16 high	1882	99	1801	103	nd		2481	101	2797	90	600	95	1667	96	nd	
EN46 low	1854	98	1678	96	nd		2383	97	2654	85	537	85	1531	88	nd	
EN46 high	nd		1755	101	2451	126	2533	104	2783	89	nd		1555	90	3290	98
EN28 low	1944	102	1684	97	nd		2484	102	nd		nd		nd		nd	
EN28 high	2015	106	1851	106	nd		2373	97	2900	93	500	79	1567	90	nd	
EN60 low	nd		nd		nd		nd		nd		nd		nd		nd	
EN60 high	nd		nd		nd		nd		nd		nd		nd		nd	
EN23 low	nd		nd		nd		nd		2720	87	602	95	1309	75	nd	
EN23 high	nd		nd		nd		nd		2974	95	533	84	1705	98	nd	
Jockey	nd		nd		nd		2529	103	nd		nd		nd		nd	
Untreated	1899	100	1743	100	1948	100	2446	100	3115	100	631	100	1736	100	3360	100

Explanation:

The treatment names eg EN27, EN46 etc are the identification numbers given to all the actinomycetes we have isolated. The actual number has no meaning, it is just the number we use to identify all the hundreds of different strains we have. “low and high” are the rates – we applied the spores at a low and a high rate.

“ Untreated” is as it sounds.

% of UT = % of untreated; nd = not done ; ¹Barque barley; ²Frame wheat; ³Bellaroi durum wheat

- 140 -

BIBLIOGRAPHY:

Bonner *et al.*, (1973) *J. Mol. Biol.* 81:123

Coombs, J.T. and Franco, C.M.M. (2003) Isolation and Identification of Actinobacteria from Surface-Sterilized Wheat Roots, *Appl. Environ. Microbiol.*, 69:5603-5608.

Coombs, J.T. and Franco, C.M.M. (2003) Visualization of an endophytic *Streptomyces* species in wheat seed. *Appl. Environ. Microbiol.* 69(7):4260-4262.

Conn, V. M. and Franco, C. M. M. (2004). Analysis of the endophytic actinobacterial population in the roots of wheat (*Triticum aestivum* L.) by Terminal Restriction Fragment Length Polymorphism (T-RFLP) and sequencing of 16S rRNA clones. *Applied and Environmental Microbiology* 70:1787-1794.

Crawford, D.L., Lynch, J.M., Whipps, J.M., Ousley, M.a. (1993) *Applied & Environmental Microbiology* 59(11):3899-3905.

Flett, F. *et al.* (1997) *FEMS Microbiol. Lett.* 155:223-229.

Glickman, E. and Dessaux, Y. (1995) *Applied and Environmental Microbiology* 61:793-796.

Kieser, T. *et al.* (2000) Practical *Streptomyces* genetics. The John Innes Foundation, Norwich.

Mazodier, P. *et al.* (1989) *J. Bacteriol.* 171:3583-3585.

Roget, D.K., Coppi, J.A., Herdina, Gupta VVSR (1999) Proceedings of the 1st Australasian Soilborne Disease Symposium Magarey (eds).

5

Sun, J. (1999) *Microbiol.* 145:2221-2227.

- 1 -

SEQUENCE LISTING

<110> FLINDERS TECHNOLOGIES PTY. LTD.

<120> A METHOD FOR PRODUCTIVITY IMPROVEMENT AND AGENTS USEFUL FOR SAME

<130> 12469560/TDO

<150> 60/485,241

<151> 2003-07-07

<160> 33

<170> PatentIn version 3.1

<210> 1

<211> 1158

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(1155)

<223> "n" is unknown nucleotide

<400> 1

cttaacacat gcaantcaag cggaaaggcc cttcggggta ctcaancggc naacgggtga	60
ttaacacntg antaacctgc ccctgactct gggataancc tgggaaactg ggtctaatac	120
cggatacaac cattttctcnc atgggatggg ggtggaaant ttttncgggtt ggggatgggc	180
tgcgggccta tcaccttggt ggtgggggtga tggcctacca aggcgacgaa cggtagcccg	240
cctgagaggg cgaccggcca cactgggact gagacaccgc ccgaactcct acgggaggca	300
gcactgggga atattgccca tgggcggaag cctgacgcag ngacgccgcg tgggggatga	360
cggccttngg gttgtaaacc tntttcagca gggacgaagt tgacgtgtac ctgtagaaga	420
agcgccggct aaatangtgc cagcagccgc ggtaatangt agggcgcgag cgtnntccgg	480

- 2 -

```

aattattggg cgtaaagagt ttgtagggtg cttgttgctt ttgccgtgaa agcccgtggc 540
ttaantacgg gtttgcggtg gatacgggca ggctagaggc tggtaggggc aagcggaatt 600
cctgggtgtag cgggtgaaatg cgcagatatc aggaggaaca ccgggtggcga aggcggcctg 660
ctggggccagt tctgacggtg aggagcgaaa gcgtggggag cgaacaggat tagataccct 720
ggtagtccac gctgtaaacg ttggggcgcta ggtgtggggg tcttccacga tctctgtgcc 780
gtagctaacg cattaagcgc cccgcctggg gagtacggcc gcaaggctaa aactcaaagg 840
aattgacggg ggcccgcaca agcggcggag catgttgctt aattcgacgc aacgcgaaga 900
accttaccaa ggtttgacat acaccgaaa cactcanana tgggtgcctc ctttggactg 960
gtgtacaggt ggtgcatggc tgtcnnccac ctctgtctgt nagatgtngg gttaagtccc 1020
gcaacgancg caacccttgg ttccatgttg ccagcacncc ctttgnngtg gtggggacnc 1080
atggganaat gccggggctn actcnggagg aaggtgggga tgacgtcaag tnatcntgcc 1140
ccttatgttc ttgnngtg 1158

```

<210> 2

<211> 1437

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(1437)

<223> "n" is unknown nucleotide

<400> 2

```

gctggcggcg tgcttaacac atgcaagtcg aacgatgaac cacttcggtg gggattagtg 60
gcgaacgggt gagtaacacg tgggcaatct gcccttcact ctgggacaag ccctggaaac 120
ggggtctaata accggataac actnctgctc tcatgggcag gggttaaaag ctccggcggg 180
gaaggatgag cccgcggcct atcagcttgt tggtagaggta atggctcacc aaggcgacga 240
cgggtagccg gcctgagagg gcgaccggcc aactggggac tgagacacgg ccagactcc 300
tacgggaggc agcagtgggg aatattgcaa caatgggcga aagcctgatg cagcgacgcc 360
gcgtgaggga tgacggcctt cgggttgtaa acctctttca gcagggaaga agcgaaagtg 420
acggtacctg cagaagaagc gccggctaac tacgtgccag cagccgcggg aatacgtagg 480
gcgcaagcgt tgtccggaat tattgggcgt aaagagcttg taggcggcct gtcacgtcgg 540

```

- 3 -

```

gtgtgaaagc ccgggggctta accccggggtc tgcatttcgat acgggctagc tagagtgtgg      600
tagggggagat cggaattcct ggtgtagcgg tgaaatgcgc agatatcagg aggaacaccg      660
gtggcgaagg cggatctctg ggccattact gacgctgagg agcgaaagcg tggggagcga      720
acaggattag ataccctggg agtccacgcc gtaaaccggtg ggaactaggt gttggcgaca      780
ttccacgtcg tcggtgccgc agctaacgca ttaagttccc cgcctgggga gtacggccgc      840
aaggctaaaa ctcaaaggaa ttgacggggg ccgcacaaag cagcggagca tgtggcttaa      900
ttcgacgcaa cgcgaagaac cttaccaagg cttgacatac accggaaagc atcagagatg      960
gtgccccctt tgtggttcgg tgtacagggt gtgcatggct gtcgtcagct cgtgtcgtga     1020
gatgttgggt taagtccgc aacgagcgc acccttgttc tgtgttgcca gcatgccctt     1080
cggggtgatg gggactcaca ggagaccgcc ggggtcaact cggaggaagg tggggacgac     1140
gtcaagtcac catgcccctt atgtcttggg ctgcacacgt gctacaatgg ccggtacaaa     1200
gagctgcgat accgtgaggt ggagcgaatc tcaaaaagcc ggtctcagtt cggattgggg     1260
tctgcaactc gaccccatga agtcggagtt gctaataatc gcanatcagc attgctgcgg     1320
tgaatacgtt cccgggcctt gtacacaccg cccgtcacgt cacgaaagtc ggtaacaccc     1380
gaagccggtg gccaaaccct tgtgggaggg agctgtcgaa ggtgggactg gcgattg      1437

```

<210> 3

<211> 317

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(311)

<223> "n" is unknown nucleotide

<400> 3

```

gtaatggcc anaaaaccgc cttcgccacc ggtgttcctc ctgatatctg cgcatttcac      60
cgctacacca ggaattccna totcccctac cacactctag ctagcccgta tcnatgcaa     120
actcgggggt aagcccnag ctttcacatc cgacgtgaca agccgcctac aanctcttta     180
cgccaataa ttccgganaa cgctcgcacc ctacntntta ccgcggctgc tggcncgtnt     240
ttagccggtg cttcttctgc aggtaccgtc actttcgctt cttccctgct naaaaagggt     300
tacaacccta nggccgt                                     .      317

```

- 4 -

<210> 4
 <211> 1048
 <212> DNA
 <213> actinomycete

<220>
 <221> misc_feature
 <222> (1)..(1043)
 <223> "n" is unknown nucleotide

<400> 4
 tgagggatga cggcnttcgg ggttgtaaac nttntcacc agggaagaag cgaaagtgnc 60
 ggtacctgca gaagaagcgc cgnctaacta cgggccagca tccgcggtaa tacgtagggc 120
 gcaatcgttg tccggaatta ntgggcgtaa agagntcgta ggcggttat cacgtcgggt 180
 gtgaaagccc ggggcttaag ccccggtct gcattcgata cgggctagct agantntgnt 240
 aggggagatc ggaattcctg gtgtagcggg gaaatgcgca gatatcagga ggaacaccgg 300
 tggcgaaggc ggatctctgg gccattactg acgctgagga gcgaaagcgt ggggagcgaa 360
 caggattaga taccctggta gtccacgccg taaacggtgg gaactaggtg ttggcgacat 420
 tccacgtcgt cggtgccgca gctaacgcat taagttcccc gcctggggag tacggccgca 480
 aggctaaaac tcaaaggaat tgacgggggc ccgcacaagc agcggagcat gtggcttaat 540
 tcgacgcaac gcgaagaacc ttaccaaggc ttgacataca ccggaaagca tcagagatgg 600
 tgccccctt gtggtcgggtg tacaggtggg gcatggctgt cgtcagctcg tgtcgtgaga 660
 tggttgggtta agtcccgcaa cgagcgcaac ccttggttct gtgttgccag catgcccttc 720
 ggggtgatgg ggactcacag gagaacgccg gggccaactc ggaggaagggt ggggacgacg 780
 tcaagtcatc atgcccccta tgtcttgggc tgcacacgtg ctacaatggc aggtaaatga 840
 gctgcgatac cgtgaggtgg agcgaatctc aaaaaagcct gtctcanttc ggattggggg 900
 ctgnaantcg accccatgaa agtcggagtt gctaattatc ccagatcaac attgctggcg 960
 gtgaatacgt tcccggggcc ttggtaaaca ccgcccgtca angtnaagaa agtcgggtaa 1020
 cacccgaaan ccggtgggcc aanccctt 1048

- 5 -

<210> 5
 <211> 508
 <212> DNA
 <213> actinomycete

<220>
 <221> misc_feature
 <222> (1)..(472)
 <223> "n" is unknown nucleotide

<400> 5
 ccgccttcgc cacoggggtgt toctoctgat atctgogcat ttcaccgcta caccaggaaa 60
 ttocnatctc ccctaccaca ctctanctan cccgtatcga atgcaaaccg ggggttaanc 120
 cccgggcttt cacaccogac ntgacaagcc gcctacaaac tctttaogcc caataattcc 180
 ggacaacgct tgcgccctac ntattacogc ggctgctggc acntatttag ccggcgcttc 240
 ttctgcaggt accgtcactt togtttcttc cctgctgaaa aaggtttaca acccgaaggc 300
 cgtcatccct cacgcggcgt cgctgcatca ggctttcgcc cattgtgcaa tattccccac 360
 tgctgcctcc cntaggaatc tgggocgtgt ctcaatccag tgtggccggt cccctctcng 420
 gcgggctacc gtentccctt ggtnaccatt anctcaccaa caactgatag gncgcgggct 480
 catcttcaog cgggaacttt caaccacc 508

<210> 6
 <211> 1420
 <212> DNA
 <213> actinomycete

<400> 6
 ggogggcgtgc ttaacacatg caagtcgaac gatgaagccc ttcgggggtgg attagtggcg 60
 aacgggtgag taacacgtgg gcaatctgcc cttcactctg ggacaagccc tggaaacggg 120
 gtctaatacc ggatacgatt cgggagggcat ctcttggtac tggaaagctc cggcggtgaa 180
 ggatgagccc gcggcctatc agcttggtgt gggtaatggc ctaccaaggc gacgacgggt 240
 agccggcctg agagggcgac cggccacact gggactgaga cacggcccag actcctacgg 300
 gaggcagcag tggggaatat tgcacaatgg gcgaaagcct gatgcagcga cgccgcgtga 360
 gggatgacgg ccttcggggtt gtaaacctct ttcagcaggg aagaagcgag agtgacggta 420

```

cctgcagaag aagcgccggc taactacgtg ccagcagccg cggtaatacg tagggcgcaa      480
gcggtgtccg gaattattgg gcgtaaagag ctcgtaggcg gcttgtcacg tcgggtgtga      540
aagcccgggg cttaaccccg ggtctgcac cgcacgggc aggctagagt gtggtagggg      600
agatcggaat tcctgggtgta gcggtgaaat gcgcagatat caggaggaac accggtggcg      660
aaggcggatc tctgggccat tactgacgct gaggagcgaa agcgtgggga gccaacagga      720
ttagataccc tggtagtcca cgccgtaaac gttggaacta ggtgttggcg acattccacg      780
tcgtcggtgc cgcagctaac gcattaagtt cccgcctgg ggagtacggc cgcaaggcta      840
aaactcaaag gaattgacgg gggcccgcac aagcagcgga gcatgtggct taattcgacg      900
caacgcgaag aaccttacca aggcttgaca tataccggaa agcgccagag atggtgcccc      960
ccttgtggtc ggtatacagg tgggtgcatgg ctgtcgtcag ctcggtcgt gagatgttgg     1020
gttaagtccc gcaacgagcg caacccttgt cctgtgttgc cagcatgcc ttccgggtga     1080
tggggactca caggagaccg ccgggggtcaa ctcgaggaa ggtggggacg acgtcaagtc     1140
atcatgcccc ttatgtcttg ggctgcacac gtgctacaat ggccggtaca aagagctgcg     1200
atgccgtgag gcggagcgaa tctcaaaaag ccggtctcag ttcggattgg ggtctgcaac     1260
tcgaccccat gaagtcggag ttgctagtaa tcgcagatca gcattgctgc ggtgaatacg     1320
ttcccgggcc ttgtacacac cgcccgtcac gtcacgaaag tcggtaacac ccgaagccgg     1380
tgggccaacc cctcggggag ggagctgtcg aaggtgggac                          1420

```

<210> 7

<211> 1239

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(1217)

<223> "n" is unknown nucleotide

<400> 7

```

gcttnttggg gggncnatgg cctaccaagg ngaggacggn tanccngcct gngagggaga      60
ccgnccacac tgggaatgng anacggcca gaatcctacg ggaggcagca nnggggaana     120
ttgcacaang ggcgaaagcc tgatgcagng angccgcgtg agggaagacg gcctttgggt     180
tgtaaacctn ttnagcagg gaagaagcga aagtgacggt acctgcagaa gaagcgccgg     240

```

- 7 -

```

ctaantangt gccagcagcc gcggttaatan gtagggcgca agcgttggtcc ggaattattg      300
ggcgtaaaga gcttgtaggc ggcttgtcan gtnggatgtg aaagcccggg gcttaacccc      360
gggtttgcat ttgatacggg ctagctagag tgtggtaggg gagatnggaa ttcctggtgt      420
agcggtgaaa tgcgcagata tcaggaggaa caccggtggc gaaggcggat ctctgggcca      480
ttactgacgc tgaggagcga aagcgtgggg agcgaacagg attagatacc ctggtagtcc      540
acgccgtaaa cgttgggaac taggtgttgg cgacattcca cgtcgtcggg gccgcagcta      600
acgcattaag ttccccgcct ggggagtacg gccgcaaggc taaaactcaa aggaattgac      660
gggggcccgc acaagcagcg gagcatgtgg cttaattcga cgcaacgcga agaaccttac      720
caaggcttga catataccgg aaagcatcag agatgggtgcc ccccttggtg tcggtataca      780
ggtggtgcat ggctgtcgtc agctcgtgtc gtgagatgtt gggttaagtc ccgcaacgag      840
cgcaaccctt gttctgtgtt gccagcatgc ccttcggggg gatggggact cacaggagac      900
tggcgggggtc aactcggagg aaggtgggga cgacgtcaag tcatcatgcc ccttatgtct      960
tggggctgca cacgtgctac aatggccggg acaatgagct gcgatgccgc gaggcggagc     1020
gaatctcaaa aagccggtct cagttcggat tgggggtctg naactcgacc ccatgaantc     1080
ggagttgcta ataatcccaa attcancatt ggtgcggtga atacttcccg ggcctggtac     1140
acnaccgccc gtcaactcac gaaagtcggg naaacccgaa accggtgggc caacccttg      1200
tggaaggaa ctggccnaag tgggactggc gattgggac      1239

```

<210> 8

<211> 431

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(424)

<223> "n" is unknown nucleotide

<400> 8

```

ccgccttcgc caccggtgtt cctcctgata tctgcgcatt tcaccgctac accaggaatt      60
ccnatctccc ctaccacact ctagctagcc cgtatcaa at gcaaaccggg ggttaagccc     120
cgggctttca catccnacgt gacaagccgc ctacaanctc ttacgccc aataattccg      180
acaacgcttg cgccctacnt attaccgagg ctgctggcac ntatttagcc ggcgcttctt     240

```

- 8 -

```

ctgcaggtag cgtaactttc gctncttccc tgctgaaana ggttttacaac ccaaaggccn      300
tcatacctcn ccggcctcnt tgcntcnggc ttncncccat tgttcaannt tccccactgc      360
tncctccccct cggaatctgg gccgntgtct cattcccntt ntggccgggc cccctcncag      420
gccngctacc c                                          431

```

<210> 9

<211> 653

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(640)

<223> "n" is unknown nucleotide

<400> 9

```

ctcagcgten gtaatggccc aaaaaccgcc ttogccaccg gtgttcctcc tgatatctgc      60
gcatttcacc gctacaccag gaattccnat ctcccctacc aactctagc tagcccgtag      120
cnaatgcaaa cccgggggta anccccgggc ttccacatcc nacntgacaa gccgcctaca      180
anctctttac gcccaataat tccggacaac gcttgcnccc tacttattac cgcggctgct      240
ggcacttatt tagccggcgc ttctttctgca ggtaccgtca ctttcgcttc ttccctgctn      300
aaaaagggttt acaaccnnaa ggccgtcatc cctcacgcgg cntcgctgca tcaggctttc      360
nccattgtg caatattccc cactgctgcc tcccgtagga ttctggggccg tntctcattc      420
ccantgtggc cggtcgcctt ctacggccgg ctacccgten tnccttggg aggccattac      480
cccaccaaca agctnatagg ccgcggggctc atccttcacc gccggaagct ttcaaccccn      540
tccatgcggg anaaattggt ntccggtatt aaaccccggt tccagggntt gtcccaaaat      600
tgaagggggg attgnccact ttttactcac ccgttcnccn ctaatccacc acc          653

```

<210> 10

<211> 1444

<212> DNA

<213> actinomycete

- 9 -

<400> 10

acgaacgctg gcggcgtgct taacacatgc aagtcgaacg atgaagccgc ttcggtggtg	60
gattagtggc gaacgggtga gtaacacgtg ggcaatctgc ccttcactct gggacaagcc	120
ctggaaacgg ggtctaatac cggataacac tctgtcccgc atgggacggg gttgaaagct	180
ccggcgggtga aggatgagcc cgcggcctat cagcttggtg gtggggtaat ggcctaccaa	240
ggcgacgacg ggtagccggc ctgagagggc gaccggccac actgggactg agacacggcc	300
cagactccta cgggaggcag cagtggggaa tattgcacaa tgggcgaaag cctgatgcag	360
cgacgccgcg tgagggatga cggccttcgg gttgtaaacc tctttcagca ggaagaagc	420
gaaagtgacg gtacctgcag aagaagcgcc ggctaactac gtgccagcag ccgcggtaat	480
acgtagggcg caagcgttgt ccggaattat tgggcgtaaa gagctcgtag gcggcttgtc	540
acgtcggatg tgaaagcccg gggcttaacc ccgggtctgc attcgatacg ggctagctag	600
agtgtggtag gggagatcgg aattcctggg ttagcgggtga aatgcgcaga tatcaggagg	660
aacaccggtg gcgaaggcgg atctctgggc cattactgac gtctgaggag cgaaagcgtg	720
gggagcgaac aggattagat accctggtag tccacgccgt aaacgttggg aactaggtgt	780
tggcgacatt ccacgtcgtc ggtgccgcag ctaacgcatt aagttccccg cctggggagt	840
acggccgcaa ggctaaaact caaaggaatt gacggggggc cgcacaagca gcggagcatg	900
tggcttaatt cgacgcaacg cgaagaacct taccaaggct tgacatatac cggaagcat	960
cagagatggg gcccccttg tggtcggtat acagggtggg catggctgtc gtcagctcgt	1020
gtcgtgagat gttgggttaa gtcccgaac gagcgcaacc cttgttctgt gttgccagca	1080
tgcccttcgg ggtgatgggg actcacagga gactgccggg gtcaactcgg aggaagggtg	1140
ggacgacgtc aagtcatcat gcccttatg tcttgggctg cacacgtgct acaatggccg	1200
gtacaatgag ctgcgatgcc gcgaggcgga gcgaatctca aaaagccggg ctgagttcgg	1260
attgggggtct gcaactcgac cccatgaagt cggagttgct agtaatcgca gatcagcatt	1320
gctgcgggtga atacgttccc gggccttgta cacaccgccc gtcacgtcac gaaagtcggg	1380
aacacccgaa gccgggtggc caacccttgt gggagggagc tgtcgaagggt gggactggcg	1440
attg	1444

- 10 -

<210> 11
 <211> 503
 <212> DNA
 <213> actinomycete

<220>
 <221> misc_feature
 <222> (1)..(499)
 <223> "n" is unknown nucleotide

<400> 11
 ccgccttcgc caccggtggt cctcctgata tctgcgcatt tcaccgctac accaggaatt 60
 ccnatctccc ctaccgaact ctançctgcc cgtatcnact gcaaaccggt ggtaagccc 120
 cgggctttca caaccgacnt gacaagccgc ctacaanctc tttaacncca ataattccgg 180
 acaacgcttg cgccctacnt attaccgctg ctgctggcac ntatttagcc ggcgcttctt 240
 ctgcaggtac cgtcactttc gcttcttccc tgctgaaaaa ggtttacaac ccgaaggccg 300
 tcntccctca cgcggcgctg ctgcatcagg ctttcgcca ttgtgcaata ttccccactg 360
 ctgcctcccg taggattctg ggccgtgtct cantcccant ntggccgggt ccctctcagg 420
 ccggnatccc gtcgtccctt ggtgaaccnc tacctcncca acaanctgat agggcgcggtg 480
 ctcanctgc acgccgganc ttt 503

<210> 12
 <211> 1173
 <212> DNA
 <213> actinomycete

<220>
 <221> misc_feature
 <222> (1)..(1144)
 <223> "n" is unknown nucleotide

<400> 12
 ttaanacatg caantcgaac gatgaaccn gtttcgggtg tggattagt gcgaacggtg 60
 agtaanangt gggcaatttg cccttcattt tggacaagcc ctggaaacgg gttaataacc 120
 ggataacatt ttntcccga tgggangggg ttgaaagntc cggcggtgaa ggatgagccc 180
 gcggcctatn agcttggttg tggggtaatg gcctacccaa gggagacggg tagccggcct 240

- 11 -

gagagggcga ccggccacac tgggaatgag anacggccca gaatcctacg ggaggcagca 300
 gtggggaata ttgcacaatg ggcgaaagcc tgatgcagcg angccgcgtg agggatgacg 360
 gccttnggggt tgtaaaccctt tttnagcagg gaagaagcga aagtgcgggt acctgcagaa 420
 gaagcgccgg ctaaataagt gccagcagcc gcggtaataa gtagggcgca agcgttgtcc 480
 ggaattattg ggcgtaaaga gcttgtaggc ggcttggtcan gtnggatgtg aaagcccggg 540
 gnttaacccc gggtttgcat ttgatacggg ctagntagag tgtggtaggg gagatnggaa 600
 ttccctgggtgt agcggtgaaa tgcgcagata tcaggaggaa caccgggtggc gaaggcggat 660
 ctctgggcca ttactgacgc tgaggagcga aagcgtgggg agcgaacagg attagatacc 720
 ctggtagtcc acgccgtaaa cgttggggaac taggtgttgg cgacattcca cgtcgtcgggt 780
 gccgcagcta acgcattaag ttccccgnct ggggagtagc gccgcaaggc taanactcaa 840
 aggaattgac gggggcccggn acaagcagcg gancatgtgg cttaattcga cgcancgcga 900
 agaaccttac caaggcttga catataccgg aaagcatcag agatgggtgcc ccccttgtgg 960
 tcgntataca ngtggtgcat gnctgtcgtc acctcgtgtc gtgagatgtt gggttaagtc 1020
 ccgcaacgag cgcnacccctt gntctgtgtt gncancatgc ccttcgggggn tgatggggac 1080
 tcacaggana ctgnccgggg tcaactccgg angaagggtg gtgacgaagt caaggtcatc 1140
 atgncccctt atgtcttgggt gctgcacacg tgc 1173

<210> 13

<211> 1404

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(493)

<223> "n" is unknown nucleotide

<400> 13

ttcggnnggtg gantagnngc gnacgggnga ccaacangng ggcaatcccc ccttcanttt 60
 nggacaaccc ctggaaacgg gttntaatac cggataacan tttntccccg catgggangg 120
 ggttgaaagc tccggcggtg aaggatgagc ccgcggccta tcagcttggt ggtggggtaa 180
 tggcctacca aggcgacgac gggtagccgg cctgagaggg cgaccggcca cactgggant 240
 gaganacggc ccagaatcct acgggaggca gcagtgggga atattgcaca atgggcgaaa 300

- 12 -

```

gcctgatgca gcgacgccgc gtgagggatg acggccttcg ggttgtaaac ctttttcagc      360
agggagaag cgaaagtgac ggtacctgca gaagaagcgc cggctaaata ngtgccagca      420
gccgcggtaa tangtagggc gcaagcgttg tccggaatta ttgggcgtaa agagnttgta      480
ggcggcttgt cangtcggat gtgaaagccc ggggcttaac cccgggtttg cattcgatac      540
gggctagcta gagtgtggta ggggagatcg gaattcctgg tgtagcggtg aaatgcgcag      600
atatcaggag gaacaccggt ggcgaaggcg gatctctggg ccattactga cgctgaggag      660
cgaaagcgtg gggagcgaac aggaattaga taccctggta gtccacgccg taaacgttgg      720
gaactaggtg ttggcgacat tccacgtcgt cggtgccgca gctaacgcat taagttcccc      780
gcctggggag tacggccccg aaggctaaaa ctcaaaggaa ttgacggggg cccgcacaag      840
cagcggagca tgtggcttaa ttcgacgcaa cgcaagaac cttaccaagg cttgacatat      900
accggaaagc atcagagatg gtgccccctt tgtggtcggg atacaggtgg tgcattggctg      960
tcgtcagctc gtgtcgtgag atgttgggtt aagtcccgca acgagcgcaa cccttggttc     1020
tgtgttggcc agcatgccct tcgggggtgat ggggactcac aggagactgg ccgggggtcaa     1080
ctcggaggaa ggtggggacg acgtcaagtc atcatgcccc ttatgtcttg gggctgcaca     1140
cgtgctacaa tggccggtac aatgagctgc gatgccgca aggcggagcg aatctcaaaa     1200
aagccggtct cagttcggat tggggctctgc aactcgacct catgaagtcg gagttgctag     1260
taatcgcaga tcagcattgc tgcggtgaat acgttcccgg gccttgtaca caccgcccgt     1320
cacgtcacga aagtcggtaa caccgaagc cggtgggtcca accccttggt ggaggagct      1380
gtcgaaggtg ggactggcga ttgg                                     1404

```

<210> 14

<211> 1411

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(1411)

<223> "n" is unknown nucleotide

<400> 14

```

aacacatgca agtcgaacga tgaagccgct tcgggtgggtg attagtggcg aacgggtgag      60
taacacgtgg ccaantgtgn ccgtcactat gggacgaaga ccttggaaac ggggtctaata     120

```

- 13 -

```

accggataac actctgtccc gcatgggacg gggttgaaag ctccggcggg gaaggatgag 180
cccgcggcct atcagcttgt tgggtgggta atggcctacc aaggcgacga cgggtagccg 240
gcctgagagg gcgaccggcc aactgggac tgagacacgg ccagactcc tacgggaggg 300
agcagtgggg aatattgcac aatgggcgaa agcctgatgc agcgacgccg cgtgagggat 360
gacggccttc gggttgtaaa cctctttcag cagggaagaa gcgaaagtga cggtacctgc 420
agaagaagcg ccggctaact acgtgccagc agccgcggta atacgtaggg cgcaagcggt 480
gtccggaatt attgggcgta aagagctcgt aggcggcttg tcacgtcgga tgtgaaagcc 540
cggggcttaa ccccggtct gcattcgata cgggctagct agagtgtggg aggggagatc 600
ggaattcctg gtgtagcggg gaaatgcgca gatattcagg aggaacaccg gtggcgaagg 660
cggatctctg ggccattact gacgctgagg agcgaaagcg tggggagcga acaggattat 720
ataccctggg agtccacgcc gtaaacgttg ggaactaggt gttggcgaca ttccacgtcg 780
tcggtgccgc agctaacgca ttaagttccc cgctgggga gtacggccgc aaggctaaaa 840
ctcaaaggaa ttgacggggg ccgcacaag cagcggagca tgtggcttaa ttcgacgcaa 900
cgcgagaac cttaccaagg cttgacatat accggaaagc atcagagatg gtgccccct 960
tgtggtcggg atacagggtg tgcattggctg tcgtcanctc gtgtcgtgag atgttgggtt 1020
aagtcccgc aagagcgcaa cccttggtct gtgttgccag catgcccttc ggggtgatgg 1080
ggactcacag gagactgccg gggtaactc ggaggaaggt ggggacgacg tcaagtcac 1140
atgcccctta tgtcttgggc tgcacacgtg ctacaatggc cgctacaatg acctgcgatg 1200
ccgcgaggcg gaccgaatct caaacaagcc cgtctcattc ggattgcggg ctgcaactcc 1260
gaccccatga agtccgactt gctagtactc gcacgtcaac attgctgcgc tgaatacgtc 1320
ccggggcctt gtacacaccg ccggtcacgt cacgaaagtc ggtaacaccc gaagccgggtg 1380
gnccaacccc ttgtgggagg gagctgtcga a 1411

```

<210> 15

<211> 562

<212> DNA

<213> actinomycete

<220> .

<221> misc_feature

<222> (1)..(547)

<223> "n" is unknown nucleotide

- 14 -

<400> 15

```

ccgccttcgc caccggtggt cctcctgata tctgcgcatt tcaccgctac accaggaatt      60
ccnatctccc ctaccacact ctagctancc cgtatcnaat gcaaaccggt ggtaaccgcc      120
cgggctttca caccnacnt nacaanccgc ctacaaactc tttagcggca ataattccgg      180
acaacgcttg cgccctactt attaccggtg ctgctggcac ttatttagcc ggcgcttctt      240
ctgcaggtac cgtcactttc gcttcttccc tgctgaaaaa ggtttacaac ccgaaggcng      300
tcatccctca cgcggcntcg ctgcatcagg ctttcgcccc ttgtgcaata ttccccactg      360
ctgcctcccg tagnantctg ggccgtntct cantcccagt gtggncgggc gccctctcag      420
gccggctacc cgtcgtcncc tnggtnaacc attanntcac caacaagctg ataggccgcg      480
ggctcatcct tcaccgocgg agctttttaac ccctgccccat gaaaacagan gtnttatccg      540
gtattanaac ccgtttccag gg                                         562

```

<210> 16

<211> 1390

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(1362)

<223> "n" is unknown nucleotide

<400> 16

```

atgcaagtcg agcggaaagg cccttcgggg tactcgagcg gcgaacgggt gagtaacacg      60
tgagttaatc tgccccaggc tctggatacc caccggaaaa cggtgattaa taccgaatac      120
gacaaccgat ttgcatgata tgggtggtgna aagtttttcg gcctgggatg tgcttcgcgg      180
cctatcagct tgttggtgag gtaatggctc acccaaggct tcgacggtag ccggcctgag      240
agggtgaccg nccacactgg gactgagaca cggcccagac tcctacggga ggcagcagtg      300
gggaatattg gacaatgggc ggaagcctga tccagcaacg ccgcgtgagg gatgacggcc      360
ttcgggttgt aaacctcttt cagcacagac gaagcgcaag tgacggtatg tgcagaagaa      420
ggaccggcca actacgtgcc agcagccgcg gtaatacgta ggggccgagc gttgtccgga      480
attattgggc gtaaagggtc cgtaggcggt ctgtcgcgtc gggagtgaaa accaggtgct      540

```

- 15 -

```

taacacctgg cctgctttcg atacgggcag nctagaggta cncaggggag aatggaattc      600
ctggtgtagc ggtgaaatgc gcagatatca ggaggaaaca ccggtggcga agncggttct      660
ctgggagtat cctgacgctg aggagcgaaa gtgtggggag cgaacaggat tagataccct      720
ggtagtccac accgtaaacg ttggggcgcta ggtgtgggac acattccacg tgttccgtgc      780
cgcagctaac gcattaancg ccccgcttgg ggagtacggc cgcaangcta aaactcanag      840
gaattgacgg gggcccgcac aagcggcgga gcatgcggat taattcgatg caacgcgaag      900
aaccttacct gggtttgaca taacaccgga agccgtacag atacggcccc ttttagtcgg      960
tgtacagggtg gtgcatggct gtcgtcagct cgctgtcgtg agatgttcgg gttaagtccc     1020
gcaacgagcg caaccctcgt cctatgttgc cagcaattcg gttggggact cataggagac     1080
tgccgggggtc aactcggagg aagggtgggga tgacgtcaag tcatcatgcc ccttatgtcc     1140
agggcttcac gcatgctaca atggccggta caaagggtcg cgatcccgtg agggtgagcg     1200
aatcccaaaa agccgggtctc agttcggatt ggggtctgca actcgacccc atgaagtcgg     1260
agtcgctagt aatcgcagat cagcaacgct gcggtgaata cgttcccggg ccttgtagac     1320
accgcccgtc acgtcacgaa agtcggcaac acccgaagcc antggcccaa ctcgtaagag     1380
agggagctgt                                     1390

```

<210> 17

<211> 1411

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(638)

<223> "n" is unknown nucleotide

<400> 17

```

gtgcttaaca catgcaagtc gaacgatgaa gccgcttcgg tggtggatta gtggcgaacg      60
ggtgagtaac acgtgggcaa tctgcccttc actctgggac aagccctgga aacgggggtct     120
aataccggat aacactctgt ccgcgatggg acgggggttga aagctccggc ggtgaaggat     180
gagcccgcgg cctatcagct tgttgggtggg taatggccta ccaaggcgac gacgggtagc     240
cggcctgaga gggcgaccgg ccacactggg actgagacac ggcccagact cctacgggag     300
gcagcagtgg ggaatattgc acaatgggcg aaagcctgat gcagcgacgc cgcgtgaggg     360

```

- 16 -

```

atgacggcct tcgggttgta aacctctttc agcaggggaag aagcgaaagt gacggtacct    420
gcagaagaag cgccggctaa ctacgtgcca gcagccgcgg taatacgtag ggcgcaagcg    480
ttgtccggaa ttattgggcg taaagagctc gtaggcggct tgtcacgtcg gatgtgaaag    540
cccggggctt aaccccgggg ctgcattcga tacgggctag ctagagtgtg gtaggggaga    600
tcggaattcc tgggtgtagcg gtgaaatgcg cagatatnca ggaggaacac cgggtggcgaa    660
ggcggatctc tggccattac tgacgctgag gagcgaaagc gtggggagcg aacaggatta    720
gataccctgg tagtccacgc cgtaaacgtt gggaactagg tgttggcgac attccacgtc    780
gtcggtgccg cagctgaacg cattaagttc cccgcctggg gagtacggcc gcaaggctaa    840
aactcaaagg aattgacggg ggcccgcaaca agcagcggag catgtggctt aattcgacgc    900
aacgcgaaga accttaccaa ggcttgacat ataccggaaa gcatcagaga tggtgcccc    960
cttgtggtcg gtatacaggt ggtgcatggc tgctgtcagc tcgtgtcgtg agatgttggg   1020
ttaagtcccg caacgagcgc aacccttggt ctgtgttgcc agcatgccct tcggggtgat   1080
ggggactcac aggagactgc cgggggtcaac tcggaggaag gtggggacga cgtcaagtca   1140
tcatgccctt tatgtcttgg gctgcacacg tgctacaatg gccggtacaa tgagctgcga   1200
tgccgcgagg cggagcgaat ctcaaaaagc cggctctcagt tcggattggg gtctgcaact   1260
cgaccccatg aagtcggagt tgctagtaat cgcagatcag cattgctgcg gtgaatacgt   1320
tcccgggcct tgtacacacc gccgtcacgt cacgaaagtc ggtaacaccc gaagccggtg   1380
gccaaccgc cttgtgggag ggaactttcc a                                     1411

```

<210> 18

<211> 1370

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(1367)

<223> "n" is unknown nucleotide

<400> 18

```

atgcaagtng aacgatgaan ccntttgggg tggattagtg gcgaacgggt gagtaanang    60
tgggcaatth gcccttcaat ttgggacaag ccctggaaac ggggtntaat accggataac   120
antntgtccc gcatgggacg gggttaaaag ctccggcggt gaaggatgag cccgcggcct   180
atnagcttgt tgggtggggtg atggcctacc aaggcgacga cgggtagccg gcctgagagg   240

```

```

gcgaccggcc acactgggac tgagacacgg cccagactcc tacgggaggg agcagtgggg 300
aatattgcac aatgggcgaa agcctgatgc agcgacggcg cgtgagggat gacggccttc 360
gggttgtaaa cctttttcag caggggaagaa gcgaaagtga cggtagctgc agaagaagcg 420
ccggctaaat angtgccagc agccgcggta atangtaggg cgcaagcggt gtccggaatt 480
attgggcgta aagagtttgt aggcggcttg tcacgtngga tgtgaaagcc cggggcttaa 540
ccccgggttt gcattcgata cgggctagct agagtgtggt aggggagatc ggaattcctg 600
gtgtagcggg gaaatgcgca gatatcagga ggaacaccgg tggcgaaggc ggatctctgg 660
gccattactg acgntgagga gcgaaagcgt ggggagcnaa cagnattaga taccctggta 720
gtccaagccg taaacgttgg gaactangtg ttggcgacat tccacgtcgt cnntgccgca 780
nctaacgcat taagttcccc gcctggggag tacggccgca aggctaana tcaaaggaat 840
tgangnnggc ccgcacaagc agcggagcat gtggcttant tcnacgcanc gcgaagaacc 900
ttaccaaggt ttgccatata ccggaaagca tcagagatgg tgccccctt gtggtcggta 960
tacagggtgg gcntggctgt cgtcagctcg tgtcgtgaca tgttggttaa gtcccgtcaa 1020
cgaggcgcaa ccottgttnt gtgtngccag catgcccttc ggggtgatgg ggactcacag 1080
gagactgccg gggtaactc ggaggaaggt ggggacgacg tcaagtcac atgcccctta 1140
tgtcttgggc tgcacacgtg ctacaatggc cggtagaatg agctgcgatg ccgcgaggcg 1200
gagcgaatct caaaaagccg gtntcagttc ggattggggg ctgcaactcg accccatgaa 1260
gtcggagttg ctagtaatcg cagatcagca ttgctgcggg gaatacgttc ccgggccttg 1320
tacacaccgc ccgtcacgtc acgaaagtcg gtaacacccg aagccgntgg 1370

```

<210> 19

<211> 1162

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(1156)

<223> "n" is unknown nucleotide

<400> 19

```

gaacgatgaa gccgtttcgg tgggtggatta gtggcgaacg gtgagtaaaa gtggcaattt 60
ncccttcatt ttggacaagc cctggaaacg ggtttaanac cggataacat tntgtccgc 120

```

- 18 -

```

atggggacggg gttgaaagnt cccggcggtg aaggatgagc ccgcggcnta tcagcttggt 180
ggtgggggtaa tggcctacca aggcgacgac gggtagccgg cctgagaggg cgaccggcca 240
cactgggant gagacacggc ccagactcct acgggaggca gcagtgggga atattgcaca 300
atggggcgaaa gcctgatgca gcgacgccgc gtgagggatg acggccttcg ggttgtaaac 360
ctntttcagc agggaagaag cgaaagtgac ggtacctgca gaagaagcgc cggctaaata 420
ngtgccagca gccgcggtaa tangtagggc gcaagcggtg tccggaatta ttgggcgtaa 480
agagcttgta ggcggcttgt cangtcggat gtgaaagccc ggggcttaac cccgggtttg 540
cattcgatac gggctagtta gagtgtggta ggggagatng gaattcctgg tgtagcggtg 600
aaatgcgcag atatcaggag gaacaccggt ggcgaaggcg gatctctggg ccattactga 660
cgctgaggag cgaaagcgtg gggagcnaac aggattagat accctggtag tccacgccgt 720
aaacgttggg aactaggtgt tggcgacatt ccacgtcgtc ggtgccgcag ctaacgcatt 780
aagttccccg cctgggggagt acggccgcaa ggctaaaact caaaggaatt gacggggggc 840
cgcacaagca gcggagcatg tggcttaatt cgacgcaacg cgaacaacct taccaaggct 900
tgacatatac cggaaagcat canagatggg gcccccttg tggtcggtat acangtggtg 960
catggctgtc gtcagctcgt gtcgtgagat gttgggttan gtcccgcaac gagcgcnaac 1020
cttgttctgt gtcgncnagc atgcccttcg nggtgatggg gactcacang agactgncgg 1080
ggtccactcg gaggaagggt gcgacnacgt canntcatca tgccccctta tgtcttggn 1140
ctggccacgt gcnacnatgg cc 1162

```

<210> 20

<211> 1411

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(1404)

<223> "n" is unknown nucleotide

<400> 20

```

gctggcgggc tgcttaacac atgcaagtcg aacgatgaag ccgcttcggt ggtggattag 60
tggcgaacgg gtgagtaaca cgtgggcaat ctgcccttca ctctgggaca agccctggaa 120
acggggtcta ataccggata acactctgtc ccgcatggga cgggggttgaa agctccggcg 180

```

- 19 -

```

gtgaaggatg agcccgcggc ctatcagctt gttggtgggg taatggccta ccaaggcgac   240
gacgggtagc cggcctgaga gggcgaccgg ccacactggg actgagacac ggcccagact   300
cctacgggag gcagcagtgg ggaatattgc acaatgggcg aaagcctgat gcagcgacgc   360
cgcgtagagg atgacggcct tcgggttgta aacctctttc agcaggggaag aagcgaaagt   420
gacggtacct gcagaagaag cgccggctaa ctacgtgcca gcagccgchg taatacgtag   480
ggcgcaagcg ttgtccggaa ttattgggcg taaagagctc gtaggcggct tgtcacgtcg   540
gatgtgaaag cccgggggctt aaccccggtt ctgcattcga tacgggctag ctagagtgtg   600
gtaggggaga tcggaattcc tgggtgtagcg gtgaaatgcg cagatatcag gaggaacacc   660
ggtgggggaag gcggatctct gggccattac tgacgctgag gagcgaaagc gtggggagcg   720
aacaggatta gataccctgg tagtccaagc cgtaaacggt gggaactang tgttggcgac   780
attccacgtc gtcggtgccg cagctaacgc attaatgtcc ccgtcctggg gagtacggcc   840
gcnaggctaa aactcaaagg aattgacggg ggcccgcaca agcagcggag catgtggctt   900
anttcgacgc nacgcgaaga accttnccaa ggctgacata taccggaaag catcacagat   960
ggtgcccccc ttgtggtcgg tatacagggt ggtgcatggc tgttcgtcag ctctgtctgt  1020
gagatgttgg gttaagtccc gcaaagagcg caaccgtgtt ctgtgttgcc agcatgccct  1080
tcggggtgat ggggactcac acgagactgt cnggggtcaac tcggaggaag gtggggacga  1140
cgtcaagttc atcatgcccc ttatgtcttg ggctgcacac gngctacaat ggccggtaca  1200
atgagnnggg atgccgcgag gcggagcgaa tctcaaaaag ccggtctcag ttcggattgg  1260
ggtctgcaac tgaccccatg aagtcggagt tgctagtaat cgcagatcag cattgctgcg  1320
gtgaatacgt ncccgggcct ngtaacacacc acccgtcacg tcacgaaagt cggtaacacc  1380
ctaagccggt gncccaaccc cttnntgggag g                                1411

```

<210> 21

<211> 549

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(431)

<223> "n" is unknown nucleotide

- 20 -

<400> 21

```

ccaganatcc gccttcgcca ccggtgttcc tcctgatatc tgcgcatttc accgctacac      60
caggaattcc gatctcccct accacaactct agctagcccg tatcgaatgc agacccgggg      120
ttaagccccg ggctttcaca tccgacgtga caagccgcct acgagctctt tacgccaat      180
aattccggac aacgcttgcg ccctacgtat taccgcggct gctggcacgt agttagccgg      240
cgcttcttct gcaggtaccg tcactttcgc ttcttccctg ctgaaagagg ttacaaccc      300
gaaggncgtc atccctcacg cggcgtcgct gcatcaggct ttcgcccatt gtgcaatatt      360
ccccactgct gcctcccgtg ggagtctggg ncgtgttcaa tnccagtggg gggccggtcg      420
ccctctcagg ncggctaccg tcgtcgcctt ggtaggcatt accacaacaa gctgataggc      480
gggggtcatc cttcaacgcc ggagcttcaa acccgcccat gcgggacaag tgtatccggt      540
attaaaccc                                         549

```

<210> 22

<211> 672

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(643)

<223> "n" is unknown nucleotide

<400> 22

```

tcagtnatgg cccagaanga tccgncttcg ccaccggtgt tcctcctgat atctgcgcat      60
ttcaccgcta caccaggaat tccgatctcc cctaccacac tctaactagc ccgtatcgaa      120
tgcagaccog gggttaagcc ccgggctttc acatccgacg tgacaagccg cctacgagct      180
cttnacgccc aataattccg gacaacgctt gcgccctacg tattaccgcg gctgctggca      240
cgtagttagc cggcgcttct totgcaggta ccgtnacttt cgcttcttcc ctgctgaaag      300
aggtttacia cccgaaggcc gtntccctc acgcggcgtc gctgcatcag gctttcgccc      360
atngtgcant attccccact gntgnctccc gtangagtct gggccgtgtc tcagtcccag      420
tgtggccggt cgnctctca ggccggctac cgtcgtcgcc ttggtaggnc attaccacc      480
aacaagctga tangtcgngg gctcatcctt caccgncgga gntttaaccc cgtncatgcg      540
ggacagagtg ttatccggtg ttanaccggt atncagggtg tgtcccatag tgaaggggag      600

```

- 21 -

atngccacgt gttatcaccg ttcgncacta atnatcancg aancggcttc atcgttcgac 660
 ttgcatgtgt ta 672

<210> 23

<211> 678

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(648)

<223> "n" is unknown nucleotide

<400> 23

ctcagcgtca gtcattggcca agagatccgc cttcgccacc ggtgttcctc ctgtatatct 60
 gcgcatttca ccgtacacc aggaattccg atctccccta ccacactcta gctagcccgt 120
 atcgaatgca gacccggggg taagccccgg gctttcacat ccgacgtgac aagccgccta 180
 cgagctcttt acgccaata attccggaca acgcttgccg cctacgtatt accgcggctg 240
 ctggcacgta gttagccggc gcttcttctg caggtaccgt cactttcgct tcttccctgc 300
 tgaaagaggt ttacaacccg aaggccgtca tccctcacgc ggcgtcgctg catcaggctt 360
 tcgcccattg tgcaatattc cccactgctg cctcccgtag gagtctgggc cgtgtctcag 420
 tcccagtggt gccggtcgcc ctctcaggcc ggctaccggt cgtcgccctg gtaggccatt 480
 acccaccaac aagctgatag gccgcgggct catccttcan cgcgggagct ttaacccgtc 540
 catgcgggac agagtgttat ccggtattaa acccgtttca gggcttgtcc canagtgaag 600
 ggcagattgc cacgtgttat cancggttcg ncactaatca cancgaancg ggttcacgt 660
 tcgacttgca tgtgttaa 678

<210> 24

<211> 688

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

- 22 -

<222> (1)..(666)

<223> "n" is unknown nucleotide

<400> 24

```

ggcccagana tccgncttcg ccaccggtgt tcctcctgaa tatctgcgca tttcacgct      60
acaccaggaa ttccgatctc ccctaccaca ctctaactag cccgtatcga atgcagaccc      120
ggggttaagc cccgggcttt cacatccgac gtgacaagcc gcctacgagc tctttacgcc      180
caataattcc ggacaacgct tgcgccctac gtattaccgc ggctgctggc acgtaattag      240
ccggcgcttc ttctgcaggt accgtcactt tcgcttcttc cctgctgaaa gaggtttaca      300
acccgaaggc cgtcatccct cacgcggcgt cgctgcatca ggctttcgcc cattgtgcaa      360
tattccccac tgctgnctcc cgtangagtc tgggccgtgt ctcagtccca gtgtggccgg      420
tcgnctcttc aggccggcta ccgtcgtcgc cttggtaggc cattaccca ccaacaagct      480
gatangccgn gggctcatcc ttcanctcgc gagctttcaa ncccgtccat gggggacaga      540
gtgttatccg gtattanacc ccgtntcagg gcttgtccan agtgaagggc agatngccac      600
gtgttatcac cgttcgccac taatnacanc gaaacggctt atcgtnccgc tgcattgtgt      660
aacacnccga gcgttcgtcc tgagccag                                         688

```

<210> 25

<211> 702

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(658)

<223> "n" is unknown nucleotide

<400> 25

```

ccctcagggt cagtaatggg ccagagatc cgccttcgcc accggtgttc ctctgaata      60
tctgcgcatt tcaccgctac accaggaatt ccgatctccc ctaccacact ctagctagcc      120
cgtatcgaat gcagacccgg ggttaagccc cgggctttca catccgacgt gacaagccgc      180
ctacgagctc tttacgcca ataattccgg acaacgcttg cgccctacgt attaccgcgg      240
ctgctggcac gtagttagcc ggcgcttctt ctgcaggtag cgtcactttc gcttcttccc      300
tgctgaaaga ggtttacaac ccgaaggccg tcatccctca cgcggcgctc ctgcatcagg      360

```

- 23 -

```

ctttcgccca ttgtgcaata ttccccactg ctgcctcccg taggagtctg ggccgtgtct 420
cagtcccagt gtggccgggtc gccctctcag gccggctanc cgtcgtcgcc ttgggtaggc 480
attancccan caacaagctg ataggncgcg ggctcatnct tcaacgccgg agctttcaan 540
cccgatccatg cgggacagag tgttatncgg tattaaaccc gtttcagggc ttgttccaga 600
gtgaagggca gattgccacg tgttatcaac cgttcggcac taatcacaac gaagcggntt 660
atcgttcgac ttgcatgtgt taacaagccg ccagcgttcg tc 702

```

<210> 26

<211> 711

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(687)

<223> "n" is unknown nucleotide

<400> 26

```

tcagtaatgg cccagagatc cgccttcgcc accggtgttc ctcttgata tctgcgcatt 60
tcaccgctac accaggaatt ccgatctccc ctaccacact ctagctagcc cgtatcgaat 120
gcagacccgg ggttaagccc cgggctttca catccgacgt gacaagccgc ctacgagctc 180
tttacgccc aataattccgg acaacgcttg cgcctacgt attaccgcgg ctgctggcac 240
gtagttagcc ggcgcttctt ctgcaggtag cgtcactttc gcttcttccc tgctgaaaga 300
ggtttacaac ccgaaggccg tcatccctca cgcggcgctc ctgcatcagg ctttcgccc 360
ttgtgcaata ttccccactg ctgcctcccg taggagtctg ggccgtgtct cagtcccagt 420
gtggccgggtc gccctctcag gccggctacc cgtcgtcgcc ttggtaggcc attacccac 480
caacaagctg ataggccgcg ggctcatcct tcaccgncgg agctttaacc ccgtcccatg 540
cgggacagag tgttatccgg tattagaacc cgtttccagg gcttggtcca gagtgaagg 600
cagattgcca cgtgttactc anccgttcgn cactaatcan caacgaagcg gcttcatcgt 660
tcgacttgca tgtgttaagc acgccgncag cgttcgtcct gagccaggat c 711

```

- 24 -

<210> 27
 <211> 522
 <212> DNA
 <213> actinomycete

<220>
 <221> misc_feature
 <222> (1)..(465)
 <223> "n" is unknown nucleotide

<400> 27
 tcagtatcng cccagagatc cgccttcgcc accggtgttt cctcctgata tctgcgcatt 60
 tcaccgctac accaggaatt ccatctccc ctaccgaact ctagcctgcc cgtatcgact 120
 gcagaccggg ggttaagccc cgggctttca caaccgacgt gacaagccgc ctacgagctc 180
 ttacgccca ataattccgg acaacgcttg cgccctacgt attaccgagg ctgctggcac 240
 gtagttagcc ggcgcttctt ctgcaggtag cgtcactttc gcttcttccc tgctgaaaga 300
 ggtttacaaa ccgaaggccg tcatccctca cgcggcgtag ctgcatcagg ctttcgcccc 360
 ttgtgcaata ttccccactg gtgnctcccg tangagtctg gggcgtgtct cantccagtg 420
 tgggcggtag cctctcaggg cggctaccgt cgtcgcttgg tgagncaacta ctcacaacaa 480
 gctgataggg gcggggtcat ctggaacggc ggagctttac ac 522

<210> 28
 <211> 670
 <212> DNA
 <213> actinomycete

<220>
 <221> misc_feature
 <222> (1)..(638)
 <223> "n" is unknown nucleotide

<400> 28
 tcagtaatgg cccaganatc cgncttcgcc accggtgttc ctcctgatat ctgcgcattt 60
 caccgctaca ccaggaattc ccatctccc taccacactc taactagccc gtatcgaatg 120
 cagaccggg gtttaagcccc gggctttcac atccgacgtg acaagccgcc tacgagctct 180
 ttacgcccac taattccgga caacgcttgc gccctacgta ttaccgaggc tgctggcacg 240

- 25 -

```

tagttagccg ggcgttcttc tgcaggtacc gtcactttcg cttcttccct gctgaaagag   300
gtttacaacc cgaaggccgt catccctcac gcggcgtcgc tgcatacaggc tttcgcccat   360
tgtgcaatat tccccactgc tgccctcccg angagtctgg gccgtgtctc agtcccagtg   420
tggccggtcg ccctctcagg ccggctaccg tcgtcgccct ggtaggccat taccaccaa   480
caagctgata ngncgngggc tcatacctca ccgncggagc tttcaanccc gtcccatgcg   540
ggacagagtg ttatccggta ttaaaccctg ntccagggtc tgtccatagt gaagggcaga   600
ttgccaagtg ttatcancg ttcgncacta atcatcancg aagcggcttc atcgttcgac   660
tgcattgtgtt                                     670

```

<210> 29

<211> 676

<212> DNA

<213> actinomycete

<220>

<221> misc_feature

<222> (1)..(666)

<223> "n" is unknown nucleotide

<400> 29

```

tcctcagnat cagtaatggc ccagagatcc gccttcgcca ccggtgttcc tcctgatata   60
tgcgcatttc accgctacac caggaattcc gatctcccct accacactct anctagcccg   120
tatcgaatgc agaccggggg ttaagccccg ggctttcaca tccgangtga caagccgcct   180
acgagctctt tacgcccatt aattccggac aangcttgcg ccctacgtat taccgcggnt   240
gctggcacgt agttagccgg cgcttcttct gcaggtaccg tcactttcgc ttcttccctg   300
ctgaaagagg ttacaacccc gaaggccgtc atccctcaen cggcgtcgct gcatcaggct   360
ttcgcccatt gtgcaatatt cccactgct gcctcccgta ggagtctggg ccgtgtctca   420
atcccantgt ggccggtcgc cctctcangc cggctaccgt cgtcgcttgg taggccatta   480
ccccaccaac aagctggata ggncgggggc tcattcttca ccgcccgaag ctttaanccc   540
gtccatgcgg gananagtgn atcccngtat taaaccngt ttcagggtt gtccanagtg   600
aagggngatt gcccnagtgt ttatcncccg ttcgccanta atcnacaacg aaagcggntt   660
cntcgnttcg acttgc                                     676

```

- 26 -

<210> 30
 <211> 626
 <212> DNA
 <213> actinomycete

<220>
 <221> misc_feature
 <222> (1)..(618)
 <223> "n" is unknown nucleotide

<400> 30
 taatggccca gaanatccgc cttcgccacc ggtgttcctc ctgaatatct gcgcatttca 60
 ccgctacacc aggaattccg atctccccta ccacactcta gctagcccgt atcgaatgca 120
 gaccocgggt taagccccgg gctttcacat ccgacgtgac aagccgccta cgagctcttt 180
 acgccaata attccggaca acgcttgccg cctacgtatt accgcggctg ctggcacgta 240
 gttagccggc gcttcttctg caggtaccgt cactttcgtt tcttccctgc tgaaagaggt 300
 ttacaaccgc aaggccgtca tccctcacgc ggcgtcgtg catcaggctt tcgcccattg 360
 tgcaatatcc cccactgctg cctcccgtag gagtctgggc cgtgtctcag tcccagtgtg 420
 gcggtcgccc tctcaggccg gntanccgtc gtgccttgg tangccatta ncccaccaac 480
 aagctgatan gccgnnggct catccttcan cgccggagct tttaaccccg tcccatgcgg 540
 gacagagtgt tatccggtat tagatcccgt ntccagggtg tgtncatagt gaagggcana 600
 ttgccacgtg ttactcancc gttcgc 626

<210> 31
 <211> 20
 <212> DNA
 <213> primer

<400> 31
 agagtttgat cmtggctcag

20

- 27 -

<210> 32

<211> 21

<212> DNA

<213> primer

<400> 32

ctgtttgctc cccacgcttt c

21

<210> 33

<211> 22

<212> DNA

<213> primer

<400> 33

tacggytacc ttggtacgac tt

22

- 141 -

CLAIMS:

1. A method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:
- 5
- (i) an effective number of endophytic actinomycetes or variants, mutants or homologues thereof, which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
- 10 (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;
- for a time and under conditions sufficient to induce, in the subject plant, said
- 15 characteristic, and wherein said actinomycete is selected from:
- (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under
- 20 low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- (b) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in
- 25 <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- (c) An actinomycete characterised either by a nucleotide sequence
- 30 corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under

- 142 -

low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 5 (d) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (f) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (h) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30

- 143 -

actinomycete

- 5 (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 2. A method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:
- 15 (i) an effective number of endophytic actinomycetes or variants, mutants or homologues thereof, which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
- (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;
- 20 for a time and under conditions sufficient to induce, in the subject plant, said characteristic, and wherein said actinomycete is selected from:
- 25 (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30 (b) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in

- 144 -

<400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5 (c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10

(d) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

(e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

(f) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of hybridising to <400>9 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

25

(g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable of hybridising to <400>11 under

30

- 145 -

low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 5 (h) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (j) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (k) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (l) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30

- 146 -

actinomycete.

- 5 (m) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (n) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable of hybridising to <400>22 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (o) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (p) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (q) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30

- 147 -

- 5 (r) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (s) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>28 or a nucleotide sequence capable of hybridising to <400>28 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (t) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>29 or a nucleotide sequence capable of hybridising to <400>29 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete
- 20 (u) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>30 or a nucleotide sequence capable of hybridising to <400>30 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25
3. The method according to claim 1 or 2, wherein said actinomycete is characterised by a nucleotide sequence which has at least about 45% similarity to all or part of the nucleotide sequence indicated by the nucleotide sequence identification number.

- 148 -

4. The method according to claim 3 wherein said similarity is 50%, preferably 55%, more preferably 60%, still more preferably 65%, even more preferably 70% and most preferably 80%.
5. The method according to claim 3 wherein said actinomycete is selected from:
- | | | | |
|-----------|----------|----------|----------|
| (a) EN2 | (b) EN3 | (c) EN16 | (d) EN23 |
| (e) EN27 | (f) EN28 | (g) EN46 | (h) EN60 |
| (i) PM87. | | | |
6. The method according to claim 3 wherein said actinomycete is selected from:
- | | | | |
|-----------|-----------|-----------|-----------|
| (a) EN5 | (b) EN6 | (c) EN7 | (d) EN9 |
| (e) EN17 | (f) EN19 | (g) EN26 | (h) EN35 |
| (i) EN39 | (j) EN57 | (k) SE1 | (l) SE2 |
| (m) PM36 | (n) PM40 | (o) PM41 | (p) PM171 |
| (q) PM185 | (r) PM208 | (s) PM228 | (t) PM252 |
| (u) PM342 | | | |
7. The method according to any one of claims 1-6 wherein said metabolite is auxin, gibberellin, cytokinin, indole acetic acid, kinetin or signal molecule able to induce resistance in plants.
8. The method according to any one of claims 1-6 wherein said metabolite is an antibiotic compound.
9. The method according to any one of claims 1-7 wherein said productivity is growth promotion characteristics and/or bio-control characteristics.

- 149 -

10. The method according to claim 9 wherein said growth promotion characteristic is one or more of rate of growth, plant vigour, yield of flower/fruit/grain, vitality of crop or improved seed germination.
- 5 11. The method according to claim 9 wherein said bio-control characteristic is a decrease in susceptibility to pathogen infection or an increase in the clearance efficiency of infection.
12. The method according to any one of claims 1-11 wherein said plant is a cereal crop.
- 10 13. The method according to claim 12 wherein said cereal crop is a wheat, barley, maize, triticale, rye, oats, canary, sorghum, millet or rice.
14. The method according to claim 11 wherein said bio-control activity is bio-control
- 15 in relation to *Gaeumannomyces graminis* var. *tritici*, *Pythium* ssp., *Rhizoctonia solani*, *Fusarium* sp., insect or nematode.
15. The method according to claim 14 wherein said insect is an aphid.
- 20 16. The method according to claim 14 or 15 wherein said plant is a cereal plant.
17. The method according to any one of claims 14-16 wherein said actinomycete is selected from EN2, EN3, EN16, EN23, EN27, EN28, EN46, EN60 or PM87.
- 25 18. The method according to any one of claims 14-16 wherein said actinomycete is selected from EN9, EN17, EN19, EN26, EN35, EN39, EN57 or SE1.
19. The method according to claim 9 wherein said actinomycete is selected from EN2, EN3, EN16, EN27, EN60 or PM87 and said improved productivity is improved
- 30 plant growth promotion.

- 150 -

20. The method according to claim 9 wherein said actinomycete is selected from EN6, EN9, EN57, SE1, SE3, PM185 or PM208 and said improved productivity is improved plant growth promotion.
- 5 21. The method according to claim 19 or 20 wherein said growth promotion is germination promotion.
22. The method according to claim 19, 20 or 21 wherein said plant is a cereal plant.
- 10 23. The method according to claim 9 wherein said actinomycete is selected from EN2, EN3, EN16, EN23, EN27, EN28, EN46, EN60 or PM87 and said improved productivity is improved bio-control activity and improved plant growth promotion.
- 15 24. The method according to claim 9 wherein said actinomycete is selected from EN9, EN35, EN57, SE1 or SE1 and said improved productivity is improved bio-control activity and improved plant growth promotion.
25. The method according to claim 23 or 24 wherein said plant is a cereal plant.
- 20 26. The method according to claim 9 wherein said actinomycete is selected from EN2, EN3, EN16, EN23, EN27, EN28, EN46 or PM87 and said improved productivity is improved bio-control activity.
- 25 27. The method according to claim 9 wherein said actinomycete is selected from EN5, EN17, EN19 or EN35 and said improved productivity is improved bio-control activity.
28. The method according to claim 26 or 27 wherein said bio-control activity is bio-control in relation to aphids.
- 30 29. The method according to claim 26, 27 or 28 wherein said plant is a cereal plant.

- 151 -

30. The method according to any one of claims 16, 22, 25 or 29 wherein said cereal plant is wheat, barley, maize, rye, triticale, oats, canary seed, sorghum, millet or rice.
- 5
31. A method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:
- 10 (i) an effective number of at least two endophytic actinomycete strains or variants, mutants or homologues thereof, which actinomycetes facilitate induction of at least one characteristic related to improved productivity; and/or
- 15 (ii) an effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent or mimetic thereof;
- for a time and under conditions sufficient to induce, in the subject plant, said characteristic, and wherein said at least two endophytic actinomycete strains are
- 20 selected from:
- (a) EN2, EN9 and EN23
- (b) EN9, EN27 and EN28
- (c) EN39 and EN46.
- 25
32. A cereal plant-derived endophytic actinomycete or variants, mutants or homologues thereof or metabolites derived therefrom or derivatives, homologues, analogues, chemical equivalents or mimetics thereof for use in the method of any
- 30 one of claims 1-31 wherein said actinomycete is selected from:

- 152 -

- 5 (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (b) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (d) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

- 153 -

- 5 (f) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (h) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete
- 20 (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 33. A cereal plant-derived endophytic actinomycete or variants, mutants or homologues thereof or metabolites derived therefrom or derivatives, homologues, analogues, chemical equivalents or mimetics thereof for use in the method of any one of claims 1-31 wherein said actinomycete is selected from:
- 30 (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in

- 154 -

<400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5 (b) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10

(c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15

(d) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

20

(e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

25

(f) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of hybridising to <400>9 under

30

- 155 -

low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

- 5 (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable of hybridising to <400>11 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (h) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (j) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (k) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30

- 156 -

actinomycete.

- 5 (l) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (m) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (n) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable of hybridising to <400>22 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (o) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (p) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30

- 157 -

- 5 (q) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (r) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (s) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>28 or a nucleotide sequence capable of hybridising to <400>28 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (t) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>29 or a nucleotide sequence capable of hybridising to <400>29 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete
- 25 (u) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>30 or a nucleotide sequence capable of hybridising to <400>30 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30

- 158 -

34. An agricultural composition comprising an endophytic actinomycete or metabolite derived therefrom together with one or more agriculturally acceptable carriers and/or diluents wherein said actinomycete is selected from:
- 5 (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (b) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (d) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under
- 30

- 159 -

low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5 (f) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

10 (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

15 (h) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete

20 (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

35. An agricultural composition comprising an endophytic actinomycete or metabolite derived therefrom together with one or more agriculturally acceptable carriers and/or diluents wherein said actinomycete is selected from:

30

- 160 -

- 5 (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (b) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (d) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>8 or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

- 161 -

- 5 (f) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>9 or a nucleotide sequence capable of hybridising to <400>9 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>11 or a nucleotide sequence capable of hybridising to <400>11 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (h) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>14 or a nucleotide sequence capable of hybridising to <400>14 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (j) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

- 162 -

- 5 (k) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (l) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (m) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>21 or a nucleotide sequence capable of hybridising to <400>21 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (n) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>22 or a nucleotide sequence capable of hybridising to <400>22 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (o) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>23 or a nucleotide sequence capable of hybridising to <400>23 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

30

- 163 -

- 5 (p) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>25 or a nucleotide sequence capable of hybridising to <400>25 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (q) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>26 or a nucleotide sequence capable of hybridising to <400>26 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (r) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>27 or a nucleotide sequence capable of hybridising to <400>27 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (s) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>28 or a nucleotide sequence capable of hybridising to <400>28 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (t) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>29 or a nucleotide sequence capable of hybridising to <400>29 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete

30

- 164 -

- 5 (u) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>30 or a nucleotide sequence capable of hybridising to <400>30 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
36. A novel, isolated endophytic actinomycete or variant, mutant or homologue thereof wherein said actinomycete is selected from:
- 10 (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence capable of hybridising to <400>1 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (b) The actinomycete of (a) wherein said actinomycete corresponds to EN2 (AGAL Deposit No. NM03/35895).
- 20 (c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>2 or a nucleotide sequence capable of hybridising to <400>2 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 25 (d) The actinomycete of (c) wherein said actinomycete corresponds to EN3 (AGAL Deposit No. NM03/36501).
- 30 (e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>7 or a nucleotide sequence capable of hybridising to <400>7 under low stringency conditions at 42°C or a variant, mutant or homologue of said

- 165 -

actinomycete.

- 5
- (f) The actinomycete of (e) wherein said aci corresponds to EN16 (AGAL Deposit No. NM03/35605).
- 10
- (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>10 or a nucleotide sequence capable of hybridising to <400>10 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- (h) The actinomycete of (g) wherein said actinomycete corresponds to EN23 (AGAL Deposit No. NM03/35605).
- 15
- (i) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>12 or a nucleotide sequence capable of hybridising to <400>12 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20
- (j) The actinomycete of (i) wherein said actinomycete corresponds to EN27 (AGAL Deposit No. NM03/35606).
- 25
- (k) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>13 or a nucleotide sequence capable of hybridising to <400>13 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30
- (l) The actinomycete of (i) wherein said actinomycete corresponds to EN28 (AGAL Deposit No. NM03/35607).

- 166 -

- 5 (m) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>16 or a nucleotide sequence capable of hybridising to <400>16 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- (n) The actinomycete of (m) wherein said actinomycete corresponds to EN46 (AGAL Deposit No. NM03/34609).
- 10 (o) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>18 or a nucleotide sequence capable of hybridising to <400>18 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (p) The actinomycete of (o) wherein said actinomycete corresponds to EN60 (AGAL Deposit No. NM03/35896).
- (q) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>24 or a nucleotide sequence capable of hybridising to <400>24 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (r) The actinomycete of (q) wherein said actinomycete corresponds to PM87 (AGAL Deposit No. NM03/35608).
- 25
37. A novel, isolated endophytic actinomycete or variant, mutant or homologue thereof wherein said actinomycete is selected from:

- 167 -

- 5 (a) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- (b) The actinomycete according to (a) wherein said actinomycete corresponds to EN5.
- 10 (c) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>4 or a nucleotide sequence capable of hybridising to <400>4 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 15 (d) The actinomycete of (c) wherein said actinomycete corresponds to EN6.
- (e) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>5 or a nucleotide sequence capable of hybridising to <400>5 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 20 (f) The actinomycete of (e) wherein said actinomycete corresponds to EN7.
- 25 (g) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>6 or a nucleotide sequence capable of hybridising to <400>6 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 30

- 168 -

- (h) The actinomycete of (g) wherein said actinomycete corresponds to EN9.
- (i) The actinomycete of (h) wherein said actinomycete is characterised either
5 by a nucleotide sequence corresponding to the nucleotide sequence
substantially as set forth in <400>8 or a nucleotide sequence capable of
hybridising to <400>8 under low stringency conditions at 42°C or a variant,
mutant or homologue of said actinomycete.
- (j) The actinomycete of (i) wherein said actinomycete corresponds to EN17.
10
- (k) An actinomycete characterised either by a nucleotide sequence
corresponding to the nucleotide sequence substantially as set forth in
<400>9 or a nucleotide sequence capable of hybridising to <400>9 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
15 actinomycete.
- (l) The actinomycete of (k) wherein said actinomycete corresponds to EN19.
- (m) An actinomycete characterised either by a nucleotide sequence
20 corresponding to the nucleotide sequence substantially as set forth in
<400>11 or a nucleotide sequence capable of hybridising to <400>11 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
actinomycete.
- (n) The actinomycete of (m) wherein said actinomycete corresponds to EN26.
25
- (o) An actinomycete characterised either by a nucleotide sequence
corresponding to the nucleotide sequence substantially as set forth in
<400>14 or a nucleotide sequence capable of hybridising to <400>14 under
30 low stringency conditions at 42°C or a variant, mutant or homologue of said
actinomycete.

- 169 -

- (p) The actinomycete of (o) wherein said subject actinomycete corresponds to EN35.
- 5 (q) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>15 or a nucleotide sequence capable of hybridising to <400>15 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- 10 (r) The actinomycete of (q) wherein said actinomycete corresponds to EN39.
- (s) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in
- 15 <400>17 or a nucleotide sequence capable of hybridising to <400>17 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- (t) The actinomycete of (s) wherein said actinomycete corresponds to EN57.
- 20 (u) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in <400>19 or a nucleotide sequence capable of hybridising to <400>19 under low stringency conditions at 42°C or a variant, mutant or homologue of said
- 25 actinomycete.
- (v) The actinomycete of (u) wherein said actinomycete corresponds to SE1.
- (w) An actinomycete characterised either by a nucleotide sequence
- 30 corresponding to the nucleotide sequence substantially as set forth in <400>20 or a nucleotide sequence capable of hybridising to <400>20 under

- 170 -

low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.

5 (x) The actinomycete of (w) wherein said actinomycete corresponds to SE2.

(y) An actinomycete characterised either by a nucleotide sequence
corresponding to the nucleotide sequence substantially as set forth in
<400>21 or a nucleotide sequence capable of hybridising to <400>21 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
10 actinomycete.

(z) The actinomycete of (y) wherein said actinomycete corresponds to PM36.

15 (aa) An actinomycete characterised either by a nucleotide sequence
corresponding to the nucleotide sequence substantially as set forth in
<400>22 or a nucleotide sequence capable of hybridising to <400>22 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
actinomycete.

(ab) The actinomycete of (aa) wherein said actinomycete corresponds to PM40.

20 (ac) An actinomycete characterised either by a nucleotide sequence
corresponding to the nucleotide sequence substantially as set forth in
<400>23 or a nucleotide sequence capable of hybridising to <400>23 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
actinomycete.

25 (ad) The actinomycete of (ac) wherein said actinomycete corresponds to PM41.

(ae) An actinomycete characterised either by a nucleotide sequence
corresponding to the nucleotide sequence substantially as set forth in
<400>25 or a nucleotide sequence capable of hybridising to <400>25 under
low stringency conditions at 42°C or a variant, mutant or homologue of said

- 171 -

actinomycete.

(af) The actinomycete of (ae) wherein said actinomycete corresponds to PM171.

(ag) An actinomycete characterised either by a nucleotide sequence
corresponding to the nucleotide sequence substantially as set forth in
5 <400>26 or a nucleotide sequence capable of hybridising to <400>26 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
actinomycete.

(ah) The actinomycete of (ag) wherein said actinomycete corresponds to PM185.

(ai) An actinomycete characterised either by a nucleotide sequence
10 corresponding to the nucleotide sequence substantially as set forth in
<400>27 or a nucleotide sequence capable of hybridising to <400>27 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
actinomycete.

(aj) The actinomycete of (ai) wherein said actinomycete corresponds to PM208.

(ak) An actinomycete characterised either by a nucleotide sequence
15 corresponding to the nucleotide sequence substantially as set forth in
<400>28 or a nucleotide sequence capable of hybridising to <400>28 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
actinomycete.

(al) The actinomycete of (ak) wherein said actinomycete corresponds to PM228.

(am) An actinomycete characterised either by a nucleotide sequence
20 corresponding to the nucleotide sequence substantially as set forth in
<400>29 or a nucleotide sequence capable of hybridising to <400>29 under
low stringency conditions at 42°C or a variant, mutant or homologue of said
25 actinomycete.


- 172 -

- (an) The actinomycete of (am) wherein said actinomycete corresponds to PM252.
- (ao) An actinomycete characterised either by a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in
5 <400>30 or a nucleotide sequence capable of hybridising to <400>30 under low stringency conditions at 42°C or a variant, mutant or homologue of said actinomycete.
- (ap) The actinomycete of (ao) wherein said actinomycete corresponds to PM342.
- 10 38. Metabolites derived from the novel actinomycetes according to claims 36 or 37 and derivatives, homologues, analogues, chemical equivalents, mutants and mimetics of said metabolites.
- 15 39. An antibody directed to the actinomycete of claims 36 or 37 or the metabolite of claim 37 or derivative, homologue, analogue, chemical equivalent or mimetic of said antibody.
- 20 40. A method of improving plant productivity said method comprising introducing into said plant or propagation material thereof:
- (i) An effective number of actinomycetes according to claims 36 or 37 or variants, mutants or homologues thereof and/or
- 25 (ii) An effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical equivalent and mimetic thereof.
- for a time and under conditions sufficient to induce, in the subject plant, said characteristic.

- 173 -

41. A method of facilitating the biodegradation of biodegradable material, said method comprising contacting said waste material with:
- 5 (i) An effective number of actinomycetes according to claims 36 or 37 or variants, mutants or homologues thereof and/or
- (ii) An effective amount of one or more metabolites derived from the actinomycetes of (i) or derivative, homologue, analogue, chemical
- 10 equivalent and mimetic thereof
- for a time and under conditions sufficient to induce or otherwise facilitate the degradation of said material.
- 15 42. A method for therapeutically and/or prophylactically treating a condition in a subject, the aberrant, unwanted or otherwise inappropriate symptoms, causes or outcomes of which condition are treatable with one or more metabolites derived from the actinomycetes of claims 36 or 37, said method comprising to said subject an effective amount of one or more of said metabolites or derivatives, homologues,
- 20 analogues, chemical equivalents or mimetics thereof for a time and under conditions sufficient to ameliorate said symptom, cause or outcome.
43. Use of the novel actinomycete of claims 35 or 36 or metabolites of claim 37 in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of a
- 25 mammalian or non-mammalian subject.
44. Use according to claim 43 wherein said non-mammalian subject is a plant.
45. Use of the novel actinomycete of claims 36 or 37 or the metabolite of claim 38 in
- 30 the manufacture of a composition for agricultural application.

1/30

**Figure 1**




Figure 2

3/30







Figure 3


4/30

**Figure 4****Figure 5**


5/30

**Figure 6**

6/30

**Figure 7**

7/30

Figure 8

8/30




Figure 9

9/30










Figure 10


10/30**11.1 Blue excitation/ green emission****11.2 UV excitation/ blue emission****11.3 Image enhanced merge****Figure 11**

11/30**12.1 Blue excitation/ green emission****12.2 UV excitation/ blue emission****12.3 Image enhanced merge****Figure 12**

12/30

13.1 Blue excitation/ green emission

13.2 UV excitation/ blue emission



13.3 Image enhanced merge







Figure 13

13/30**14.1 Blue excitation/ green emission****14.2 UV excitation/ blue emission****14.3 Image enhanced merge****Figure 14**

14/30

FIGURE 15

EN2

SEQ ID NO:1

CTTAACACATGCAANTCAAGCGGAAAGGCCCTTCGGGGTACTCAANCGGCNAACGGGTGATTAACACNTGANTAA
CCTGCCCCCTGACTCTGGGATAANCCTGGGAAACTGGGTCTAATACCGGATACAACCATTTCTCNCATGGGATGGT
GGTGGAAANTTTTTNCGGTTGGGGATGGGCTCGCGGCCTATCACCTTGTTGGTGGGGTGATGGCCTACCAAGGCg
ACgAACGGTAgCCCGCCTGAgAGGGCgACCGGCCaCaCTGGGACTGAgACaCCGCCCGAACTCCTaCgGGAGGCA
gCACTgGGGAATaTTGCCCATGGGCGGAAGCCTGACGCAGNGACGCCGCGTGGGGGATGACGGCCTTNGGGTTGT
AAACCTNTTTCAGCAGGGAÇGAAGTTGACGTGTACCTGTAGAAGAAGCGCCGGCTAAATANGTGCCAGCAGCCGC
GGTAATANGTAGGGCGCGAGCGTTNTCCGGAATTATTGGGCGTAAAGAGTTTGTAGGTGGCTTGTTCGTTTGCC
GTGAAAGCCCGTGGCTTAANTACGGGTTTTCGGTGGATACGGGCAGGCTAGAGGCTGGTAGGGGCAAGCGGAATT
CCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGCTTGCTGGGCCAgTTCTGA
CGGTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATAACCCTGGTAGTCCACGCTGTAAACGTTGGGCGCTA
GGTGTGGGGTCTTCCACGATCTCTGTGCCGTAGCTAACGCATTAAGCGCCCCGCTGGGGAGTACGGCCGCAAG
GCTAAAACTCAAAGGAATTGACGGGGGCCCCGCACAAGCGGCGGAGCATGTTGCTTAATTTCGACGCAACGCGAAGA
ACCTTACCAAGGTTTGACATACACCGGAAACACTCANANATGGGTGCCTCCTTTGGACTGGTGTACAGGTGGTGC
ATGGCTGTCNNCACCTTCGTGTCGTNAGATGTNGGGTTAAGTCCCGCAACGANCGCAACCCTTGTTCCATGTTG
CCAGCACNCCCTTTGNGGTGGTGGGGACNCATGGGANAATGCCGGGGTCNACTCNGGAGGAAGGTGGGGATGACG
TCAAGTNATCNTGCCCTTATGTTCTTGNNGTG

EN3

SEQ ID NO:2

GCTGGCGGCGTGCTTAACACATGCAAGTCGAACGATGAACCACTTCGGTGGGGATTAGTGGCGAACGGGTGAGTA
ACACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATAACACTNCTGCTC
TCATGGGCAGGGGTAAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGAGGTAATGGC
TCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCAGACTCC
TACGGGAGGCAGCAGTGGGGAATATTGCaCAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACG
GCCTTCGGGTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAAC
TACGTGCCAGCAGCCGCGGTAAACGTAAGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTtGTAgGC
GGCTTGTCACGTGCGGTGTGAAAGCCCCGGGGCTTAACCCcGGGTCTGCATTTCGATACGGGCTAgCTAgAGTGTGG
TAGGGGAGATCGGAATTcTGGTGTAGCGGTGAAATGCgCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGaT
cTcTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATAACCCTGGTAGTCCACGCC
GTAAACGGTGGGAACCTAGGTGTTGGCGACATTCCACGTGTCGGTGGCGCAGCTAACGCATTAAGTTCCCCGCCT
GGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCCGCACAAGCAGCGGAGCATGTGGCTTAA
TTCGACGCAACGCGAAGAACCCTTACCAAGGCTTGACATACACCGGAAAGCATCAGAGATGGTGCCCCCTTGTGG
TtCGGTGTACAGGTGGTGCATGGCTGTCGTGAGCTCGTGTGAGATGTTGGGTAAAGTCCCGCAACGAGCGCA
ACCCTTGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACCGCCGGGGTCAACTCGGAG
GAAGGTGGGGACGACGTCAAGTCATCATGCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGcCGGTACAAA
GAGCTGCGATACCGTGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCagTTCGGATTGGGGTcTGCAACTCGAcCC
CATGAAGTCGGAGTTGcTAATAATCgCANATCagCATTGCTGCGGTGAATACGTTcCCGGGCCTTGTACAcACCG
CCcGTCACGTcACGAAAGTCGgTAAcACCcGAAgCCGGTGGCCAACCCCTTgTGGGAGGgAGCTGTCGAAGGTGG
GACTGGCGATTG

15/30

[FIGURE 15 CONTINUED]**EN16****SEQ ID NO:7**

GCTTNTTGGTGGGNCNATGGCCTACCAAGGNGAGGACGGNTANCCNGCCTGNGAGGGAGACCGNCCACACTGGGA
ATGNGANACGGCCCAGAATCCTACGGGAGGCAGCANNGGGGAANATTGCACAANGGGCGAAAGCCTGATGCAGNG
ANGCCGCGTGAGGGAAGACGGCCTTTGGGTTGTAAACCTNTTTNAGCAGGGAAGAAGCGAAAGTGACGGTACCTG
CAGAAGAAGCGCCGGCTAANTANGTGCCAGCAGCCGCGGTAATANGTAGGGCGCAAGCGTTGTCCGGAATTATTG
GGCGTAAAGAGCTTGTAGGCGGCTTGTGANGTNGGATGTGAAAGCCCGGGGCTTAACCCCGGGTTTGCATTTGAT
ACGGGCTAGCTAGAGTGTGGTAGGGGAGATNGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAA
CACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAG
ATACCCTGGTAGTCCACGCCGTAAACGTTGGGAAGTAGGTGTTGGCGACATTCACGTCGTCGGTGCCGCAGCTA
ACGCATTAAGTTCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAAG
CAGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCAG
AGATGGTGCCCCCCTTGTGGTCGGTATACAGGTGGTGCATGGCTGTCTGTCAGCTCGTGTCTGAGATGTTGGGTT
AAGTCCCGCAACGAGCGCAACCCTTGTCTGTGTGTCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGAC
TGGGGGTCTGNAACTCGACCCCATGAANTCGGAGTTGCTAATAATCCCAAATTCANCATTGGTGCAGTGAATACT
TCCCGGGCCTGGTACACNACCGCCCGTCAACTCACGAAAGTCGGTNAAACCCGAAACCGGTGGGCCAACCCCTTG
TGGGAAGGAAGTGGCCNAAGTGGGACTGGCGATTGGGAC

EN23**SEQ ID NO:10**

ACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGATGAAGCCGCTTCGGTGGTGGATTAGTGGCGAACG
GGTGAGTAACACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATAACAC
TCTGTCCCGCATGGGACGGGGTTGAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTGTTGGTGGG
GTAATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCC
CAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGG
GATGACGGCCTTCGGGTGTGAAACCTCTTTTACGACAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCC
GGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCT
CGTAGGCGGCTTGTACGTCGGATGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCATTCGATACGGGCTAgCTAG
AGTGTGGTAGGGGAGATCGGAATTCCTGGTGTAgCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAA
GGCGGATCTCTGGGCCATTACTGACgTcTGAGGAGCGAAAGCGTGGGgAgCGAACAGGATTAGATACCCTGgTAG
TCCACGCCGTAAACGTTGGgAACTAGgTGTGGCGACATTCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTT
CCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAAGCAGCGGAGCATG
TGGCTTAATTGACGCAACGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCAGAGATGGTGCCCC
CCTTGTGGTCGGTATACAGGTGGTGCATGGCTGTCTGTCAGCTCGTGTCTGAGATGTTGGGTAAAGTCCCGCAAC
GAGCGCAACCCTTGTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACTGCCGGGGTCAA
CTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCG
GTACAATGAGCTGCGATGCCGCGAGGCGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAAC
TCGACCCCATGAAGTCGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTA
CACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCTTGTGGGAGGGAGCTGTCTG
AAGGTGGGACTGGCGATTG

16/30

[FIGURE 15 CONTINUED]**EN27****SEQ ID NO:12**

TTAANACATGCAANTCGAACGATGAACCCNGTTTCGGTGGTGGATTAGTGGCGAACGGTGAGTAANANGTGGGCA
ATTTGCCCTTCATTTTGGACAAGCCCTGGAAACGGGTTTAATACCGGATAACATTTTNTCCCGCATGGGANGGGG
TTGAAAGNTCCGGCGGTGAAGGATGAGCCCGCGGCCTATNAGCTTGTTGGTGGGGTAATGGCCTACCCAAGGGAG
ACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGAATGAGANACGGCCCAGAATCCTACGGGAGGCAGCA
GTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGANGCCGCGTGAGGGATGACGGCCTTNNGGTTGTAA
ACCTTTTTNAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAAATAAGTGCCAGCAGCC
GCGGTAATAAGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTTGTAGGCGGCTTGTCANGTNNG
ATGTGAAAGCCCGGGGNTTAACCCCGGTTTGCATTTGATACGGGCTAGNTAGAGTGTGGTAGGGGAGATNGGAA
TTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCATTACT
GACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGTTGGGAAC
TAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCCCGNCTGGGGAGTACGGCCGC
AAGGCTAANACTCAAAGGAATTGACGGGGGCCCCGNACAAGCAGCGGANCATGTGGCTTAATTCGACGCANCGCGA
AGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCAGAGATGGTGCCCCCCTTGTTGGTCGNTATACANGTGG
TGCATGNCTGTCGTCACCTCGTGTGTCGTGAGATGTTGGGTAAAGTCCCGCAACGAGCGCNACCCTTGNTCTGTGTT
GNCANCATGCCCTTCGGGGNTGATGGGGACTCACAGGANACTGNCCGGGGTCAACTCCGGANGAAGGTGGGTGAC
GAAGTCAAGGTCATCATGNCCCCTTATGTCTTGGTGCTGCACACGTGC

EN28**SEQ ID NO:13**

TTCGGNGGTGGANTAGNGGCGNACGGGNGACCAACANGNGGGCAATCCCCCCTTCANTTTNGGACAACCCCTGGA
AACGGGTTNTAATACCGGATAACANTTTNTCCCGCATGGGANGGGGTGAAAGCTCCGGCGGTGAAGGATGAGC
CCGCGGCCTATCAGCTTGTTGGTGGGGTAATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACC
GGCCACACTGGGANTGAGANACGGCCCAGAATCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAA
GCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTTTTTTCAGCAGGGAAGAAGCGAAA
GTGACGGTACCTGCAGAAGAAGCGCCGGCTAAATANGTGCCAGCAGCCGCGGTAAATANGTAGGGCGCAAGCGTTG
TCCGGAATTATTGGGCGTAAAGAGNTTGTAGGCGGCTTGTCANGTCGGATGTGAAAGCCCGGGGCTTAACCCCGG
GTTTGCATTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAG
ATATCAGGAGGAACACCGGTGGCGAAGGCGGaTcTcTGGGCCATTACtGACGcTGAGGAGCGAAAGCGTGGGgAG
CGAACAGgAATTAGATACCCTGgTAGTCCACGCCGTAAACGTTGGgAAcTAGgTGTGGcGACATTCCACGTcGT
CGgTGCCGCAGCTAACGCATTAAGTTCCCCGCCTGGGGAGTACGgCCCGCAAGGCTAAAACTCAAAGGAATTGAC
GGGGgCCCGCACAAGCAGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATAT

ACCGGAAAGCATCAGAGATGGTGCCCCCCTTGTTGGTGGTATACAGGTGGTGCATGGCTGTGTCGTCAGCTCGTGTC
GTGAGATGTTGGGTAAAGTCCCGCAACGAGCGCAACCCTTGgTTCTGTGTTGgCCAGCATGCCCTTCGGGGTGAT
GGGGACTCACAGGAGACTGgCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCCTTATG
TCTTGGGgCTGCACACGTGCTACAATGGCCGGTACAATGAGCTGCGATGCCGCGAaGGCGGAGCGAATCTCAAAA
AaGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTTGCTAGTAATCGCAGATCAGC
ATTGCTGCGGTGAATACGTTCCCGGGCCTTGTAACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGC
CGGTGGTCCAACCCCTTGTTGGGAGGGAGCTGTCGAAGGTGGGACTGGCGATTGG

17/30

[FIGURE 15 CONTINUED]**EN46****SEQ ID NO:16**

ATGCAAGTCGAGCGGAAAGGCCCTTCGGGGTACTCGAGCGGCGAACGGGTGAGTAACACGTGAGTTAATCTGCCC
CAGGCTCTGGATACCCACCGGAAACGGTGATTAATACCGAATACGACAACCGATTTGCATGATCTGGTgGTGNA
AAGTTTTTCGGCCTGGGATGTGCTTCGCGGCCTATCAGCTTGTGGTGAGGTAATGGCTCACCCAAGGCTTCGAC
GGTAGCCGGCCTGAGAGGGTGACCGNCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTG
GGGAATATTGGACAATGGGCGGAAGCCTGATCCAGCAACGCCGCGTGAGGGATGACGGCCTTCGGGTGTAAACC
TCTTTCAGCACAGACGAAGCGCAAGTGACGGTATGTGCAGAAGAAGGACCGGCCAACTACGTGCCAGCAGCCGCG
GTAATACGTAGGGTCCGAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCTCGTAGGCGGTCTGTGCGCTCGGGAG
TGAAAACCAGGTGCTTAACACCTGGCCTGCTTTCGATACGGGCAGNCTAGAGGTACNCAGGGGAGAATGGAATTC
CTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAAACACCGGTGGCGAAGNCGGTTCTCTGGGAGTATCCTGA
CGCTGAGGAGCGAAAGTGTGGGGAGCGAACAGGATTAGATAACCTGGTAGTCCACACCGTAAACGTTGGGCGCTA
GGTGTGGGACACATTCCACGTGTTCCGTGCCGCAGCTAACGCATTAANCGCCCCGCTGGGGAGTACGGCCGCAA
NGCTAAAACTCANAGGAATTGACGGGGGCCCCGACAAAGCGGCGGA_gCATGCGGATTAATTCGATGCAACGCGAAG
AACCTTACCTGGGTTTGACATACACCGGAAAGCCGTACAGATACGGCCCCCTTTTAGT_{Cg}GTGT_aCAGGTGGTGCA
TGGCTGT_{Cgt}C_{Ag}Ct_{Cg}CTGTCTGAGATGT_tCGGGTTAAGTCCCGCAACGAGCGCA_aCCCTC_gTCCTATGTTGC
CaGCAATTTCGGTTG_gGGA_gCTCATAGGA_gACTGCC_gGGGT_{Ca}ACTCGGAGGAAGGTGGGGATGACGTCAAGTCATC
ATGCCCCCTTATGTCCAGGGCTTCACGCATGCTACAATGGCCGGTACAAAGGGCTGCGATCCCGTGAGGGTGAGCG
AATCCCCAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTCGCTAGTAATCG
CAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGCCTTGACACACCGCCCGTCACGTCACGAAAGTCGGCAAC
ACCCGAAGCCANTGGCCCAACTCGTAAGAGAGGGAGCTGT

EN60**SEQ ID NO:18**

ATGCAAGTNGAACGATGAANCCNTTTGGGGTGGATTAGTGGCGAACGGGTGAGTAANANGTGGGCAATTTGCCCT
TCAATTTGGGACAAGCCCTGGAAACGGGGTNTAATACCGGATAACANTNTGTCCCGCATGGGACGGGGTTAAAG
CTCCGGCGGTGAAGGATGAGCCCCGCGGCCTATNAGCTTGTGGTGGGGTGATGGCCTACCAAGGCGACGACGGGT
AGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGG
AATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTGTAAACCTTT
TTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAAATANGTGCCAGCAGCCGCGGTA
ATANGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGTTTGTAGGCGGCTTGTACAGTNGGATGTGA
AAGCCCGGGGCTTAACCCCGGGTTTGCAATTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGATCGGAATTCCTG
GTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGG_{aTcTc}TGGGCCATTACTGACGNT
GAGGAGCGAAAGCGTGGGGAGCNAACAGNATTAGATAACCTGGTAGTCCAAGCCGTAAACGTTGGGA_gACTANGTG
TTGGCGACATTCCACGTCTGTCNNTGCCGCANCTAACGCATTAAGTTC_{CCCCG}CCTGGGGAGTACGGCCGCAAGGCT
AANACTCAAAGGAATTGANGNNGGCCCGCACAAAGCAGCGGAGCATGTGGCTTANTTCNACGCANCGCAAGAACC
TTACCAAGGTTTGCCATATA_{cCGGAAgCaTCAgAgATg}GCCCCCCT_{tGTGGT}CGGTATACAG_gTGGTGCNTG
GCTGTCTGTC_gCTCGTGTCTGAC_{tGt}GGTTAA_{gTCCCGTCAaCGAGgCGCAACCCTTGT}TNTGTGTNGCCAG
CATGCCCTTCGGGGTGATGGGGACTCACAGGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAG
TCATCATGCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGCTGCGATGCCGCGAGGCG
GAGCGAATCTCAAAAAGCCGGTNTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTTGCTAGT
AATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGACACACCGCCCGTCACGTCACGAAAGTCG
GTAACACCCGAAGCCGNTGG

18/30

[FIGURE 15 CONTINUED]

PM87

SEQ ID NO:24

GGCCCAGANATCCGNCTTCGCCACCGGTGTTCCCTCCTGAATATCTGCGCATTTCACCGCTACACCAGGAATTCCG
ATCTCCCCTACCACACTCTAACTAGCCCGTATCGAATGCAGACC CGGGGTTAAGCCCCGGGCTTTCACATCCGAC
GTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCCGGACAACGCTTGCGCCCTACGTATTACCGCGGCTG
CTGGCACGTAATTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGCTGAAAGAGGTTTACA
ACCCGAAGGCCGTCATCCCTCACGCGGCGTCGCTGCATCAGGCTTTCGCCCATTGTGCAATATTCCCCACTGCTG
NCTCCCGTANGAGTCTGGGCGGTGTCTCAGTCCCAGTGTGGCCGGTCGNCCTCTCAGGCCGGCTACCGTCGTCGC
CTTGGTAGGCCATTACCCACCAACAAGCTGATANGCCGNGGGCTCATCCTTCANCGTCGGAGCTTTCANCCCG
TCCATGCGGGACAGAGTGTTATCCGGTATTANACCCCGTNTCAGGGCTTGTCCANAGTGAAGGGCAGATNGCCAC
GTGTTATCACCGTTCGCCACTAATNACANCGAAACGGCTTATCGTNCGACTGCATGTGTTAACACNCGCAGCGTT
CGTCCTGAGCCAG

19/30

FIGURE 16

EN5

SEQ ID NO: 3

GTAATGGCCCANAAAACCGCCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACCGCTACACCAGGAAT
TCCNATCTCCCCTACCACACTCTAGCTAGCCCGTATCNAATGCAAACCTCGGGGTAAAGCCCNAGCTTTCACATC
CGACGTGACAAGCCGCCTACAANCTCTTTACGCCCAATAATTCCGGANAACGCTCGCACCCCTACNTNTTACCGCG
GCTGCTGGCNCGTNTTTAGCCGGTGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGCTNAAAAGGTT
TACAACCCTANGGCCGT

EN6

SEQ ID NO: 4

TGAGGGATGACGGCNTTCGGGGTTGTAAACNTTTNTCACCAGGGAAGAAGCGAAAGTGNCGGTACCTGCAGAAGA
AGCGCCGNCTAACTACGGGCCAGCATCCGCGGTAATACGTAGGGCGCAATCGTTGTCCGGAATTANTGGGCGTAA
AGAGNTCGTAGGCGGCTTATCACGTCCGGTGTGAAAGCCCGGGGCTTAAGCCCCGGGTCTGCATTTCGATACGGGC
TAGCTAGANTNTGNTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGgAGGAACACCGg
TGGCGAAGGCGGATCTcTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCC
TGGTAGTCCACGCCGTAAACGGTGGGAAC TAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCAT
TAAGTTCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCCGCACAAGCAGCGG
AGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATCAGAGATGG
TGCCCCCCTTGTGGTCGGTGTACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCTGAGATGTTGGGTAAAGTCC
CGCAACGAGCGCAACCCTTGGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGAACGCCG
GGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCTTATGTCTTGGGCTGCACACGTGCTACA
ATGGCAGGTAAATGAGCTGCGATACCGTGAGGTGGAGCGAATCTCAAAAAGCCTGTCTCANTTCGGATTGGGGT
CTGNAANTCGACCCCATGAAAGTCGGAGTTGCTAATTATCCCAGATCAACATTGCTGGCGGTGAATACGTTCCCG
GGGCCTTGGTAAACACCGCCCGTCAANGTNAAGAAAGTCGGGTAAACACCCGAAANCCGGTGGGCCAANCCCCCT

EN7

SEQ ID NO: 5

CCGCCTTCGCCACCGGGTGTTCCCTCCTGATATCTGCGCATTTACCGCTACACCAGGAAATTCNATCTCCCCTA
CCACACTCTANCTANCCCGTATCGAATGCAAACCCGGGGTTAANCCCCGGGCTTTCACACCCGACNTGACAAGCC
GCCTACAAACTCTTTACGCCCAATAATTCCGGACAACGCTTGCGCCCTACNTATTACCGCGGCTGCTGGCACNTA
TTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGCTGAAAAAGGTTTACAACCCGAAGGC
CGTCATCCCTCACGCGGCGTGCCTGCATCAGGCTTTCGCCCATTGTGCAATATTCCCCACTGCTGCCTCCCN TAG
GAATCTGGGCCGTGTCTCAATCCAGTGTGGCCGGTCCCCTCTCNGGCCGGCTACCGTCNTCCCTTGGTNACCATT
ANCTACCAACAACCTGATAGGNCGCGGGCTCATCTTCACGCGGGAACTTTCAACCACC

EN9

SEQ ID NO: 6

GGCGGCGTGCTTAACACATGCAAGTCGAACGATGAAGCCCTTCGGGGTGGATTAGTGGCGAACGGGTGAGTAACA
CGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATACGATTCGgGAGGCAT
CTCCTGGT aCTGGAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCcTATCAGCTTGTTGTGGGTAAATGGCCTACC
AAGGCGACGACGGgTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGG
GAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTC
GGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAGAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTG
CCAGCAGCCGCGGTAAACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTG
TCACGTCGGGTGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCATCCGATACGGGCAGGCTAGAGTGTGGTAGGGG
AGATCGGAATTCTTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGG
GCCATTACTGACGCTGAGGAgCgAAAGCGTGGGGAGCCaACAGGATTAGATACCCTGGTAGTCCACGCCGTAAAC
GTTGGAAC TAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCCCGCcTGGGGAGT
ACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCCGCACAAGCAGCGGAGCATGTGGCTTAATTCGACG
CAACGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCGCCAGAGATGGTGCCCCCTTGTGGTGGGTAT
ACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCTGAGATGTTGGGTAAAGTCCCGCAACGAGCGCAACCCTTGT

20/30

[FIGURE 16 CONTINUED]

CCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACCGCCGGGGTCAACTCGGAGGAAGGTGG
GGACGACGTCAAGTCATCATGCCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAAAGAGCTGCG
ATGCCGTGAGGCGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGT
CGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCAC
GTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCCTCGGGGAGGGAGCTGTCTGAAGGTGGGAC

EN17**SEQ ID NO:8**

CCGCCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACGCTACACCAGGAATTCC
NATCTCCCCTACCACACTCTAGCTAGCCCGTATCAAATGCAAACCCGGGGTTAAGCCCCGGGCTTTC
ACATCCNACGTGACAAGCCGCCTACAANCTCTTTACGCCCAATAATTCCGGACAACGCTTGCGCCCT
ACNTATTACCGCGGCTGCTGGCACNTATTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCT
NCTTCCCTGCTGAAANAGGTTTACAACCCAAAGGCCNTCATCCCTCNCCGGCNCNTTGCNTCNGGC
TTNCNCCCATTGTTCAANNTTCCCCACTGCTNCCTCCCCTCGGAATCTGGGCCGNTGTCTCATTTCCCN
TTNTGGCCGGTCCCCCTCNCAGGCCNGCTACCC

EN19**SEQ ID NO:9**

CTCAGCGTCNGTAATGGCCCAAAAACCGCCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACGCTAC
ACCAGGAATTCCNATCTCCCCTACCACACTCTAGCTAGCCCGTATCNAATGCAAACCCGGGGTTAANCCCCGGGC
TTTCACATCCNACNTGACAAGCCGCCTACAANCTCTTTACGCCCAATAATTCCGGACAACGCTTGCCNCCCTACTT
ATTACCGCGGCTGCTGGCACTTATTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGCTN
AAAAAGGTTTACAACCCNAAGGCCGTATCCCTCACGCGGCNTCGCTGCATCAGGCTTTCNCCCATTGTGCAATA
TTCCCCACTGCTGCCTCCCGTAGGATTCTGGGCCGTNTCTCATTTCCANTGTGGCCGGTTCGCCCTCTCAGGCCGG
CTACCCGTCNTCNCCTTGGTAGGCCATTACCCACCAACAAGCTNATAGGCCGCGGGCTCATCCTTCACCGCCGG
AAGCTTTCACCCCNCTCCATGCGGGANAAATTGTTNTCCGGTATTAAACCCCGTTTCCAGGGNTTGTCCCAAAT
TGAAGGGGGGATTGNCCACTTTTTACTCACCCGTTCCNCCNCTAATCCACCACC

EN26**SEQ ID NO:11**

CCGCCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACGCTACACCAGGAATTCCNATCTCCCCTACC
GAACTCTANCCGTGCCCGTATCNACTGCAAACCCGGGGTTAAGCCCCGGGCTTTCACAACCGACNTGACAAGCCGC
CTACAANCTCTTTACNCCCAATAATTCCGGACAACGCTTGCGCCCTACNTATTACCGCGGCTGCTGGCACNTATT
TAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGCTGAAAAAGGTTTACAACCCGAAGGCCG
TCNTCCCTCACGCGGCGTCGCTGCATCAGGCTTTCGCCCATTGTGCAATATTCCCCACTGCTGCCTCCCGTAGGA
TTCTGGGCCGTGTCTCANTCCCANNTTGGCCGGTCCCCTCTCAGGCCGGNTACCCGTCGTCCCTTGGTGAACCNC
TACCTCNCCAACAANCTGATAGGGCGCGGGCTCANCNTGCACGCCGGANCTTT

EN35**SEQ ID NO:14**

AACACATGCAAGTCGAACGATGAAGCCGCTTCGGTGGTGGATTAGTGGCGAaCGGGTGA_gTAACACGtGGCCAAN
TGTGNCCGTCACTaTGGGAC_gAAGaCCTTGGAACGGGGTCTAATACCGGATAAACTCTGTCCCGCATGGGACG
GGGTTGAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCATCAGCTTGTTGGTGGGGTAATGGCCTACCAAGGC
GACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCAGACTCCTACGGGAGGC
AGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTT
GTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGC
AGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACG
TCGGATGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCATTGATACGGGCTAGCTAGAGTGTGGTAGGGGAGATC
GGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATTAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCA
TTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTATATACCTGGTAGTCCACGCCGTAAACGTTG
GGAAGTAGGTGTTGGCGACATTCCACGTCGTGCGTGCCGCAGCTAACGCATTAAGTTCCCCGCCTGGGGAGTACG
GCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCCGCACAAGCAGCGGAGCATGTGGCTTAATTCGACGCAA
CGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCA_gAGATGGTGGCCCCCTTGTGGTGGGTATACA

21/30

[FIGURE 16 CONTINUED]

GGTGGTGCATGGCTGTCGTCANCTCGTGTGCTGAGATGTTGGGTAAAGTCCCGCAACGAGCGCAACCCTTGTTCT
GTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACTGCCGgGGTCAaCTCGGAGGAAGGTGGGGA
CGACgTCaAGTCATCATGCCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGCTACAATGACCTGCgATG
CCGCgAGGCgGACCGAATCTCAaACAAGCCCGTCTCATTCCGATTGCGGTCTGCaActcCGACCCCATgAAgTCC
GACTtGCTAgTACTCGCACgTCAACaTtGCTGCGCTGaATACgTCCCCGGGCCTTGTACACACCGCCCGTCACGT
CACGAAAGTCGGTAACACCCGAAGCCGGTGGNCCAACCCCTTGTGGGAGGGAGCTGTGCGAA

EN39**SEQ ID NO:15**

ccgccttcgccaccggtgttcctcctgatatactgcgcatttcaccgctacaccaggaattccnatctcccctacc
acactctagctancccgatcnaatgcaaaccgggggttaacccccgggctttcacacccnacntnacaanccgc
ctacaaactctttacgcccaataattccggacaacgcttgccgctacttattaccgcggctgctggcacttatt
tagccggcgcttcttctgcaggtaccgtcactttcgccttcttccctgctgaaaaagggtttacaacccgaaggcng
tcatccctcacgcggcntcgtgcatcaggctttcgcgccattgtgcaatattccccactgctgcctcccgtagna
ntctgggcccgtntctcantcccagtggtggnccggtcgccctctcaggccggctaccgctcgtcncctnggtnaacc
attanntaccaacaagctgataggccgcgggctcatccttcaccgcggagcttttaacccctgcccattgaaaa
cagangtnttatccggtattanaaacccgtttccaggg

EN57**SEQ ID NO:17**

GTGCTTAACACATGCAAGTCGAACGATGAAGCCGCTTCGGTGGTGGATTAGTGGCGAACGGGTGAGTAACACGTG
GGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATAAACTCTGTCCCGCATGGG
ACGGGGTTGAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTGTTGGTGGGTAATGGCCTACCAAG
GCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCAGACTCCTACGGGAG
GCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGG
TTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCA
GCAGCCGCGGTAAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCA
CGTCGGATGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCATTTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGA
TCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATNCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGCC
ATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGTT
GGGAAGTAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTgAACGCATTAAGTTCCCCGCCTGGGGAGTA
CGGCCGCAAGGCTAAACTCAAAGGAATTGACGGGGGCCCGCACAAAGCAGCGGAGCATGTGGCTTAATTGACGC
AACGCGAAGAACCTTACCAAGGCTTGACATATAACGGAAAGCATCAGAGATGGTGCCCCCCTTGTGGTTCGGTATA
CAGGTGGTGCATGGCTGTGCTCAGCTCGTGTGCTGAGATGTTGGGTAAAGTCCCGCAACGAGCGCAACCCTTGTT
CTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAgACTGcCGGGGTCAACTCGGAGGAAGGTGGG
GACGACGTCAAGTCATCATGCCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGCTGCGA
TGCCgCGAgGCGGAgCgAATCTCAAAAAGCCGGTCTCAgTTCGGATTGGGGTCTGCAACtCGACCCCATGAAGTC
GGAgTTGCTAgTAATCgCAgATCAgCATTGCTGcGGTGAATACGTTCCCGGGCCTTGTACACACCGCCGTCAcGT
CACGAAAGTCGGTaACACCCGAAGcCGGTGGCCCAACCgCCTTGTGGGAAGGAACTTTCCA

22/30

FIGURE 17

SE1

SEQ ID NO:19

GAACGATGAAGCCGTTTCGGTGGTGGATTAGTGGCGAACGGTGAGTAAAAGTGGCAATTTNCCCTTCATTTTGGAC
CAAGCCCTGGAAACGGGTTTAAANACCGGATAACATTNTGTCCCGCATGGGACGGGGTTGAAAGNTCCCGGCGGTG
AAGGATGAGCCCGCGGCNTATCAGCTTGTGGTGGGGTAATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGA
GAGGGCGACCGGCCACACTGGGANTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACA
ATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTGTAAACCTNTTTCAGCAGGGA
AGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAAATANGTGCCAGCAGCCGCGGTAATANGTAGGGC
GCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTTGTAGGCGGCTTGTGANGTCGGATGTGAAAGCCCGGGGC
TTAACCCCGGGTTTGCATTGATACGGGCTAGTTAGAGTGTGGTAGGGGAGATNGGAATTCCTGGTGTAGCGGTG
AAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGACGCTGAGGAGCGAAA
GCGTGGGGAGCNAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGTTGGGAAGTAGGTGTTGGCGACATT
CCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCTCGCCTGGGGAGTACGGCCGCAAGGCTAAAGCTCAAAG
GAATTGACGGGGGGCCCGCACAAGCAGCGGAGCATGTGGCTTAATTCGACGCAACGCGAACAACCTTACCAAGGCT
TGACATATACCGGAAAGCATCANAGATGGTGCCCCCTTGTGGTGGTATACANGTGGTGCATGGCTGTCGTCAG
CTCGTGTGTCGTGAGATGTTGGGTANGTCCCGCAACGAGCGCNACCCTTGTCTGTGTCGNCNAGCATGCCCTTCG
NGGTGATGGGGACTCACANGAGACTGNCGGGGTCCACTCGGAGGAAGGTGGCGACNACGTCANNTCATCATGCC
CCTTATGTCTTGGGNCTGGCCACGTGCNACNATGGCC

SE2

SEQ ID NO:20

GCTGGCGGCGTGCTTAACACATGCAAGTCGAACGATGAAGCCGCTTCGGTGGTGGATTAGTGGCGAACGGGTGAG
TAACACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATAACACTCTGTC
CCGCATGGGACGGGGTTGAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTGGTGGGGTAATG
GCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACT
CCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGAC
GGCCTTCGGGTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAA
CTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGg
CGGCTTGTACGTCGGATGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCATTGATACGGGCTAgCTAgAGTGTG
GTAGGGGAGATCGGAATTCCTGGTGTAgCGGTGAAATGCGCaGATATCAgGAGGAACAacCGGTGGgAAGgcGGA
TCTCTGGGcCAtTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCAAGC
CGTAAACGTTGGGAAGTANGTGTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCTCGTC
CTGGGGAGTACGGCCGCNAGGCTAAAGCTCAAAGGAATTGACGGGGGGCCCGCACAAGCAGCGGAGCATGTGGCTT
ANTTCGACGCNACGCGAAGAACCTTNCCAAGGCTGACATATACCGgAAAGCATCAcAGATGGTGCCCCCTTGTG
GTCGGTATACAGGgTGGTGCATGGCTGTtCGtCaGCTCGTGTGtGAGATGTTGGGTAAgTCCCGCAAAGAGCG
CAACCgTGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCAcAcGAgACTGTCNNGGTCAACTCgga
GGAAGGTGGgGACGACgTCAAGTtCATCATGCCCTTATGTCTTGGGCTGCACACGNGCTACAATGGCCGGTACA
ATGAGNNGGGATGCCGCGAGGCGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTGACC
CCATGAAGTCGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTNCCCGGGCCTNGTACACACC
ACCGTCACGTCACGAAAGTCGGTAACACCCTAAGCCGGTGNCCCAACCCCTTNTGGGAGG

23/30

FIGURE 18

PM36

SEQ ID NO:21

CCAGANATCCGCCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACCGCTACACCAGGAATTCCGATCT
CCCCTACCACACTCTAGCTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCCCGGGCTTTCACATCCGACGTGA
CAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCGGGACAACGCTTGCGCCCTACGTATTACCGCGGCTGCTGG
CACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGCTGAAAGAGGTTTACAACCC
GAAGGNCGTCAATCCCTCACGCGGCGTGCCTGCATCAGGCTTTCGCCCATTGTGCAATATTCCCCACTGCTGCCTC
CCGTAGGAGTCTGGGNCGTGTTCAATNCCAGTGGTGGGCGGTCGCCCTCTCAGGNCGGCTACCGTCGTGCGCTT
GGTAGGCATTACCACAACAAGCTGATAGGCGGGGGTCATCCTTCAACGCCGGAGCTTCAAACCCGTCCATGCGGG
ACAAGTGTATCCGGTATTAAACCC

PM40

SEQ ID NO:22

TCAGTNATGGCCCAGAANGATCCGNCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACCGCTACACCA
GGAATTCCGATCTCCCCTACCACACTCTAACTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCCCGGGCTTTC
ACATCCGACGTGACAAGCCGCCTACGAGCTCTTNACGCCCAATAATTCGGGACAACGCTTGCGCCCTACGTATTA
CCGCGGCTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTNACTTTCGCTTCTTCCCTGCTGAAAG
AGGTTTACAACCCGAAGGCCGTCTCCCTCACGCGGCGTGCCTGCATCAGGCTTTCGCCCATTNGTGCANTATTCC
CCACTGNTGNCTCCCGTANGAGTCTGGGCGGTGTCTCAGTCCCAGTGTGGCCGGTCGNCCTCTCAGGCCGGCTAC
CGTCGTGCGCTTGGTAGGNCATTACCCACCAACAAGCTGATANGTCGNNGGCTCATCCTTCACCGNCGGAGNTTT
AACCCCGTNCATGCGGGACAGAGTGTTATCCGGTATTANACCCGTATNCAGGGCTTGTCCCATAGTGAAGGGNAG
ATNGCCACGTGTTATCACCGTTCGNCACTAATNATCANCGAANC GGCTTCATCGTTCGACTTG CATGTGTTA

PM41

SEQ ID NO:23

CTCAGCGTCAGTCATGGCCAAGAGATCCGCCTTCGCCACCGGTGTTCCCTCCTGTATATCTGCGCATTTACACCGCT
ACACCAGGAATTCCGATCTCCCCTACCACACTCTAGCTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCCCGG
GCTTTCACATCCGACGTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCGGGACAACGCTTGCGCCCTAC
GTATTACCGCGGCTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGC
TGAAAGAGGTTTACAACCCGAAGGCCGTCAATCCCTCACGCGGCGTGCCTGCATCAGGCTTTCGCCCATTGTGCAA
TATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCGGTGTCTCAGTCCCAGTGTGGCCGGTCGCCCTCTCAGGCC
GGCTACCCGTCGTGCGCTTGGTAGGCCATTACCCACCAACAAGCTGATAGGCCGCGGGCTCATCCTTCANCGNCG
GAGCTTTAACCCGTCCATGCGGGACAGAGTGTTATCCGGTATTAAACCCGTTTCAGGGCTTGTCCCANAGTGAAG
GGCAGATTGCCACGTGTTATCANCCGTTCGNCACTAATCACANCGAANC GGGTTCATCGTTCGACTTG CATGTGT
TAA

PM171

SEQ ID NO:25

CCCTCAGGGTCAGTAATGGGCCCAGAGATCCGCCTTCGCCACCGGTGTTCCCTCCTGAATATCTGCGCATTTACCC
GCTACACCAGGAATTCCGATCTCCCCTACCACACTCTAGCTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCC
CGGGCTTTCACATCCGACGTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCGGGACAACGCTTGCGCCC
TACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCC
TGCTGAAAGAGGTTTACAACCCGAAGGCCGTCAATCCCTCACGCGGCGTGCCTGCATCAGGCTTTCGCCCATTGTG
CAATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCGGTGTCTCAGTCCCAGTGTGGCCGGTCGCCCTCTCAG
GCCGGCTANCCGTCGTGCGCTTGGGTAGGCATTANCCCANCAACAAGCTGATAGGNCGCGGGCTCATNCTTCAAC
GCCGGAGCTTTCAANCCCGTCCATGCGGGACAGAGTGTTATNCGGTATTAAACCCGTTTCAGGGCTTGTTCAGA
GTGAAGGGCAGATTGCCACGTGTTATCAACCGTTCGGCACTAATCACAACGAAGCGGNTTATCGTTCGACTTGCA
TGTGTTAACAAGCCGCCAGCGTTCGTC

24/30

[FIGURE 18 CONTINUED]**PM185****SEQ ID NO:26**

TCAGTAATGGCCCAGAGATCCGCCTTCGCCACCGGTGTTCCCTCCTGGATATCTGCGCATTTACACGCTACACCAG
GAATTCGATCTCCCCTACCACACTCTAGCTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCCCGGGCTTTCA
CATCCGACGTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCGGGACAACGCTTGCGCCCTACGTATTAC
CGCGGCTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTGCTTCTTCCCTGCTGAAAGA
GGTTTACAACCCGAAGGCCGTCATCCCTCACGCGGCGTCGCTGCATCAGGCTTTGCCCCATTGTGCAATATTCCC
CACTGCTGCCTCCCGTAGGAGTCTGGGCGGTGTCTCAGTCCCAGTGTGGCCGGTCGCCCTCTCAGGCCGGCTACC
CGTCGTCGCCTTGGTAGGCCATTACCCACCAACAAGCTGATAGGCCGCGGGCTCATCCTTCACCGNCGGAGCTT
TAACCCCGTCCCATGCGGGACAGAGTGTTATCCGGTATTAGAACCCGTTTCCAGGGCTTGTCCAGAGTGAAGGG
CAGATTGCCACGTGTTACTCANCCGTTTCGNCACTAATCANCAACGAAGCGGCTTCATCGTTCGACTTGCATGTGT
TAAGCACGCCGNCAGCGTTCGTCCTGAGCCAGGATC

PM208**SEQ ID NO:27**

TCAGTATCNGCCCAGAGATCCGCCTTCGCCACCGGTGTTTCCCTCCTGATATCTGCGCATTTACACGCTACACCAG
GAATTCGATCTCCCCTACCGAACTCTAGCCTGCCCGTATCGACTGCAGACCCGGGGTTAAGCCCCGGGCTTTCA
CAACCGACGTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCGGGACAACGCTTGCGCCCTACGTATTAC
CGCGGCTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTGCTTCTTCCCTGCTGAAAGA
GGTTTACAACCCGAAGGCCGTCATCCCTCACGCGGCGTCGCTGCATCAGGCTTTGCCCCATTGTGCAATATTCCC
CACTGGTGNCTCCCGTANGAGTCTGGGGCGGTGTCTCANTCCAGTGTGGGCGGTGCGCTCTCAGGGCGGCTACCGT
CGTCGCTTGGTGAGNCACTACTCACAACAAGCTGATAGGCGCGGGCTCATCTGGAACGGCGGAGCTTTACAC

PM228**SEQ ID NO:28**

TCAGTAATGGCCCAGANATCCGNCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACGCTACACCAGG
AATTCGATCTCCCCTACCACACTCTAACTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCCCGGGCTTTTAC
ATCCGACGTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCGGGACAACGCTTGCGCCCTACGTATTACC
GCGGCTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTGCTTCTTCCCTGCTGAAAGAG
GTTTACAACCCGAAGGCCGTCATCCCTCACGCGGCGTCGCTGCATCAGGCTTTGCCCCATTGTGCAATATTCCCC
ACTGCTGCCTCCCGTANGAGTCTGGGGCGGTGTCTCAGTCCCAGTGTGGCCGGTCGCCCTCTCAGGCCGGCTACCG
TCGTCGCCTTGGTAGGCCATTACCCACCAACAAGCTGATANGNCGNGGGCTCATCCTTCACCGNCGGAGCTTTCA
ANCCCGTCCCATGCGGGACAGAGTGTTATCCGGTATTAAACCCGTNTCCAGGGCTTGTCCATAGTGAAGGGCAGA
TTGCCAAGTGTTATCANCCGTTTCGNCACTAATCATCANCAAGCGGCTTCATCGTTCGACTGCATGTGTT

PM252**SEQ ID NO:29**

TCCTCAGNATCAGTAATGGCCCAGAGATCCGCCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACGC
TACACCAGGAATTCGATCTCCCCTACCACACTCTANCTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCCCG
GGCTTTTACATCCGANGTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCGGGACAANGCTTGCGCCCTA
CGTATTACCGCGGNTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTGCTTCTTCCCTG
CTGAAAGAGGTTTACAACCCGAAGGCCGTCATCCCTCACNCGGCGTCGCTGCATCAGGCTTTGCCCCATTGTGCA
ATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGGCGGTGTCTCAATCCCANTGTGGCCGGTCGCCCTCTCANGC
CGGCTACCGTCGTCGCTTGGTAGGCCATTACCCACCAACAAGCTGGATAGGNCGGGGGCTCATTTCTTACCGCC
GGAAGCTTTAANCCCGTCCATGCGGGANANAGTGNATCCNGTATTAAACCCNGTTTCAGGGCTTGTCCANAGTG
AAGGGNGATTGCCCNAGTGTTTATCNCCCGTTCGCCANTAATCNACAACGAAGCGGNTTCNTCGNTTCGACTTG
C

25/30

[FIGURE 18 CONTINUED]

PM342

SEQ ID NO:30

TAATGGCCCAGAANATCCGCCTTCGCCACCGGTGTTCCCTCCTGAATATCTGCGCATTTACCGCTACACCAGGAA
TTCCGATCTCCCCTACCACACTCTAGCTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCCCGGGCTTTCACAT
CCGACGTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCCGGACAACGCTTGCGCCCTACGTATTACCGC
GGCTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGCTGAAAGAGGT
TTACAACCCGAAGGCCGTCATCCCTCACGCGGCGTCGCTGCATCAGGCTTTCGCCCATTTGTGCAATATTCCCCAC
TGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCGGTTCGCCCTCTCAGGCCGGNTANCCGTC
GTCGCCTTGGTANGCCATTANCCCACCAACAAGCTGATANGCCGNGGGCTCATCCTTCANCGCCGGAGCTTTTAA
CCCCGTCCCATGCGGGACAGAGTGTTATCCGGTATTAGATCCCGTNTCCAGGGCTTGTNCATAGTGAAGGGCANA
TTGCCACGTGTTACTCANCCGTTTCGC

26/30

FIGURE 19

EN4

GGCGGCGTGCTTAACACATGCAAGTCGAACGATGAACCACTTCGGTGGGGATTAGTGGCGAACGGGTGAGTAACA
CGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTtAATACCGGATAACACTCCCCTCTC
CTGAGTGGGGGTAAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGAGGTAATGGCTC
ACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTA
CGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCC
TTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTAC
GTGCCAGCAGCCGCGGTAAACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGC
TTGTACGTCGGGTGTGAAAGCCCCGGGGCTTAACCCCGGGTCTGCATTTCGATACGGGCTAGCTAGAGTGTGGTAG
GGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATTCAGGAGGAACACCGGTGGCGAAGGCGGATCT
CTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGT
AAACGGTGGGAAGTAGGTtGTTGGCGACATTCACGTCGTCGGTGCCGCGAGCTAACGCATTAAGTTCCCCGCCTG
GGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGGCCCGCACAAAGCAGCGGAGCATGTGGCTTAAT
TCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATCAGAGATGGTGCCCCCTTGTGGT
CGGTGTACAGGTGGTGCATGGCTGTCTGTCAGCTCGTGTCTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAAC
CCTTGTCTGTGTTGCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACCGCCGGGGTCAACTCGGAGGAA
GGTGGGGACgACGTCAAGTCATCATGCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCAGGTACAATGAG
CTGCGATACCGTGAGGTGGAGCGAATCTCAAAAAGCCTGTCTCAgTTCGGATTGGGGTCTGCAACTCGACCCcaT
GAAGTCGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC
GTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCCTTGTGGGAGGGAGCTGTCAAGGTGGGA
CTGGCGATTGGG

EN10

GAGTTTGATCNNGGCTCAGACGAACGCTGGCGGCGTGTTAACACAANCCAAGTCGAANGNTGAACCACTTCGTTG
GGATTAGTGCGAACGGTGNTAACACGNTGGCAATGTGCCCTTCACTNTGGGACAAGNCCTGGAAACGGGGTTCTA
ATACCGGATACCACTACCCGCGAGGCATCTGTGGTGTGTTGAAAGCTCCGCCGTTGAAGGATGAGCCCGCGGCCTAT
CAGCTTGTTGGTGAGGTAATGGCTCACCCAAGGCGACGACGGATAGCCGGCCTGAGAGGGCGACCGGCCACACTG
GGACTGAGACACGGCCCAGACTCCTACGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAG
CGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACC
TGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTAT
TGGGCGTAAAGAGCTCGTAGGCGGCTTGTACGTCGGGTGTGAAAGCCCCGGGGCTTAACCCCGGGTCTGCATTCTG
ATACGGGCTAGCTAGAGTGTGGTAGGGGAGATCGGAATTCCTGGTGTACCCGGTGAAATGCGCAGATATCAGGAG
GAACACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGAT
TAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGAAGTAGGTGTTGGCGACATTCACGTCGTCGGTGCCGCGAG
CTAACGCATTAAGTTCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGGCCCGCAC
AAGCAGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACGCCGGAAGCAT
CAGAGATGGTGCCCCCTTGTGGTCCGTGTACAGGTGGTGCATGGCTGTCTGTCAGCTCGTGTCTGAGATGTTGG
GTTAAGTCCCGCAACGAGCGCAAcCCTTGTCCTGTGTTGcCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGA
GACCGCCGGGGTCAACTCGGAGGAAGGTGGNGACGACGTCgAGTCATCATGCCCTTATGTCTTGGGGCTGCACA
CGTGCTACNATGgCaGGTACAATGAGCTGCGATACCGTGAGGTGGAGCgCATCTnnnnnAGCctGTCTCAGTTC
GgATTGGGGTCTGcAACTCGACCCCcaTGAAGTCGgAGTTGCTAgATAATCgCAgATCAGCATTGCTGCGgTGAAT
ACGTtCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCC
TTGTGGGAGGGAGCTGTCAANGTGG

27/30

[FIGURE 19 CONTINUED]**EN22**

TCCTCAGCGTCAGTAATGGCCCCAAAACCGCCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACCGCT
ACACCAGGAATTCCNATCTCCCCTACCACTCTAGCTAGCCCGTATCNAATGCAAACCCGGGGTTAANCCCCGG
GCTTTCACATCCNACNTGACAAGCCGCCTACAANCTCTTTACGCCCAATAATTCCGGACAACNCTTGCGCCCTAC
TTATTACCGCGGCTGCTGGCACTTATTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGC
TGAAAAAGGTTTACAACCCNAAGGCCGTATCCCTCACGCGGCNTCNCCTGCATCAGGCTTTCNCCCATTGTGCAA
TATTCCCCACTGCTGCCTCCCGTAGGATTCTGGGCCGTNTCTCANTCCANTGTGGCCGGTCGCCCTCTCAGGCC
GGCTACCCGTCGTCNCCTTGGTAGGCCATTACCCCNCCAACAANCTGATAGGCCGCGGGCTCNCCTTACCCGCC
GGAGCTTTC AACCCCGTCCCATGCGGGANAAANTGTTNTCCGGTATTAAACCCGTTTCCAGGGNTTGTCCAAAA
TTGAAGGGNANATTGCCCACTTTTNTTACCCGTTCCCCACTAATCCACCACCGAA

EN30

TGGNGGNGTGCTTAACACATGCAAGTCGAACGATGAANCCTTTCGGGGTGGATTAGTGGCGAACGGGTGAGTAAC
ACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATAACACTCTGTCCCGC
ATGGGACGGGGTTAAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCT
ACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTA
CGGGAGGCAGCAGTGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCC
TTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTAC
GTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTANGCGGC
TTGTACGTCGGATGTGAAAGCCCCGGGGCTTAACCCGGGTCTGCATTTCGATACGGGCTAACTAAAATGTGGTAGG
GGAGATCGGAATTCCTGGTGTANCGGTGAAATGCGCAGATATCAAGAGGAACANCGGTGGCGAANGCGGATCTCT
GGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAA
ACGTTGGGAAGTAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGACGCTAACGCATTAAGTTCCCCGCCTGGGG
AGTACGGCCGCAAGGCTAAACTCAAAGGAATTGACGGGGGGCCGCACAAGCAGCGGAGCATGTGGCTTAATTCG
ACGCAACGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCAGAGATGGTGCCCCCTTGTGGTCCG
TATACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTGTCGTGAGATGTTGGGTAAAGTCCCGCAACGAGCGCAACCCT
TGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACTGCCGGGGTCAACTCGGAGGAAGG
TGGGGACGACGTCAAGTCATCATGCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGCT
GCGATGCCGCGAGGCGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGcAACTCGACCCcATGA
AGTCGgAGTTGCTAgTAATCgCAgATCAgCATTGCTGCGGTGAATACgTTNCCGGGCCTtGTACAcACCGCCCGT
CACGTCACgAAAGTCGGTAACACCCGAAGNCCGGTGGTCCAACCCCTTGTGGGAGGGAGACTGTCAAGGTGGGA
CTGGCGATTGG

EN43

CTCAGCGTCACTATCGGCCCCAAAANACCGCCTTCGCCACCGGTGTTCCCTCCTGATATCTGCGCATTTACACCGCTA
CACCAGGAAATTCCANTCTCCCCTACCGAACTCTANCCTGCCCGTATCAACCGCAGGCTTGGGGTTAAGCCCCAA
TTTTTACGGTCAACGCNACAAGCCGCCTACAAGCTCTTTACGCCCAATAAATCCGGACAACGCTCGCACCCCTAC
TTCTTACCGCGGCTGCTGGCACTTATTTGGCCGGTGCTTCTTCTGCAGGTACCGTCACTCTCGCTTCGTCCCTGC
TNAAAAAGGTTTACAACCCGAAGGCCGTATCCCTCACGCGGCNTCGCTGCATCAGGCTTCCGCCCATTGTGCAA
TATTCCCCACTGCTGCCTCCCGTAGGATTCTGGGCCGTNTCTCANTCCAGTGTGGCCGGTCGCCCTCTCAGGCC
GGCTACCCGTCGTCGCCTTGGTAGGCCATCACCCACCAACAAGCTGATAGGCCGCNAAGCCCATCCCAAGCCGA
AAAACTTTCCACCACCAGCCATGCGGCCAAAATTCTATTCGGTATTAGCCCCCGTTTCCNAAGGTTNTCCCAA
GCTTGGGGCAGGTTGCTCACTTTTACTCACCCGTTCCCGCTCAATTACCCCNAAAGGGGNTTTCCTCAACTTGC
AT

28/30


[FIGURE 19 CONTINUED]**EN47**

CGCTGGCGGCGTGCTTAACACATGCAAGTCGAGCGGAAAGGCCCTTCGGGgTACTCGAGCGGCGAACGGGTGAGT
AACACGTGAGTAATCTGCCCCAGGCTCTGGGATAGCCACCGGAAACGGTGATTAATACCGGATACGACAACCGAT
TGCATGATCTGGTTGTGGAAAGTTTTTCGGCCTGGGATGTGCTCGCGGCCCTATCAGCTTGTTGGTGAGGTAATGG
CTCACCAAGGCTTCGACGGGTAGCCGGCCTGAGAGGGTGACCGGCCACACTGGGACTGAGACACGGCCCAGACTC
CTACGGGAGGCAGCAGTGGGGAATATTGGACAATGGGCGGAAGCCTGATCCAGCAACGCCGCGTGAGGGATGACG
GCCTTCGGGTGTAAACCTCTTTCAGCACAGACGAAGCGCAAGTGACGGTATGTGCAGAAGAAGGACCGGCCAAC
TACGTGCCAGCAGCCGCGGTAATACGTAGGGTCCGAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCTCGTAGGC
GGTCTGTGCGCTCGGGAGTGAAAACCAGGTGCTTAACACCTGGCCTGCTTTCGATACGGGCAGACTAGAGGTACT
CAGGGGAGAATGGAATTCCTgGTGTAGCGGTGAAATGCGCAGATATTCAGGAGGAACACCGGTGGCGAAGGCGGT
TCTCTGGGAGTATCCTGACGcTTGAAGAGCGAAAGTGTGGGGAGCGAACAGGATTAGATANTNTGGTAGTCCACA
CCGTAAACgTTGGGCGcTAGgTGTGGGACACATTCACGTGTTCCGTGCCGCAGCTAACGCATTAAGCGCCCCGC
CTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAAGCGGCGGAGCATGCGGATT
AATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATACACCGGAAAGCCGTAGAGATACGGCCCCCTTTTAG
TCGGTGTACAGGTGGTGCATGGCTGTGCTCAGCTCGTGTGCTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAA
CCCTCGTCCTATGTTGCCAGCAATTCGGTTGGGGACTCATAGGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGG
GATGACGTCAAGTCATCATGCCCCCTTATGTCCAGGGCTTCACGCATGCTACAATGGCCGGTACAAAGGGCTGCGA
TCCCGTGAGGGTGAGCGAATCCCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTC
GGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACG
TCACGAAAGTCGGCAACACCCGAAGCCAGTGGCCCAACCCTTGTGGGGGGAGCTGTGCAAGGTGGGGCTGGCGAT
TG

EN59

GGGNATTAGTGGGGAACGGGTGAGTAAAANGTGGCCANTTTCCCCTGNATTTTGGACANCCCCNGGAAANGGNTT
NTAAAACNGGATANTGACCACCTTGGCATCCAAGTTTTNGAACTTCCGGCGGTGCAGGATGAGCCNGCGGCNTA
TNAGCTTGTTGGNGAGGTAATGGNTCACCAAGGGANGACGGGTAGCCGGCCTGAGAGGGGACCNGCCACANTGGG
ANTGAGANACGGCCCAGANTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGG
ANNCCGCGTGAGGGANGACGGCCTTNGGGTTGTAAACNTTTTTNAGCAGGGAAGAAGCGAAAGTGACGGTACCTG
CAGAAGAAGCGCCGGCTAAATAAGTGCCAGCAGCCGCGGTAATAAGTAGGGNGCGAGCGTTGTNCGGAATTATTG
GGNGTAAAGAGTTTGTAGGCGGNTTGTNAAGTNGGTTGTGAAAGCCCGGGGNTTAACCCCGGGTTTGCAGTTGAT
ACGGGCAGGNTAGAGTTCGGTAGGGGAGATNGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAA
CACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAG
ATACCCTGGTAGTCCACGCCGTAAACGGTGGGAACTAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTA
ACGCATTAAGTTCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAAG
CAGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACGGAAAGCATCAG
AGATGGTGCCCCCCTTGTGGTGGTGTACAGGTGGTGCATGGCTGTGCTCAGCTCGTGTGCTGAGATGTTGGGTT
AAGTCCCGCAACGAGCGCAACCCTTGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGAC
CGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCTTATGTCTTGGGCTGCACACGTG
CTACAATGGCCGGTACAAAGAGCTGCGATACCGTGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATT
GGGGTCTGCAACTCGANCCCATGAANTCGGAGTTGCTAATTAATCGCAAAATCAAGCATTGCTGGCGGTGAATAC
GTTCCC

29/30

**Figure 20**

30/30**Figure 21**